|
ACURA PHARMACEUTICALS, INC - 10-K - 19990331 - PART_I
PART I
ITEM 1. BUSINESS.
GENERAL
The Company, a New York corporation established in 1935, and its
subsidiaries, are engaged in the manufacture, sale and distribution of generic
drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name
drug for which patent protection has expired. A generic drug may only be
manufactured and sold if patents (and any additional government-granted
exclusivity periods) relating to the brand-name equivalent of the generic drug
have expired. A generic drug is usually marketed under its generic chemical name
or under a brand name developed by the generic manufacturer. The Company sells
its generic drug products under its Halsey label and under private-label
arrangements with drugstore chains and drug wholesalers. While subject to the
same governmental standards for safety and efficacy as its brand-name
equivalent, a generic drug is usually sold at a price substantially below that
of its brand-name equivalent.
The Company manufactures its products at facilities in New York and
Indiana. During the last several years, the Company has sought to diversify its
businesses through strategic acquisitions and through the development,
manufacture and sale of bulk chemical products used by others as raw materials
in the manufacture of finished drug forms.
RECENT EVENTS
Regulatory Compliance
During the past several years, the Company's business has been adversely
affected by the discovery of various manufacturing and record keeping problems
identified with certain products manufactured at its Brooklyn, New York plant.
In October 1991, the U.S. Food and Drug Administration (the "FDA") placed the
Company on the FDA's Application Integrity Policy list and its restrictions
(collectively, the "AIP"). Under the AIP, the FDA suspended all of the parent
company's applications for new drug approvals, including Abbreviate New Drug
Applications ("ANDAs") and Supplements to ANDAs. During the period that
followed, the U.S. Department of Justice ("DOJ") conducted an investigation into
the manufacturing and record keeping practices at the Company's Brooklyn plant.
As a consequence, on June 21, 1993, the Company entered into a plea agreement
(the "Plea Agreement") with the DOJ to resolve the DOJ's investigation. Under
the terms of the Plea Agreement, the Company agreed to plead guilty to five
counts of adulteration of a single drug product shipped in interstate commerce
and related record keeping violations. The Plea Agreement also required the
Company to pay a fine of $2,500,000 over five years in quarterly installments of
$125,000 commencing in September 1993. As of February 28, 1998, the Company was
in default of the payment terms of the Plea Agreement and had made payments
aggregating $350,000. On March 27, 1998, the Company and the DOJ signed a Letter
Agreement serving to amend the Plea Agreement relating to the terms of the
Company's satisfaction of the fine assessed under the Plea Agreement. The Letter
Agreement provides, among other things, that the Company will satisfy the
remaining $2,150,000 of the fine through the payment of $25,000 on a monthly
basis commencing June 1, 1998, plus interest on the outstanding balance. See
"Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations -- Liquidity and Capital Resources" for a more detailed
description of the Letter Amendment to the Plea Agreement between the DOJ and
the Company.
On June 29, 1993, the Company entered into a consent decree (the "Consent
Decree") with the U.S. Attorney for the Eastern District of New York on behalf
of the FDA that resulted from the FDA's investigation into the Brooklyn plant's
compliance with the FDA's Current Good Manufacturing Practices ("CGMP")
regulations. Under the terms of the Consent Decree, the Company was enjoined
from shipping any solid dosage drug products (i.e., excluding liquid drug
formulations) manufactured at the Brooklyn plant until the Company established,
to the satisfaction of the FDA, that the methods used in, and the facilities and
controls used for, manufacturing, processing, packing, labeling and holding any
drug, were established, operated, and administered in conformity with the
Federal Food, Drug, and Cosmetic Act and all CGMP
3
Regulations. As part of satisfying these requirements, the Company was required
to validate the manufacturing processes for each solid dosage drug product prior
to manufacturing and shipping the drug product.
On October 23, 1996, the Company withdrew four of its ANDAs, including its
ANDA (the "Capsules ANDA") for acetaminophen/oxycodone capsules (the
"Capsules"), and halted sales of the affected products. Net sales derived from
the withdrawn Capsule ANDA were approximately $3 million and $8 million for the
years ended December 31, 1996 and December 31, 1995, respectively, and accounted
for approximately 24% and 40% of the Company's total net sales during such
twelve month periods. The Company instituted the withdrawal of the Capsule ANDA
at the suggestion of the FDA and in anticipation of its release from the AIP. At
the FDA's suggestion, the Company retained outside consultants to perform
validity assessments of its drug applications. Thereafter, in October 1996, the
FDA recommended that several applications, including the Capsule ANDA, be
withdrawn. As a basis for its decision, the FDA cited questionable and
incomplete data submitted in connection with the applications. The FDA indicated
that the withdrawal of the four ANDAs was necessary for the release of the
Company from the AIP. The FDA further required submission by the Company of a
Corrective Action Plan, which was prepared and submitted by the Company and
accepted by the FDA.
On December 19, 1996, the FDA released the Company from the AIP. As a
consequence, for the first time since October 1991, the Company was permitted to
submit ANDAs to the FDA for review. Since its release from the AIP in December
1996, through the fiscal year ended December 31, 1998, the Company submitted 13
ANDAs for review by the FDA, including a new ANDA with respect to the Capsules.
During the period from the Company's release from the AIP to March 15, 1999, the
Company received the following ANDA approvals, all of which relate to ANDA
filings made with the FDA subsequent to the Company's release from the AIP:
PRODUCT NAME
(DRUG CLASS) STRENGTH TRADE NAME STATUS
------------ ----------- ------------- -----------------------------
Hydrocodone Bitartate and..... 5mg/500mg Vicodin(R)(1) FDA approval of ANDA received
Acetaminophen Tablets September 26, 1997.
(narcotic analgesic)
Hydrocodone Bitartate and..... 7.5mg/750mg VicodinES(R)(1) FDA approval of ANDA received
Acetaminophen Tablets September 26, 1997.
(narcotic analgesic)
Hydrocodone Bitartate and..... 7.5mg/650mg Lorcet FDA approval of ANDA received
Acetaminophen Tablets, CIII Plus(R)(2) November 26, 1997.
(narcotic analgesic)
Hydrocodone Bitartrate and.... 10mg/650mg Lorcet(R)(2) FDA approval of ANDA received
Acetaminophen Tablets, CIII November 26, 1997.
(narcotic analgesic)
Oxycodone HCI and............. 5mg/50mg Tylox(R)(3) FDA approval of ANDA received
Acetaminophen Capsules, CII January 22, 1998.
(narcotic analgesic)
Oxycodone HCI/Oxycodone....... 4.5mg/325mm Percodan(R)(4) FDA approval of ANDA received
Terephthalate Tablets, CII July 24, 1998
(narcotic analgesic)
|
(1) Registered trademark of Knoll Pharmaceutical Co.
(2) Registered trademark of Forest Laboratories, Inc.
(3) Registered trademark of McNeil Consumer Products Company
(4) Registered Trademark of DuPont Merck
As of March 15, 1999, the Company had submitted one ANDA for review by the
FDA in fiscal 1999 and anticipates the submission of five additional ANDAs
during the balance of fiscal 1999. Although the Company has been successful in
receiving the ANDA approvals described above since its release from the AIP in
December 1996, there can be no assurance that any of its newly submitted ANDAs,
or those contemplated to
4
be submitted, will be approved by the FDA. The Company will not be permitted to
market any new product unless and until the FDA approves the ANDA relating to
such product. Failure to obtain FDA approval for the Company's pending ANDAs, or
a significant delay in obtaining such approval, would adversely affect the
Company's business operations and financial condition.
Private Offerings and Bridge Financing
On March 10, 1998, the Company completed a private offering of securities
(the "Offering") to Galen Partners III, L.P., Galen Partners International III,
L.P., Galen Employee Fund III, L.P., (collectively, "Galen") and each of the
Purchasers listed on the signature page to a certain Debenture and Warrant
Purchase Agreement dated March 10, 1998 between the Company and such Purchasers
(inclusive of Galen, collectively the "Galen Investor Group"). The securities
issued in the Offering consisted of 5% convertible senior secured debentures
(the "Debentures") and common stock purchase warrants (the "Warrants")
exercisable for an aggregate of 4,202,020 shares of the Company common stock.
The net proceeds to the Company from the Offering, after the deduction of
related Offering expenses, was approximately $19.6 million. In addition, in
accordance with the terms of the Debenture and Warrant Purchase Agreement
pursuant to which the Offering was completed, the Company granted the Galen
Investor Group an option to invest an additional $5 million in the Company at
any time within 18 months from the date of the closing of the Offering in
exchange for Debentures and Warrants having terms identical to those issued in
the Offering (the "Galen Option"). In June 1998, the Galen Investor Group
exercised this option.
The net proceeds of the Offering have, in large part, been used to satisfy
a substantial portion of the Company's liabilities and accounts payable.
Additionally, pursuant to agreements reached with other large creditors in
anticipation of the completion of the Offering, including the Company's landlord
and the DOJ, the Company has been able to bring these creditors current and will
be in compliance with installment payment agreements providing favorable terms
to the Company. The net proceeds from the exercise of the Galen Option have been
used, in large part, to fund working capital, including the purchase of raw
materials, payroll expenses and other Company expenses.
In addition to the net proceeds from the Offering and the exercise of the
Galen Option, the Company secured bridge financing from Galen and certain
investors in the Offering in the aggregate amount of $9,504,111 funded through
seven separate bridge loan transactions between the period from August through
and including December, 1998, as well as an additional bridge loan in March,
1999 (collectively, the "Bridge Loans"). The Bridge Loans were consolidated on
December 2, 1998 pursuant to an Amended, Restated and Consolidated Bridge Loan
Agreement (the "Consolidated Bridge Loan"). The Consolidated Bridge Loan bears
interest at 10% per annum, is secured by a first lien on all of the Company's
assets and has a maturity date of May 30, 1999. Approximately $9,120,000 in the
principal amount of the Consolidated Bridge Loan was advanced by Galen with the
balance of approximately $384,000 advanced by certain investors in the Offering.
The Consolidated Bridge Loan was secured by the Company in order to provide
necessary working capital. See "Item 7. Management's Discussion and Analysis of
Financial Condition and Results of Operations" for a more detailed discussion of
the Consolidated Bridge Loan transaction.
Lease of Congers, New York Facility
Effective March 22, 1999, the Company leased, as sole tenant, a
pharmaceutical manufacturing facility located in Congers, New York (the "Congers
Facility") from Par Pharmaceuticals, Inc. ("Par") pursuant to an Agreement to
Lease (the "Lease"). The Congers Facility contains office, warehouse and
manufacturing space and is approximately 35,000 square feet. The Lease provides
for a term of three years, with a two year renewal option and provides for
annual fixed rent of $500,000 per year during the primary term of the Lease and
$600,000 per year during the option period. The Lease also covers certain
manufacturing and related equipment previously used by Par in its operations at
the Congers Facility (the "Leased Equipment"). In connection with the execution
of the Lease, the Company and Par entered into a certain Option Agreement
pursuant to which the Company may purchase the Congers Facility and the Lease
Equipment at any time during the lease term for $5 million.
5
As part of the execution of the Lease, the Company and Par entered into a
certain Manufacturing and Supply Agreement (the "M&S Agreement") having a
minimum term of twenty seven months. The M&S Agreement provides for the
Company's contract manufacture of certain designated products manufactured by
Par at the Congers Facility prior to the effective date of the Lease. The M&S
Agreement also provides that Par will purchase a minimum of $1,150,000 in
product during the initial 18 months of the Agreement. The M&S Agreement further
provides that the Company will not manufacture, supply, develop or distribute
the designated products to be supplied by the Company to Par under the M&S
Agreement to or for any other person for a period of three years.
Cessation of California Operations
On March 20, 1998, the Company discontinued the operations of H.R. Cenci
Laboratories, a wholly-owned subsidiary. H.R. Cenci Laboratories had been a
manufacturer of drug products in liquid preparations. Continuing operating
losses and the Company's inability to leverage the manufacturing capacity of
Cenci Laboratories were among factors considered by the Board and Management in
its determination to cease such operations.
On March 30, 1998, the Company completed the sale of substantially all of
the non-real property assets of Cenci Powder Products, a wholly-owned
subsidiary, to Zuellig Botanical. The purchase price for the assets consisted of
the forgiveness by Zuellig Botanical of approximately $262,000 in indebtedness
owed by Cenci Powder to Zuellig Botanical related to the purchase of raw
materials. The Agreement provided further that Zuellig Botanical would satisfy
the manufacture and delivery requirements of Cenci Powder at its located
facility in Fresno, California, under an existing third party supply contract.
On December 4, 1998, the Company disposed of the real property owned by Cenci
Powder in Fresno, California to an unrelated third party for a net sales price
of approximately $73,000. Continuing operating losses and the Company's
inability to leverage the manufacturing capacity of Cenci Powder were among the
factors considered by the Board and Management in its determination to terminate
the operations of Cenci Powder.
6
PRODUCTS AND PRODUCT DEVELOPMENT
Generic Drug Products
The Company historically has manufactured and sold a broad range of
prescription and over-the-counter drug products. The Company's pharmaceutical
product list currently includes a total of approximately 28 products, consisting
of 18 dosage forms and strengths of prescription drugs and 10 dosage forms and
strengths of over-the-counter drugs. Each dosage form and strength of a
particular drug is considered in the industry to be a separate drug product. The
Company's drug products are sold in various forms, including liquid and powder
preparations, compressed tablets and two-piece, hard-shelled capsules.
Most of the generic drug products manufactured by the Company can be
classified within one of the following categories:
1. Antibiotics,
2. Narcotic analgesics,
3. Anti-infective and anti-tubercular drugs,
4. Antihistamines and antihistaminic decongestants, or
5. Antitussives.
During fiscal 1998, sales of antitussives and narcotic analgesics accounted
for approximately 75% of total net sales during such year. The Company
anticipates that sales of antitussives and narcotic analgesics will continue to
represent a significant portion of the Company's revenue.
The Company's development strategy for new drug products has been to focus
on the development of a broad-range of generic form drugs, each of which (i) has
developed a solid market acceptance with a wide base of customers, (ii) can be
sold on a profitable basis notwithstanding intense competition from other drug
manufacturers, and (iii) is no longer under patent protection. The Company has
also diversified its current product line to include some less widely prescribed
drugs as to which limited competition might be expected. In addition, the
Company will continue to pursue the development of its existing pharmaceutical
business as well as the development of the chemical products business of its
Houba subsidiary.
Development activities for each new generic drug product begin several
years in advance of the patent expiration date of the brand-name drug
equivalent. This is because the profitability of a new generic drug usually
depends on the ability of the Company to obtain FDA approval to market that drug
product upon or immediately after the patent expiration date of the equivalent
brand-name drug. Being among the first to market a new generic drug product is
vital to the profitability of the product. As other off-patent drug
manufacturers receive FDA approvals on competing generic products, prices and
revenues typically decline. Accordingly, the Company's ability to attain
profitable operations will, in large part, depend on its ability to develop and
introduce new products, the timing of receipt of FDA approval of such products
and the number and timing of FDA approvals for competing products.
Active Pharmaceutical Ingredients
In the last few years, the Company has increased its efforts to develop and
manufacture active pharmaceutical ingredients also known as bulk chemical
products. The development and sale of active pharmaceutical ingredients
generally is not subject to the same level of regulation as is the development
and sale of drug products; accordingly, active pharmaceutical ingredients may be
brought to market substantially sooner than drug products. While the Company
currently is focusing on the development and manufacture of active
pharmaceutical ingredients for use in production of finished dosage products at
the Company's Brooklyn and Congers, New York facilities, active pharmaceutical
ingredients eventually may be marketed and sold to third parties.
7
RESEARCH AND DEVELOPMENT
The Company conducts research and development activities at each of its
Brooklyn and Indiana facilities. The Company's research and development
activities consist primarily of new generic drug product development efforts and
manufacturing process improvements, as well as the development for sale of new
chemical products. New drug product development activities are primarily
directed at conducting research studies to develop generic drug formulations,
reviewing and testing such formulations for therapeutic equivalence to brand
name products and additional testing in areas such as bioavailability,
bioequivalence and shelf-life. For fiscal years 1998, 1997 and 1996, total
research and development expenditures were $651,000, $979,000 and $1,854,000,
respectively. During 1999, the Company's research and development efforts will
cover products in a variety of therapeutic applications.
As of March 15, 1999, the Company maintained a full-time staff of five in
its Research and Development Departments.
MARKETING AND CUSTOMERS
The application of the AIP to the Company's operations until December 1996,
combined with the Company's continuing operating losses and lack of adequate
working capital during fiscal 1997 and the first quarter of 1998 resulted in the
Company's inability to maintain sufficient raw materials and finish goods
inventories to permit the Company to actively solicit customer orders, and when
orders were received, to fill such orders promptly. Following the completion of
the Offering, new Management adopted a marketing strategy focused on developing
and maintaining sufficient raw materials and finish goods inventories so as to
permit a targeted sales effort by the Company to a core customer group, with an
emphasis on quality, prompt product delivery and excellent customer service. The
Company's products are sold by Stephanie Heitmeyer, Vice President of Sales, and
three salaried sales persons. Sales of the Company's drugs in dosage form are
made primarily to drug wholesalers, drugstore chains, distributors and other
manufacturers and are not concentrated in any specific region.
During 1998, the Company had net sales to one customer aggregating 11.5% of
total sales. The sales to such customer were made pursuant to a certain contract
manufacturing agreement entered into with the Company as part of the Company's
sale of its ANDA for oxycodone HCI/325 mg acetaminophen tablets in March, 1995.
The Company anticipates that net sales to this customer (which aggregated
approximately 22.3% of total sales in 1997) will continue to decline during 1999
and thereafter. The Company does not believe that the continuing decline of net
sales to this customer will have a material adverse effect on the Company.
Also during 1998, the Company had net sales to two customers aggregating
approximately 19.1% of total sales. The Company believes that the loss of these
customers would have a material adverse effect on the Company. During 1997 the
Company had net sales to one customer in excess of 10% of total sales,
aggregating 22.3% of total sales. During 1996, the Company had net sales to one
customer in excess of 10% of total sales, aggregating 10% of total sales.
The estimated dollar amount of the backlog of orders for future delivery as
of March 15, 1999 was approximately $500,000 as compared with approximately
$800,000 as of March 15, 1998. Although these orders are subject to
cancellation, management expects to fill substantially all orders by the second
quarter of 1999. The decline in the Company's backlog as of March 15, 1999
compared to that in 1998 is largely a function of the Company's increased
efficiency in the processing and filling of customer orders.
GOVERNMENT REGULATION
General
All pharmaceutical manufacturers, including the Company, are subject to
extensive regulation by the Federal government, principally by the FDA, and, to
a lesser extent, by state and local governments. Additionally, the Company is
subject to extensive regulation by the DEA as a manufacturer of controlled
substances. The Company cannot predict the extent to which it may be affected by
legislative and other
8
regulatory developments concerning its products and the healthcare industry
generally. The Federal Food, Drug, and Cosmetic Act, the Generic Drug
Enforcement Act of 1992, the Controlled Substance Act and other Federal statutes
and regulations govern or influence the testing, manufacture, safe labeling,
storage, record keeping, approval, pricing, advertising, promotion, sale and
distribution of pharmaceutical products. Noncompliance with applicable
requirements can result in fines, recall or seizure of products, criminal
proceedings, total or partial suspension of production, and refusal of the
government to enter into supply contracts or to approve new drug applications.
The FDA also has the authority to revoke approvals of new drug applications. The
ANDA drug development and approval process now averages approximately eight
months to two years. The approval procedures are generally costly and time
consuming.
FDA approval is required before any "new drug," whether prescription or
over-the-counter, can be marketed. A "new drug" is one not generally recognized
by qualified experts as safe and effective for its intended use. Such general
recognition must be based on published adequate and well controlled clinical
investigations. No "new drug" may be introduced into commerce without FDA
approval. A drug which is the "generic" equivalent of a previously approved
prescription drug also will require FDA approval. Furthermore, each dosage form
of a specific generic drug product requires separate approval by the FDA. In
general, as discussed below, less costly and time consuming approval procedures
may be used for generic equivalents as compared to the innovative products.
Among the requirements for drug approval is that the prospective manufacturer's
methods must conform to the CGMPs. CGMPs apply to the manufacture, receiving,
holding and shipping of all drugs, whether or not approved by the FDA. CGMPs
must be followed at all times during which the drug is manufactured. To ensure
full compliance with standards, some of which are set forth in regulations, the
Company must continue to expend time, money and effort in the areas of
production and quality control. Failure to so comply risks delays in approval of
drugs, disqualification from eligibility to sell to the government, and possible
FDA enforcement actions, such as an injunction against shipment of the Company's
products, the seizure of noncomplying drug products, and/or, in serious cases,
criminal prosecution. The Company's manufacturing facilities are subject to
periodic inspection by the FDA.
In addition to the regulatory approval process, the Company is subject to
regulation under Federal, state and local laws, including requirements regarding
occupational safety, laboratory practices, environmental protection and
hazardous substance control, and may be subject to other present and future
local, state, Federal and foreign regulations, including possible future
regulations of the pharmaceutical industry.
Drug Approvals
There are currently three ways to obtain FDA approval of a new drug.
1. New Drug Applications ("NDA"). Unless one of the procedures discussed
in paragraph 2 or 3 below is available, a prospective manufacturer must conduct
and submit to the FDA complete clinical studies to prove a drug's safety and
efficacy, in addition to the bioavailability and/or bioequivalence studies
discussed below, and must also submit to the FDA information about manufacturing
practices, the chemical make-up of the drug and labeling.
2. Abbreviated New Drug Applications ("ANDA"). The Drug Price Competition
and Patent Term Restoration Act of 1984 (the "1984 Act") established the ANDA
procedure for obtaining FDA approval for those drugs that are off-patent or
whose exclusivity has expired and that are bioequivalent to brand-name drugs. An
ANDA is similar to an NDA, except that the FDA waives the requirement of
conducting complete clinical studies of safety and efficacy, although it may
require expanded clinical bioavailability and/or bioequivalence studies.
"Bioavailability" means the rate of absorption and levels of concentration of a
drug in the blood stream needed to produce a therapeutic effect.
"Bioequivalence" means equivalence in bioavailability between two drug products.
In general, an ANDA will be approved only upon a showing that the generic drug
covered by the ANDA is bioequivalent to the previously approved version of the
drug, i.e., that the rate of absorption and the levels of concentration of a
generic drug in the body are substantially equivalent to those of a previously
approved equivalent drug. The principle advantage of this approval mechanism is
that an ANDA applicant is not required to conduct the same preclinical and
clinical studies to demonstrate that the product is safe and effective for its
intended use.
9
The 1984 Act, in addition to establishing the ANDA procedure, created new
statutory protections for approved brand-name drugs. In general, under the 1984
Act, approval of an ANDA for a generic drug may not be made effective until all
product and use patents listed with the FDA for the equivalent brand name drug
have expired or have been determined to be invalid or unenforceable. The only
exceptions are situations in which the ANDA applicant successfully challenges
the validity or absence of infringement of the patent and either the patent
holder does not file suit or litigation extends more than 30 months after notice
of the challenge was received by the patent holder. Prior to enactment of the
1984 Act, the FDA gave no consideration to the patent status of a previously
approved drug. Additionally, under the 1984 Act, if specific criteria are met,
the term of a product or use patent covering a drug may be extended up to five
years to compensate the patent holder for the reduction of the effective market
life of that patent due to federal regulatory review. With respect to certain
drugs not covered by patents, the 1984 Act sets specified time periods of two to
ten years during which approvals of ANDAs for generic drugs cannot become
effective or, under certain circumstances, ANDAs cannot be filed if the
equivalent brand-name drug was approved after December 31, 1981.
3. "Paper" NDA. An alternative NDA procedure is provided by the 1984 Act
whereby the applicant may rely on published literature and more limited testing
requirements. While that alternative sometimes provides advantages over the ANDA
procedure, it is not frequently used.
Generic Drug Enforcement Act
As a result of hearings and investigations concerning the activities of the
generic drug industry and the FDA's generic drug approval process, Congress
enacted the Generic Drug Enforcement Act of 1992 (the "Generic Drug Act"). The
Generic Drug Act confers significant new authority upon the FDA to impose
debarment and civil penalties for individuals and companies who commit certain
illegal acts relating to the generic drug approval process.
The Generic Drug Act requires the mandatory debarment of companies or
individuals convicted of a federal felony for conduct relating to the
development or approval of any ANDA, and gives the FDA discretion to debar
corporations or individuals for similar conduct resulting in a federal
misdemeanor or state felony conviction. The FDA may not accept or review during
the period of debarment (one to ten years in the case of mandatory, or up to
five years in the case of permissive, debarment of a corporation) any ANDA
submitted by or with the assistance of the debarred corporation or individual.
The Generic Drug Act also provides for temporary denial of approval of generic
drug applications during the investigation of crimes that could lead to
debarment. In addition, in more limited circumstances, the Generic Drug Act
provides for suspension of the marketing of drugs under approved generic drug
applications sponsored by affected companies. The Generic Drug Act also provides
for fines and confers authority on the FDA to withdraw, under certain
circumstances, approval of a previously granted ANDA if the FDA finds that the
ANDA was obtained through false or misleading statements. The Company was not
debarred as a result of the FDA investigation and settlement and the Consent
Decree with the FDA makes no provision therefor.
Healthcare Reform
Several legislative proposals to address the rising costs of healthcare
have been introduced in Congress and several state legislatures. Many of such
proposals include various insurance market reforms, the requirement that
businesses provide health insurance coverage for all their employees,
significant reductions in the growth of future Medicare and Medicaid
expenditures, and stringent government cost controls that would directly control
insurance premiums and indirectly affect the fees of hospitals, physicians and
other healthcare providers. Such proposals could adversely affect the Company's
business by, among other things, reducing the demand, and the prices paid, for
pharmaceutical products such as those produced and marketed by the Company.
Additionally, other developments, such as (i) the adoption of a nationalized
health insurance system or a single payor system, (ii) changes in needs-based
medical assistance programs, or (iii) greater prevalence of capitated
reimbursement of healthcare providers, could adversely affect the demand for the
Company's products.
10
COMPETITION
The Company competes in varying degrees with numerous companies in the
health care industry, including other manufacturers of generic drugs (among
which are divisions of several major pharmaceutical companies) and manufacturers
of brand-name drugs. Many of the Company's competitors have substantially
greater financial and other resources and are able to expend more money and
effort than the Company in areas such as marketing and product development.
Although a company with greater resources will not necessarily receive FDA
approval for a particular generic drug before its smaller competitors,
relatively large research and development expenditures enable a company to
support many FDA applications simultaneously, thereby improving the likelihood
of being among the first to obtain approval of at least some generic drugs.
One of the principal competitive factors in the generic pharmaceutical
market is the ability to introduce generic versions of brand-name drugs promptly
after a patent expires. The Company believes that it was at a competitive
disadvantage until its release from the AIP program and the FDA's resumption of
review of ANDAs submitted by the Company's Brooklyn plant. See "Government
Regulation -- Generic Drug Enforcement Act" above. Other competitive factors in
the generic pharmaceutical market are price, quality and customer service
(including maintenance of sufficient inventories for timely deliveries).
RAW MATERIALS
The raw materials essential to the Company's business are bulk
pharmaceutical chemicals purchased from numerous sources. Raw materials are
generally available from several sources. The Federal drug application process
requires specification of raw material suppliers. If raw materials from a
supplier specified in a drug application were to become unavailable on
commercially acceptable terms, FDA supplemental approval of a new supplier would
be required. During 1998, the Company purchased approximately $2,583,000 of its
raw materials (constituting 29% of its aggregate purchases of raw materials)
from Mallinckrodt. Although the Company is now able to submit Supplements to the
FDA in order to allow the Company to purchase raw materials from alternate
sources, there can be no assurance that if the Company were unable to continue
to purchase raw materials from this supplier, that the Company would be
successful in receiving FDA approval to such Supplement or that it would not
face difficulties in obtaining raw materials on commercially acceptable terms.
Failure to receive FDA approval for, and to locate, an acceptable alternative
source of raw materials would have a material adverse effect on the Company.
The United States Drug Enforcement Administration (the "DEA") limits the
quantity of the Company's inventories of certain raw materials used in the
production of controlled substances based on historical sales data. In view of
the Company's recently depressed sales volume, these DEA limitations could
increase the likelihood of raw material shortages and of manufacturing delays in
the event the Company experiences increased sales volume or is required to find
new suppliers of these raw materials.
SUBSIDIARIES
The Company's Indiana manufacturing operations are conducted by Houba,
Inc., an Indiana corporation and wholly-owned subsidiary of the Company. Halsey
Pharmaceuticals, Inc., a Delaware corporation, is a wholly-owned subsidiary
which is currently inactive. The Company also has the following additional
subsidiaries, each of which is currently inactive and anticipated to be
dissolved during the remainder of the 1999 fiscal year: Indiana Fine Chemicals
Corporation, a Delaware corporation, H.R. Cenci Laboratories, Inc., a California
corporation, Cenci Powder Products, Inc., a Delaware corporation, Blue Cross
Products, Inc., a New York corporation, and The Medi-Gum Corporation, a Delaware
corporation.
EMPLOYEES
As of March 15, 1999, the Company had approximately 160 full-time
employees. Approximately 39 employees are administrative and professional
personnel and the balance are in production and shipping. Among the professional
personnel, 5 are engaged in research and product development. Approximately 45
employees at the Company's Brooklyn plant are represented by a local collective
bargaining unit. The collective bargaining agreement between the Company and the
union was extended on March 5, 1998
11
(retroactive to July 2, 1997) and expires June 30, 2000. Management believes
that its relations with its employees and the union are satisfactory.
ITEM 2. PROPERTIES.
Halsey leases, as sole tenant, a pharmaceutical manufacturing facility of
approximately 35,000 square feet located at 77 Brenner Drive, Congers, New York.
The Agreement of Lease, with an unaffiliated third party, contains a three year
term with a two year renewal option and provides for annual fixed rent of
$500,000 per year during the primary term of the Lease and $600,000 per year
during the renewal period. The primary term of the Lease expires on March 21,
2002. The Leased facility houses a portion of the Company's manufacturing
operations and includes office and warehouse space. The Lease also contains an
option pursuant to which the Company may purchase the leased premises and
improvements (including certain production and related equipment) for a purchase
price of $5 million, exercisable at any time during the Lease term.
Halsey leases, as sole tenant, a total of approximately 112,300 square feet
in three buildings on Pacific Street and Dean Street in Brooklyn, New York. Each
of these leases is between Halsey and unaffiliated lessors. The approximate
aggregate minimum rental commitments under these operating leases are as
follows: $1,023,000 for the year 1999, $1,075,000 for the year 2000 and
$1,128,000 for the year 2001. These leases expire on December 31, 2005. The
buildings leased by Halsey in Brooklyn house its research and development
operations and a portion of its manufacturing operations.
Halsey leases approximately 4,700 square feet of office space located at
695 North Perryville Road, Building No. 2, Rockford, Illinois. The lease is
between the Company and an unaffiliated lessor. The lease has a term of two
years expiring March 30, 2000 and calls for annual rental, including maintenance
and common area expense, of approximately $50,000 per year. This leased facility
houses the Company's principal executive offices, including its sales,
administration and finance operations.
Houba owns approximately 45,000 square feet of building space on
approximately 30 acres of land in Culver, Indiana, which includes a 15,000
square foot manufacturing facility. This manufacturing facility houses separate
plants for the production of Doxycycline raw materials, Doxycycline capsules and
tablets. In 1996, in conjunction with a settlement with two former employees,
the Company acquired real property, improved by a residential property, in
Culver, Indiana adjacent to the manufacturing facility.
ITEM 3. LEGAL PROCEEDINGS.
GOVERNMENTAL PROCEEDINGS
By letter dated October 23, 1995, the Company was notified by the New York
State Education Department (the "Department") that the Professional Conduct
Officer of the Office of Professional Discipline had determined that there was
sufficient evidence of professional misconduct on the Company's part to warrant
a disciplinary proceeding under New York law. Upon contacting the Deputy
Director of the Office of Professional Discipline, counsel for the Company was
advised that the alleged misconduct related to the same activities that were the
subject of the DOJ investigation. The Company submitted a written response to
the Department on November 16, 1995. The Company and the Department entered into
a consent order effective July 18, 1997, concluding any disciplinary
proceedings. The consent order requires that the Company pay $175,000 in fines
over a period of five years. The consent order also provides that the Company's
registration as a manufacturer of drugs in New York State is revoked, but such
revocation is stayed and the Company has been placed on probation for a maximum
period of five years. The Company has the right to apply for removal from
probation two years after the effective date of the consent order. At December
3, 1998, the Company is current in its payment obligations and the remaining
balance is $140,000.
Immediately prior to the completion of the Offering, the Company was in
default under the consent order with the Department for failure to satisfy two
of the monthly installments of the fine as provided in the consent order. Prior
to the completion of the Offering, the Company advised the Department as to the
existence of the default and that such deficiencies would be corrected upon the
completion of the Offering. The Company has
12
satisfied these outstanding amounts and is now current under the consent order
with the Department. Based on discussions between representatives of the
Department and the Company's outside counsel handling this matter, the Company
has been advised that the revocation of the Company's registration as a
manufacturer of drugs in the State of New York will remain stayed and that the
Company continues to have the right to apply for removal from probation after
two years from the effective date of the consent order.
Reference is also made to the discussion of the Company's Plea Agreement
and Letter Agreement with the DOJ contained in "Item 1. Business -- Recent
Events" and "Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operations."
OTHER LEGAL PROCEEDINGS
Beginning in 1992, actions were commenced against the Company and numerous
other pharmaceutical manufacturers in the Pennsylvania Court of Common Pleas,
Philadelphia Division, in connection with the alleged exposure to
diethylstilbestrol ("DES"). The defense of all of such matters was assumed by
the Company's insurance carrier, and a substantial number have been settled by
the carrier. Currently, five actions remain pending with the Company as a
defendant, and the insurance carrier is defending each action. Similar actions
were brought in Ohio, and have been dismissed based on Ohio law. The Company
does not believe any of such actions will have a material impact on the
Company's financial condition.
The Company has been named as a defendant in four additional actions, each
of which has been referred to the Company's insurance carrier and has been
accepted for defense. The first action, Alonzo v. Halsey Drug Co., Inc. and
K-Mart Corp., No. 64DOT-95111-CT-2736 (Indiana Superior Court, Porter County),
was commenced on November 7, 1995 and involves a claim for unspecified damages
relating to the alleged ingestion of "Doxycycline 100." At this early stage of
the proceedings, the Company is unable to predict with any degree of certainty
the likely outcome of these claims and whether they will have a material adverse
effect on the Company's financial condition. The second action, Files v. Halsey
Drug Co., Index No. 198787/93 (New York Supreme Court, Suffolk County),
commenced on September 16, 1993, seeking $10,000,000 in damages for wrongful
death allegedly caused by the ingestion of Isoniazid. Halsey has been dismissed
from this action on motion for summary judgment. The third and fourth actions,
entitled Hunt v. Halsey Drug Co., Inc., and McCray v. Halsey Drug Co., Inc. (New
York State Supreme Court, Kings County), were commenced on October 21, 1993,
seeking the recovery of $8,000,000 for alleged personal injuries suffered by two
Well Fargo security guards who responded to an alarm and were shot, resulting in
the death of one and the injury to the other. The Company is being defended by
its insurance carrier. The Company has impleaded the former security service
used by the Company as a third-party defendant. These actions were settled at a
conference before the Court on December 21, 1998. The settlement documents have
been executed, and the settlement is expected to be consummated shortly.
The Company has been named as a defendant in a complaint filed with the
United States District Court, Eastern District of New York, on June 30, 1998
(the "Complaint") by Quality Products and Services, L.L.C. The Complaint alleges
the existence of a Joint Venture Agreement between the Plaintiff and the Company
concerning the development, manufacture and marketing of a single product. The
Complaint also alleges that the Company has breached the Agreement by failing to
satisfy its respective obligations defined in the Agreement. The Complaint seeks
monetary damages of approximately $20 million. The Company believes that the
allegations contained in the Complaint are without basis in fact, and that is
has meritorious defenses to each of the allegations. The Company has retained
counsel and intends to vigorously defend this action. This matter is currently
in discovery. The Company has filed a third-party complaint against Rosendo
Ferran, the Company's former President, in connection with the Complaint.
The Company has been named as a defendant in an action in Suffolk County,
New York, by Designed Laboratories, Inc., for construction work allegedly
performed at the Company's facilities in Brooklyn. Plaintiffs is seeking
approximately $148,000. The Company has no records of work being performed by
this entity, and is therefore defending the action.
The Company's former President, Rosendo Ferran, has instituted an
arbitration against the Company, seeking sums allegedly due under his employment
contract in the amount of $225,000.00, deferred salary in
13
the approximate amount of $100,000.00, and unspecified damages upon allegations
of age, ethnic and religious discrimination. The Company believes it has
meritorious defenses to the allegations claimed in the arbitration. The Company
does not believe this claim will have a material adverse effect on the Company's
financial condition.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
No matters were submitted to a vote of security holders during the fourth
quarter of 1998.
PART II
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED SECURITY HOLDER
MATTERS.
MARKET AND MARKET PRICES OF COMMON STOCK
The Company's Common Stock is listed on the American Stock Exchange (the
"Exchange") under the symbol "HDG." Set forth below for the periods indicated
are the high and low sales prices for the Common Stock as reported on the
Exchange.
PERIOD HIGH LOW
------ ---- ---
1999 Fiscal Year
First Quarter (through March 15, 1999).................... 1 9/16 1
1998 Fiscal Year
First Quarter............................................. 3 5/8 1 1/4
Second Quarter............................................ 3 1/8 2 3/8
Third Quarter............................................. 2 3/4 1 1/2
Fourth Quarter............................................ 1 7/8 1
1997 Fiscal Year
First Quarter............................................. 6 4 3/8
Second Quarter............................................ 5 1/8 2 9/16
Third Quarter............................................. 4 13/16 2 5/16
Fourth quarter............................................ 4 13/16 1 5/16
|
The Company does not meet certain of the Exchange's criteria for continued
listing. Accordingly, there can be no assurance that the Company's common stock
will remain listed on the American Stock Exchange or that the Exchange will not
commence a review of the Company's continued listing eligibility. If the Common
Stock should become delisted from the Exchange, trading, if any, in the Common
Stock would continue on the OTC Bulletin Board, an NASD-sponsored inter-dealer
quotation system, or in what is commonly referred to as the "Pink Sheets". In
such event, a shareholder may find it more difficult to dispose of, or to obtain
accurate quotations as to the market value of the Common Stock.
HOLDERS
There were 827 holders of record of the Company's common stock on March 15,
1999. This number, however, does not reflect the ultimate number of beneficial
holders of the Company's common stock.
DIVIDEND POLICY
The payment of cash dividends from current earnings is subject to the
discretion of the Board of Directors and is dependent upon many factors,
including the Company's earnings, its capital needs and its general financial
condition. The terms of the Company's 5% convertible senior secured debentures
and the Consolidated Bridge Loan prohibit the Company from paying cash
dividends. The Company does not intend to pay any cash dividends in the
foreseeable future.
14
PRIVATE OFFERINGS
The Company secured bridge financing from Galen and certain investors in
the Offering in the aggregate amount of $9,504,111, funded through seven
separate bridge loan transactions between the period August through and
including December, 1998, as well as an additional bridge loan completed in
March, 1999 (collectively, the "Bridge Loans"). The Bridge Loans were
consolidated on December 2, 1998 pursuant to an Amended, Restated and
Consolidated Bridge Loan Agreement, as amended to permit the March, 1999 bridge
loan (the "Consolidated Bridge Loan"). The Consolidated Bridge Loan is evidenced
by ten (10%) percent convertible senior secured promissory notes which are
convertible at any time prior to the maturity date of May 30, 1999 into shares
of the Company's Common Stock at a conversion price of approximately $1.368 per
share with respect to approximately $7,820,000 of such indebtedness, $1.331 per
share with respect to approximately $284,000 of such indebtedness, and $1.197
per share with respect to approximately $1,400,000 of such indebtedness, for an
aggregate of 7,099,338 shares of Common Stock (such conversion prices equal the
fair market value of the Common Stock at the date of issuance of the convertible
promissory notes). In addition, in consideration for the initial extension for
the Bridge Loans and the extension of the maturity dates of the Bridge Loans
pursuant to the consolidation of such loans on December 2, 1998, the Company
issued common stock purchase warrants to the lenders in the Consolidated Bridge
Loan to purchase an aggregate of approximately 1,009,909 shares of the Company's
Common Stock. The Bridge Loan warrants are substantially identical to those
issues in the debenture and warrant offering completed March 10, 1998.
Each of the lenders in the Consolidated Bridge Loan transaction are
accredited investors as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act of 1933, as amended (the "Act"). The convertible notes and
warrants issued in connection with the Consolidated Bridge Loan were issued
without registration under the Act in reliance upon Section 4(2) of the Act and
Regulation D promulgated thereunder.
ITEM 6. SELECTED FINANCIAL DATA.
The selected consolidated financial data presented on the following pages
for the years ended December 31, 1998, 1997, 1996, 1995 and 1994 are derived
from the Company's audited Consolidated Financial Statements. The Consolidated
Financial Statements as of December 31, 1998 and December 31, 1997, and for each
of the years in the three year period ended December 31, 1998, and the report
thereon, are included elsewhere herein. The selected financial information as of
and for the years ended December 31, 1995 and 1994 are derived from the audited
Consolidated Financial Statements of the Company not presented herein.
The information set forth below is qualified by reference to, and should be
read in conjunction with, the Consolidated Financial Statements and related
notes thereto included elsewhere in this Report and "Item 7. Management's
Discussion and Analysis of Financial Condition and Results of Operations."
15
YEARS ENDED DECEMBER 31,
----------------------------------------------------------------
1998 1997 1996 1995 1994
----------- ----------- ---------- ---------- ----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
OPERATING DATA:
Net sales.......................... $ 8,841 $ 9,088 $ 12,379 $ 20,225 $ 24,182
Costs and expenses
Cost of sales.................... 12,712 15,407 16,826 18,097 21,584
Research and development........... 651 979 1,854 818 502
Selling, general and
administrative................... 8,078 6,308 7,486 6,098 7,128
Interest expense................... 1,946 1,144 1,708 1,307 735
Loss (Gain) on sale of assets...... (1,822) 264 (1,000) (2,288) --
Income (loss) before provision for
income taxes..................... (12,724) (15,014) (14,495) (3,807) (5,767)
Provision (benefit) for
income taxes..................... -- -- -- 296 --
Net income (loss).................. (12,724) $ (15,014) $ (14,495) $ (4,103) $ (5,767)
=========== =========== ========== ========== ==========
Net income (loss) per share........ $ (.92) $ (1.12) $ (1.49) $ (.52) $ (.80)
=========== =========== ========== ========== ==========
Weighted average common shares
outstanding...................... 13,812,529 13,434,215 9,724,106 7,886,101 7,173,908
=========== =========== ========== ========== ==========
|
DECEMBER 31,
-------------------------------------------------------
1998 1997 1996 1995 1994
-------- -------- -------- -------- -------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
BALANCE SHEET DATA:
Working capital (deficiency)......... $ (6,665) $(22,304) $(12,201) $ (7,393) $(4,451)
Total assets......................... 15,913 7,667 11,982 18,862 19,276
Total liabilities.................... 44,866 27,524 19,063 20,402 19,924
Retained earnings
(accumulated deficit).............. (57,221) (44,497) (29,484) (14,989) (10,886)
Stockholders' equity (deficit)....... (28,953) (19,857) (7,081) (1,540) (468)
|
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Certain statements set forth under this caption constitute "forward-looking
statements" within the meaning of the Reform Act. See "Special Note Regarding
Forward-Looking Statements " on page 1 of this Report for additional factors
relating to such Statements.
OVERVIEW
The Company reported a net loss of $12,724,000 or $.92 per share for the
year ended December 31, 1998 as compared with the net loss of $15,015,000 or
$1.12 per share for 1997. Sales for the year ended December 31, 1998 were
approximately $8,841,000 as compared to sales of approximately $9,088,000 for
1997. Notwithstanding these results, the Company had the following achievements
in 1998:
- Received infusion of capital enabling the Company to settle past
obligations and provide for future opportunities.
- Reestablished itself in the marketplace as a dependable supplier of
quality products, expanded its customer base and reduced reliance upon a
single customer.
- Reestablished relationships with suppliers.
- Received approval from the FDA of two ANDA's, submitted five others for
approval and continued development on additional products for submission
in 1999.
- Discontinued certain non-core operations and reduced the workforce by
approximately 25%.
16
RESULTS OF OPERATIONS
The following chart reflects expenses, earnings, income, losses and profits
expressed as a percentage of net sales for the years 1998, 1997 and 1996.
PERCENTAGE CHANGE
YEAR-TO-YEAR
INCREASE (DECREASE)
PERCENTAGE OF NET SALES YEARS ENDED
YEAR ENDED DECEMBER DECEMBER 31,
-------------------------- ----------------------------
1998 1997 1996 1997 TO 1998 1996 TO 1997
------ ------ ------ ------------ ------------
Net sales.............................. 100% 100% 100.0% (2.7) (26.6)
Cost of Goods.......................... 143.8 169.5 135.9 (17.5) (8.47)
Gross Profit........................... (43.8) (69.5) (35.9) (38.7) 42.1
Research & Development................. 7.4 10.8 15.0 (33.5) 47.2
Selling, general and administrative
expense.............................. 91.4 69.4 60.5 29.5 (15.7)
(Loss) from operations................. (142.5) (149.7) (111.4) (6.7) (1.3)
Interest expense....................... 22.0 12.6 13.9 70.1 (33.0)
Other (income) expenses................ (20.6) 2.9 (8.2) -- (126.4)
(Loss) before income taxes............. (143.9) (165.2) (117.1) (14.6) 3.6
Net (loss)............................. (143.9)% (165.2)% (117.1)% (14.6)% 3.6%
====== ====== ======
|
NET SALES
Net sales for 1998 of $8,841,000 represents a decrease of $247,000 as
compared to net sales for 1997. The decrease is attributable in part to a
reduction in toll manufacturing revenue from Mallinckrodt of approximately
$878,000 from the prior year. Additionally, the Company was unable to market
successfully to the retail pharmacy marketplace until the third quarter of 1998
because during fiscal 1996 and 1997, the Company had failed to pay required
rebates to state Medicaid agencies. This caused those states to deny medicaid
reimbursement to the retail pharmacies on their sales of the Company's products.
Commensurate with the infusion of new capital and personnel in March, 1998, the
Company began reestablishing itself in good standing with all states. This task
was completed by July, 1998. Also during much of 1988, the Company experienced
difficulty in obtaining certain raw materials which reduced sales. These
shortages were remedied by December 31, 1998.
Net sales for 1997 of $9,088,000 represents a decreased of $3,291,000 as
compared to net sales for 1996. This decrease is primarily attributable to a
lack of sufficient working capital necessary to purchase raw materials. Without
adequate inventory, the Company was unable to satisfy customer orders in a
timely fashion and caused customers to procure products from competitors.
GROSS MARGINS
The Company's gross margin for 1998 of (43.8)% is a 38.7% improvement over
gross margin for 1997. This improvement is due, in part, to the elimination of
non-core manufacturing operations in California, tighter inventory controls and
a general reduction in manufacturing labor. Additionally, the Company's revenues
in 1998 from sales to Mallinckrodt under a toll manufacturing agreement
decreased by approximately $878,000. The gross margins on these products were
substantially less than on the Company's other products.
The Company's gross margin for 1997 of (69.5)% is a 42.1% reduction over
gross margin for 1996. This deterioration occurred because the Company failed to
react quickly enough to falling sales by decreasing manufacturing expenses.
Additionally, the Company incurred approximately $1,572,000 of manufacturing
costs in operating non-core facilities that generated sales of only $495,000.
17
RESEARCH & DEVELOPMENT EXPENSES
For 1998, research and development expenses amounted to $651,000 as
compared to $979,000 for 1997. The decrease primarily reflects the costs of
biostudies performed in 1997 that were not duplicated in 1998.
For 1997, research and development expenses amounted to $979,000 as
compared to $1,854,000 for 1996. This decrease was a result of reductions in
personnel necessitated by the Company's liquidity crisis.
The Company expects research and development expenses to increase
significantly in 1999 consistent with its plans to increase the number of ANDA
submissions as compared to 1998.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative costs were $8,078,000 (91.4% of net
sales) for 1998 compared to $6,308,000 (69.4% of net sales) for 1997. This
increase is primarily due to costs associated with capital financing, legal
expenses and settlement costs of certain litigation, severance costs associated
with personnel reductions, installation of a new information system and costs
associated with expanded regulatory and compliance departments.
Selling, general and administrative costs were $6,308,000 (69.4% of net
sales) for 1997 compared to $7,486,000 (60.5% of net sales) for 1996. This
decrease is due primarily to a reduction in legal expenses and litigation
settlements as compared to 1996.
INTEREST EXPENSE
Interest expense for 1998 increased by 62% over that of 1997 reflecting the
substantial new debt in the form of $25,800,000 of convertible debentures that
was added in 1998 [include bridge loan debt?]. Interest expense for 1997
decreased 33.0% as compared to 1996 due primarily to the conversion in the
latter part of 1996 of $7,740,000 of convertible debentures bearing interest at
10% into common stock. Interest expense for 1996 increased 77.8% as compared to
1995 as a result of a higher level of borrowings due to the issuance of
convertible subordinated debentures, as well as fees payable to the Company's
banks.
OTHER INCOME
Included in other income for 1998 is $1,900,000 realized from the sale of
certain assets to Mallinckrodt. This transaction was entered into in 1997 but
the conditions for realization of the gain from the sale were not met until
1998.
PROVISION FOR INCOME TAXES
The Company had no tax (benefit) provision for 1998, 1997 and 1996 since
the available loss carry back to prior years was completely utilized by the net
operating loss for 1993 carry back to the prior three years. At December 31,
1998, the Company has a Federal tax refund claim of approximately $1,000,000
pending before the tax authorities. In the meantime, the IRS is holding up
action to collect approximately $1,300,000 of past due payroll taxes.
Additionally, the Company has negotiated payment plans for approximately
$500,000 of past due state and local taxes. The Company has net operating loss
carryforwards of approximately $45,600,000 which expire in the years 2011
through 2018.
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1998, the Company had cash and cash equivalents of
$1,850,000 as compared to $26,000 at December 31, 1997. The Company had a
working capital deficit at December 31, 1998 of $(6,665,000).
On March 10, 1998, the Company completed the Offering to Galen Partners
III, L.P., Galen Partners International III, L.P., Galen Employee Fund III, L.P.
(collectively, "Galen") and each of the Purchasers (along with Galen,
collectively the "Galen Investor Group") listed on the signature page to a
certain Debenture and Warrant Purchase Agreement dated March 10, 1998 (the
"Purchase Agreement"). The net
18
proceeds to the Company from the Offering, after deduction of related Offering
expenses, were approximately $19.6 million. The securities issued in the
Offering consisted of 5% convertible senior secured debentures (the
"Debentures") and common stock purchase warrants (the "Warrants") exercisable
for an aggregate of 4,202,020 shares of the Company's common stock. In addition,
in accordance with the terms of the Purchase Agreement, the Company granted the
Galen Investor Group an option to invest an additional $5 million in the Company
at any time within 18 months from the date of the closing of the Offering in
exchange for Debentures and Warrants having terms identical to those issued in
the Offering (the "Option"). In June 1998, the Galen Investor Group exercised
the Option.
The net proceeds of the Offering were, in large part, used to satisfy a
substantial portion of the Company's liabilities and accounts payable. Such
liabilities include the full satisfaction of the Company's Bank indebtedness and
related fees, payment of arrearages in rent to the landlord of the Brooklyn
facility and satisfaction of outstanding judgments and liens. Additionally,
pursuant to agreements reached with other large creditors in anticipation of the
completion of the Offering, including the Department of Justice, the Company has
been able to bring these creditors current and bring the Company into compliance
with installment payment agreements providing more favorable terms to the
Company. The Offering proceeds also allowed the Company to satisfy its
outstanding state and Federal payroll tax obligations and meet current payroll
tax obligations. The net proceeds from the exercise of the Option were used to
fund working capital, including the purchase of raw materials, payroll expenses
and other Company expenses.
Prior to the completion of the Offering, the Company was in negotiations
with the DOJ to restructure the payment of the $2,500,000 fine that had been
levied under the Plea Agreement in order to address the Company's failure to
satisfy the $125,000 quarterly installments provided for under the Plea
Agreement. On March 30, 1998, the Company and the DOJ signed a Letter Agreement
serving to amend the Plea Agreement relating to the terms of the Company's
satisfaction of the fine assessed under the Plea Agreement. Specifically, the
Letter Agreement provides that the Company will satisfy the remaining $2,150,000
of the fine through the payment of $25,000 on a monthly basis commencing June 1,
1998, plus interest on such outstanding balance (at the rate calculated pursuant
to 28 U.S.C. Section 1961)(currently 5.319%). Such payment schedule would result
in the full satisfaction of the DOJ fine in January, 2006. The Letter Agreement
also provides certain restrictions on the payment of salary or compensation to
any individual in excess of $150,000 without the written consent of the United
States District Court for the District of Maryland, subject to certain
exceptions. In addition, the Letter Agreement requires the prepayment of the
outstanding fine to the extent of 25% of the Company's after tax profit and 25%
of the net proceeds received by the Company on any sale of a capital asset for a
sum in excess of $10,000.
During the period from May 1997 through July 1997, the Company borrowed
approximately $3 million from Mylan Laboratories, Inc. pursuant to five
unsecured, demand promissory notes. The advances made by Mylan Laboratories,
Inc. were part of a proposed investment by Mylan Laboratories, Inc. in the
Company, including the proposed purchase of the Company's Houba Indiana facility
as well as a partial tender offer for the Company's common stock. The Company
used the proceeds of these borrowings for working capital. To date, $236,000 has
been paid by the Company to Mylan against such indebtedness in the form of
product deliveries to Mylan. Pursuant to an agreement reached between the
parties, the Company is required to satisfy interest on the outstanding
indebtedness on an annual basis while the indebtedness remains outstanding and
to satisfy the principal amount of such indebtedness in the form of product
deliveries to Mylan until such time as the indebtedness is satisfied in full.
The Company secured bridge financing from Galen and certain investors in
the Offering in the aggregate amount of $9,504,111, funded through seven
separate bridge loan transactions between the period from August through and
including December, 1998, as well as an additional bridge loan in March, 1999
(collectively, the "Bridge Loans"). The Bridge Loans were consolidated on
December 2, 1998 pursuant to an Amended, Restated and Consolidated Bridge Loan
Agreement, as amended to permit the March, 1999 bridge loan (the "Consolidated
Bridge Loan"). The Consolidated Bridge Loan bears interest at 10% per annum, is
secured by a first lien on all of the Company's assets and has a maturity date
of May 30, 1999. Approximately $9,120,000 in the principal amount of the
Consolidated Bridge Loan was advanced by Galen with the balance of approximately
$384,000 advanced by certain investors in the Offering. The Consolidated Bridge
Loan is
19
evidenced by 10% convertible senior secured promissory notes which are
convertible at any time prior to maturity into shares of the Company's Common
Stock at a conversion price of approximately $1.368 per share with respect to
approximately $7,820,000 of such indebtedness, $1.331 per share with respect to
approximately $284,000 of such indebtedness, and $1.197 per share with respect
to approximately $1,400,000 of such indebtedness, for an aggregate of 7,099,338
shares of common stock (such conversion prices equal the fair market value of
the Common Stock at the date of issuance of the convertible promissory notes).
In addition, in consideration for the initial extension of the Bridge Loans and
the extension of the maturity dates of the Bridge Loans pursuant to the
consolidation of such loans on December 2, 1998, as amended to permit the March,
1999 bridge loan, the Company issued common stock purchase warrants to Galen and
the other investors in the Consolidated Bridge Loan, to purchase an aggregate of
approximately 1,009,909 shares of the Company's common stock (representing
warrants to purchase 50,000 shares of Common Stock for each $1,000,000 in
principal amount of Bridge Loan having a term of 90 days from the date of the
making of the Bridge Loan). The Bridge Loan warrants are substantially identical
to those issued by the Company in its Debenture and Warrant Offering completed
on March 10, 1998.
The Consolidated Bridge Loan was obtained by the Company in order to
provide necessary working capital. In view of the Company's current cash
reserves and projections for revenues through May 30, 1999, the Company will be
unable to satisfy the Consolidated Bridge Loan in full at the stated maturity
date of May 30, 1999. Galen, the holder of approximately 96% of such
indebtedness, has indicated to the Company a willingness to cooperate in the
restructuring of the indebtedness evidenced by the Consolidated Bridge Loan to
extend the maturity date of such debt and/or convert the debt into common stock
or longer-term convertible indebtedness. The terms of such restructuring will
depend, to a large extent, on the terms and timing of any third-party
investment, as described below. Accordingly, the terms of any such restructuring
have yet to be agreed to by the parties and will be subject to the negotiation
and preparation of definitive agreements.
The Company is in preliminary discussions with an unaffiliated third party
concerning the terms of a proposed investment in the Company in an amount of up
to $15 million, to be funded in three equal increments based on the achievement
of certain milestones. The structure of the investment will likely take the form
of convertible debentures and common stock purchase warrants, similar in many
respects to the debentures and warrants issued by the Company in its March 10,
1998 offering. The discussions with this third party investor are in the
preliminary stages and no assurance can be given that final terms acceptable to
the Company will result and/or that if consummated, that the Company will be
successful in achieving the milestones necessary to fund all or any portion of
the proposed investment.
In the event the Company is successful in restructuring the Consolidated
Bridge Loan and completing a third party investment of the type and size
described above, the Company will have sufficient cash reserves to satisfy its
working capital requirements for at least the next 12 months. The Company is
also seeking to secure a senior revolving line of credit from a banking
institution. There can be no assurance, however, that the Company will be able
to obtain such third party investment or a bank facility. If the Company is
unable to complete the third party investment described above or obtain other
sources of working capital, including a bank line of credit or proceeds from the
issuance of debt and/or equity securities, the Company's cash reserves will be
sufficient to satisfy the Company's working capital requirements for
approximately two to three months. Failure to obtain a third party investment of
the type described above, a bank line of credit or alternative sources of
financing of a comparable amount in the near term will materially adversely
affect the Company's working capital position and financial condition and
results of operations.
CAPITAL EXPENDITURES
The Company's capital expenditures during 1998, 1997 and 1996 were
$1,545,000, $85,000 and $390,000. The increase in capital expenditures in 1998
as compared to prior years is attributable to the implementation of certain
equipment and facility upgrades that had been delayed in prior years due to the
Company's cash conservation measures in those years.
20
YEAR 2000 COMPLIANCE
The Company is aware of issues associated with the programming code in
existing computer systems as the Year 2000 approaches and has undertaken a
compliance program to assess the Company's potential exposure to business
interruptions due to the possible Year 2000 computer software failures,
including necessary remediation and testing. In 1999, the Company installed a
new information system, including hardware and software, which the Company
believes, based on its testing, is Year 2000 compliant.
At this time, the Company is not aware of any material Year 2000 issues
with respect to dealings with third parties, however, the assessment phase of
such risks of third parties is in the early stage of review.
In the event the Year 2000 issues were to disrupt the Company and its
operations, such disruption may have a material impact on the Company and its
results of operations. Given that no significant issues have arisen based on the
assessments to date, the Company has identified a preliminary contingency plan
and is prepared to make necessary corrections to its systems in the event a
problem should occur. The Company will continue to assess the Year 2000
compliance issue on an on-going basis in an effort to resolve any Year 2000
issues in a timely manner.
IMPACT OF INFLATION
The Company believes that inflation did not have a material impact on its
operations for the periods reported. Significant increases in labor, employee
benefits and other expenses could have a material adverse effect on the
Company's performance.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
The response to this item is submitted as a separate section of this Report
commencing on page F-1.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
Not Applicable.
PART III
In accordance with General Instruction G(3) of Form 10-K, the information
called by Item 10, Directors and Executive Officers of the Registrant, Item 11,
Executive Compensation, Item 12, Security Ownership of Certain Beneficial Owners
and Management, and Item 13, Certain Relationships and Related Transactions, of
Part III of this Report is incorporated by reference to the Company's definitive
Proxy Statement for its 1999 Annual Meeting of Shareholders.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
(a) Financial Statements -- See Index to Financial Statements.
(b) Reports on Form 8-K
No reports on Form 8 K were filed during the last quarter of the fiscal
year covered by this Annual Report on Form 10-K.
(c) Exhibits
The following exhibits are included as a part of this Annual Report on Form
10-K or incorporated herein by reference.
21
EXHIBIT
NUMBER DOCUMENT
------- --------
*3.1 Certificate of Incorporation and amendments.
3.2 Restated Bylaws (incorporated by reference to Exhibit 3.1 to
the Registrant's Quarterly Report on Form 10-Q for the
quarter ended June 30, 1993).
*3.3 Restated By-Laws
10.1 Credit Agreement, dated as of December 22, 1992, among the
Registrant and The Chase Manhattan Bank, N.A. (incorporated
by reference to Exhibit 10.1 to the Registrant's Annual
Report on Form 10-K for the year ended December 31, 1992
(the "1992 Form 10-K")).
10.2 Amendment Two, dated as of January 12, 1994, to Credit
Agreement among the Registrant and The Chase Manhattan Bank,
N.A., together with forms of Stock Warrant and Registration
Rights Agreement (incorporated by reference to Exhibit 10.1.
to the Registrant's Annual Report on Form 10-K for the year
ended December 31, 1993 (the "1993 Form 10-K")).
10.3 Amendment Three, dated as of May 31, 1994, to Credit
Agreement among the Registrant and The Chase Manhattan Bank,
N.A. (incorporated by reference to Exhibit 6(a) to the
Registrant's Quarterly Report on Form 10-Q for the quarter
ended March 31, 1994).
10.4 Amendment Four, dated as of July 1994, to Credit Agreement
among the Registrant and The Chase Manhattan Bank, N.A.
(incorporated by reference to Exhibit 6(a) to the
Registrant's Quarterly Report on Form 10-Q for the quarter
ended June 30, 1994).
10.5 Amendment Five, dated as of March 21, 1995, to Credit
Agreement among the Registrant and The Chase Manhattan Bank,
N.A. (incorporated by reference to Exhibit 10.7 to the
Registrant's Current Report on Form 8-K dated March 21, 1995
(the "March 8-K")).
10.5(l) Form of Warrants issued to The Bank of New York, The Chase
Manhattan Bank, N.A. and the Israel Discount Bank
(incorporated by reference to Exhibit 10.5(i) to the
Registrant's Annual Report on Form 10-K for the year ended
December 31, 1995 (the "1995 Form 10-K")).
10.5(2) Letter Agreement, dated July 10, 1995, among Halsey Drug
Co., Inc., The Chase Manhattan Bank, N.A., The Bank of New
York and Israel Discount Bank of New York (incorporated by
reference to Exhibit 6(a) to the Registrant's Quarterly
Report on Form 10-Q for the quarter ended June 30, 1995 (the
"June 10-Q")).
10.5(3) Letter Agreement, dated November 16, 1995, among Halsey Drug
Co., Inc., The Chase Manhattan Bank, N.A., The Bank of New
York and Israel Discount Bank of New York (incorporated by
reference to Exhibit 10.25(iv) to the 1995 10-K).
10.5(4) Amendment 6, dated as of August 6, 1996, to Credit Agreement
among Halsey Drug Co., Inc., The Chase Manhattan Bank, N.A.,
The Bank of New York and Israel Discount Bank of New York
(incorporated by reference to Exhibit 10.1 to Amendment No.
1 to the Registrant's Quarterly Report on Form 10-Q for the
quarter ended June 30, 1996 (the "June 1996 10-Q").
10.5(5) Letter Agreement, dated March 25, 1997 among Halsey Drug
Co., Inc., The Chase Manhattan Bank, as successor in
interest to The Chase Manhattan Bank (National Association),
The Bank of New York and Israel Discount Bank.
10.6 Agreement Regarding Release of Security Interests dated as
of March 21, 1995 by and among the Company, Mallinckrodt
Chemical Acquisition, Inc. and The Chase Manhattan Bank,
N.A. (incorporated by reference to Exhibit 10.9 of the March
8-K).
10.7 Consulting Agreement dated as of September, 1993 between the
Registrant and Joseph F. Limongelli (incorporated by
reference to Exhibit 10.6 to the 1993 Form 10-K).
10.8 Employment Agreement, dated as of January 1, 1993, between
the Registrant and Rosendo Ferran (incorporated by reference
to Exhibit 10.2 to the 1992 Form 10-K).
10.10(1) Halsey Drug Co., Inc. 1984 Stock Option Plan, as amended
(incorporated by reference to Exhibit 10.3 to the 1992 Form
10-K).
10.10(2) Halsey Drug Co., Inc. 1995 Stock Option and Restricted Stock
Purchase Plan (incorporated by reference to Exhibit 4.1 to
the Registrant's Registration Statement on Form S-8, File
No. 33-98396).
10.10(3) Halsey Drug Co., Inc. Non-Employee Director Stock Option
Plan.
|
22
EXHIBIT
NUMBER DOCUMENT
------- --------
10.11 Leases, effective February 13, 1989 and January 1, 1990,
respectively, among the Registrant and Milton J. Ackerman,
Sue Ackerman, Lee Hinderstein, Thelma Hinderstein and
Marilyn Weiss (incorporated by reference to Exhibits 10.6
and 10.7, respectively, to the Registrant's Annual Report on
Form 10-K for the year ended December 31, 1989).
10.12 Lease, effective as of April 15, 1988, among the Registrant
and Milton J. Ackerman, Sue Ackerman, Lee Hinderstein,
Thelma Hinderstein and Marilyn Weiss, and Rider thereto
(incorporated by reference to Exhibit 10.12 to the
Registrant's Annual Report on Form 10-K for the year ended
December 31, 1987).
10.12(l) Lease, as of October 31, 1994, among Registrant and Milton
J. Ackerman, Sue Ackerman, Lee Hinderstein, Thelma
Hinderstein and Marilyn Weiss, together with Modification,
Consolidation and Extension Agreement (incorporated by
reference to Exhibit 10. 12(i) to the 1995 Form 10-K).
10.13 Asset Purchase Agreement dated as of March 21, 1995 among
Mallinckrodt Chemical Acquisition, Inc. ("Acquisition"),
Mallinckrodt Chemical, Inc., as guarantor and the Registrant
(incorporated by reference to Exhibit 10.1 to the March
8-K).
10.14 Toll Manufacturing Agreement for APAP/Oxycodone Tablets
dated as of March 21, 1995 between Acquisition and the
Registrant (incorporated by reference to Exhibit 10.2 to the
March 8-K).
10.15 Capsule ANDA Option Agreement dated as of March 21, 1995
between Acquisition and the Registrant (incorporated by
reference to Exhibit 10.3 to the March 8-K).
10.16 Tablet ANDA Noncompetition Agreement dated as of March 21,
1995 between the Registrant and Acquisition (incorporated by
reference to Exhibit 10.4 to the March 8-K).
10.17 Subordinated Non-Negotiable Promissory Term Note in the
amount of $1,200,00 dated March 21, 1995 issued by the
Registrant to Acquisition (incorporated by reference to
Exhibit 10.5 to the March 8-K).
10.18 Term Note Security Agreement dated as of March 21, 1995
among the Company, Houba, Inc. and Acquisition (incorporated
by reference to Exhibit 10.6 to the March 8-K).
10.19 Amendment dated March 21, 1995 to Subordination Agreement
dated as of July 21, 1994 between Mallinckrodt Chemical,
Inc., Mallinckrodt Chemical Acquisition, Inc., the
Registrant, The Chase Manhattan Bank (National Association),
Israel Discount Bank of New York, The Bank of New York, and
The Chase Manhattan Bank (National Association)
(incorporated by reference to Exhibit 10.8 to the March
8-K).
10.20 Agreement dated as of March 30, 1995 between the Registrant
and Zatpack, Inc. (incorporated by reference to Exhibit
10.10 to the March 8-K).
10.21 Waiver and Termination Agreement dated as of March 30, 1995
between Zuellig Group, W.A., Inc. and Indiana Fine Chemicals
Corporation (incorporated by reference to Exhibit 10.11 to
the March 8-K).
10.22 Convertible Subordinated Note of the Registrant dated
December 1, 1994 issued to Zatpack, Inc. (incorporated by
reference to Exhibit 10.12 to the March 8-K).
10.23 Agreement dated as of March 30, 1995 among the Registrant,
Indiana Fine Chemicals Corporation, Zuellig Group, N.A.,
Inc., Houba Inc., Zetapharm, Inc. and Zuellig Botanical,
Inc. (incorporated by reference to Exhibit 10.13 to the
March 8-K).
10.24 Supply Agreement dated as of March 30, 1995 between Houba,
Inc. and ZetaPharm, Inc. (incorporated by reference to
Exhibit 10.14 to the March 8-K).
10.25 Form of 10% Convertible Subordinated Debenture (incorporated
by reference to Exhibit 6(a) to the June 10-Q).
10.26 Form of Redeemable Common Stock Purchase Warrant
(incorporated by reference to Exhibit 6(a) to the June
10-Q).
10.27 Form of 10% Convertible Subordinated Debenture (incorporated
by reference to Exhibit 4.1 to the Registrant's Current
Report on Form 8-K dated December 4, 1995 (the "December
8-K")).
10.28 Form of Redeemable Common Stock Purchase Warrant
(incorporated by reference to Exhibit 4.2 to the December
8-K).
10.29 Form of 10% Convertible Subordinated Debenture (incorporated
by reference to Exhibit 99 to the June 1996 10-Q).
|
23
EXHIBIT
NUMBER DOCUMENT
------- --------
10.30 Form of Redeemable Common Stock Purchase Warrant
(incorporated by reference to Exhibit 4.1 to Amendment No. 1
to the June 1996 10-Q).
10.31 Form of 5% Convertible Senior Secured Debenture
(incorporated by reference to Exhibit 4.1 to the
Registrant's Current Report on Form 8-K dated March 24, 1998
(the "March 1998 8-K")).
10.32 Form of Common Stock Purchase Warrant (incorporated by
reference to Exhibit 4.2 to the March 1998 8-K).
10.33 Debenture and Warrant Purchase Agreement dated March 10,
1998, by and among the Registrant, Galen Partners III, L.P.
and the other Purchasers listed on the Signature Page
thereto (incorporated by reference to Exhibit 10.1 to the
March 1998 8-K).
10.34 Form of General Security Agreement of Halsey Drug Co., Inc.
dated March 10, 1998 (incorporated by reference to Exhibit
10.2 to the March 1998 8-K).
10.35 Form of Agreement of Guaranty of Subsidiaries of Halsey Drug
Co., Inc. dated March 10, 1998 (incorporated by reference to
Exhibit 10.3 to the March 1998 8-K).
10.36 Form of Guarantor General Security Agreement dated March 10,
1998 (incorporated by reference to Exhibit 10.4 to the March
1998 8-K).
10.37 Stock Pledge Agreement dated March 10, 1998 by and between
the Registrant and Galen Partners III, L.P., as agent
(incorporated by reference to Exhibit 10.5 to the March 1998
8-K).
10.38 Form of Irrevocable Proxy Agreement (incorporated by
reference to Exhibit 10.6 to the March 1998 8-K).
10.39 Agency Letter Agreement dated March 10, 1998 by and among
the Purchasers a party to the Debenture and Warrant Purchase
Agreement, dated March 10, 1998 (incorporated by reference
to Exhibit 10.7 to the March 1998 8-K).
10.40 Press Release of Registrant dated March 13, 1998
(incorporated by reference to Exhibit 99.1 to the March 1998
8-K).
10.41 Current Report on Form 8-K as filed by the Registrant with
the Securities and Exchange Commission on March 24, 1998.
10.42 Letter Agreement between the Registrant and the U.S.
Department of Justice dated March 27, 1998 relating to the
restructuring of the fine assessed by the Department of
Justice under the Plea Agreement dated June 21, 1993.
10.43 Employment Agreement dated as of March 10, 1998 between the
Registrant and Michael K. Reicher.
10.44 Employment Agreement dated as of March 10, 1998 between the
Registrant and Peter Clemens.
*10.45 Amended, Restated and Consolidated Bridge Loan Agreement
dated as of December 2, 1998 between the Company, Galen
Partners III, L.P., Galen Partners International III, L.P.,
Galen Employee Fund III, L.P. and the other signatures
thereto.
*10.46 First Amendment to Amended, Restated and Consolidated Bridge
Loan Agreement dated December 7, 1998 between the Company
and the lenders listed on the signature page thereto.
*10.47 Second Amendment to Amended, Restated and Consolidated
Bridge Loan Agreement dated March 8, 1999 between the
Company and the lenders listed on the signature page
thereto.
*10.48 Form of 10% Convertible Secured Note due May 30, 1999.
*10.49 Form of Common Stock Purchase Warrant issued pursuant to be
Amended, Restated and Consolidated Bridge Loan Agreement.
*10.50 Amended and Restated General Security Agreement dated
December 2, 1998 between the Company and Galen Partners III,
L.P., as Agent.
*10.51 Subordination Agreement dated December 2, 1998 between the
Registrant and Galen Partners III, L.P., as Agent.
*10.52 Agency Letter Agreement dated December 2, 1998 by and among
the lenders a party to the Amended, Restated and
Consolidated Bridge Loan Agreement, as amended.
*10.53 Lease Agreement dated March 17, 1999 between the Registrant
and Par Pharmaceuticals, Inc.
|
24
EXHIBIT
NUMBER DOCUMENT
------- --------
*10.54 Lease Agreement dated September 1, 1998 between the
Registrant and Crimson Ridge Partners.
*10.55 Manufacturing and Supply Agreement dated March 17, 1999
between the Registrant and Par Pharmaceuticals, Inc.
*10.56 Halsey Drug Co., Inc. 1998 Stock Option Plan.
21 Subsidiaries of the Registrant (incorporated by reference to
Exhibit 22 to the 1993 Form 10-K).
*23.1 Consent of Grant Thornton LLP, independent certified public
accountants.
*27 Financial Data Schedule, which is submitted electronically
to the Securities and Exchange Commission for informational
purposes only and not filed.
|
* Filed herewith.
25
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
HALSEY DRUG CO., INC.
By: /s/ MICHAEL REICHER
------------------------------------
Michael Reicher, President and
Chief Executive Officer (Principal
Executive
Officer)
Date: March 31, 1999
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
/s/ WILLIAM G. SKELLY Chairman and Director March 31, 1999
-----------------------------------------------------
William G. Skelly
/s/ MICHAEL REICHER President, Chief Executive March 31, 1999
----------------------------------------------------- Officer and Director
Michael Reicher (Principal Executive
Officer)
/s/ PETER CLEMENS Vice President, Chief March 31, 1999
----------------------------------------------------- Financial Officer
Peter Clemens (Principal Financial and
accounting Officer) and
Director
/s/ ALAN J. SMITH Director March 31, 1999
-----------------------------------------------------
Alan J. Smith
/s/ BRUCE F. WESSON Director March 31, 1999
-----------------------------------------------------
Bruce F. Wesson
/s/ WILLIAM SUMNER Director March 31, 1999
-----------------------------------------------------
William Sumner
/s/ SRINI CONJEEVARAM Director March 31, 1999
-----------------------------------------------------
Srini Conjeevaram
/s/ ZUBEEN SHROFF Director March 31, 1999
-----------------------------------------------------
Zubeen Shroff
|
26
INDEX TO FINANCIAL STATEMENTS
PAGE
----
Report of Independent Certified Public Accountants.......... F-2
Consolidated Balance Sheets................................. F-3
Consolidated Statements of Operations....................... F-4
Consolidated Statement of Stockholders' Equity.............. F-5
Consolidated Statements of Cash Flows....................... F-6
Notes to Consolidated Financial Statements.................. F-8 - F-24
|
F-1
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Board of Directors
Halsey Drug Co., Inc.
We have audited the accompanying consolidated balance sheets of Halsey Drug
Co., Inc. and Subsidiaries as of December 31, 1998 and 1997, and the related
consolidated statements of operations, stockholders' equity and cash flows for
each of the three years in the period ended December 31, 1998. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of Halsey Drug
Co., Inc. and Subsidiaries as of December 31, 1998 and 1997, and the
consolidated results of their operations and their consolidated cash flows for
each of the three years in the period ended December 31, 1998, in conformity
with generally accepted accounting principles.
GRANT THORNTON LLP
New York, New York
March 5, 1999
F-2
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31,
--------------------
1998 1997
-------- --------
(IN THOUSANDS)
CURRENT ASSETS
Cash...................................................... $ 1,850 $ 26
Accounts receivable -- trade, net of allowances for
doubtful accounts of $280 and $542 in 1998 and 1997,
respectively........................................... 1,439 62
Inventories............................................... 6,354 2,456
Prepaid insurance and other current assets................ 148 274
-------- --------
Total current assets.............................. 9,791 2,818
PROPERTY, PLANT AND EQUIPMENT, NET.......................... 4,787 4,630
DEFERRED PRIVATE OFFERING COSTS............................. 1,335 219
-------- --------
$ 15,913 $ 7,667
======== ========
CURRENT LIABILITIES
Notes payable............................................. $ 10,850 $ 4,825
Bank overdraft............................................ 159
Due to banks.............................................. 2,476
Convertible subordinated debentures....................... 2,244
Accounts payable.......................................... 1,834 6,086
Accrued expenses.......................................... 3,972 7,232
Deferred gain............................................. 1,900
Other current liabilities................................. 300 200
-------- --------
Total current liabilities.............................. 16,956 25,122
LONG-TERM DEBT, NET......................................... 26,186
OTHER LIABILITIES........................................... 2,224 2,402
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock -- $.01 par value; authorized, 40,000,000
shares; issued 14,443,212 shares and 14,029,718 shares
in 1998 and 1997, respectively......................... 144 140
Additional paid-in capital................................ 29,113 25,489
Accumulated deficit....................................... (57,221) (44,497)
-------- --------
(27,964) (18,868)
Less treasury stock -- at cost (439,603 shares in 1998 and
1997, respectively).................................... (989) (989)
-------- --------
(28,953) (19,857)
-------- --------
$ 15,913 $ 7,667
======== ========
|
The accompanying notes are an integral part of these statements.
F-3
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEAR ENDED DECEMBER 31,
--------------------------------------
1998 1997 1996
---------- ---------- ----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Net sales.................................................. $ 8,841 $ 9,088 $ 12,379
Cost of goods sold......................................... 12,712 15,406 16,826
-------- -------- --------
Gross margin.......................................... (3,871) (6,318) (4,447)
Research and development................................... 651 979 1,854
Selling, general and administrative expenses............... 8,078 6,308 7,486
-------- -------- --------
Loss from operations.................................. (12,600) (13,605) (13,787)
Interest expense........................................... (1,946) (1,144) (1,708)
Other income (expense)..................................... 1,802 (264) 1,000
-------- -------- --------
NET LOSS.............................................. $ 12,724 $(15,013) $(14,495)
======== ======== ========
Basic loss per common share................................ $ (.92) $ (1.12) $ (1.49)
======== ======== ========
Weighted average number of outstanding shares.............. 13,813 13,434 9,724
======== ======== ========
|
The accompanying notes are an integral part of these statements.
F-4
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 1998, 1997 AND 1996
COMMON STOCK, TREASURY STOCK,
$.01 PAR VALUE ADDITIONAL AT COST
--------------- PAID-IN ACCUMULATED ----------------
SHARES AMOUNT CAPITAL DEFICIT SHARES AMOUNT TOTAL
------ ------ ---------- ----------- ------ ------- --------
(IN THOUSANDS)
Balance at January 1, 1995............. 8,974 $ 90 $14,459 $(14,989) (500) $(1,100) $ (1,540)
Issuance of common stock conversion of
debentures........................... 3,504 35 6,724 6,759
Issuance of shares as settlement....... 60 262 25 56 318
Issuance of warrants with convertible
subordinated debentures.............. 355 355
Exercise of warrants of convertible
debentures........................... 589 6 1,363 1,369
Stock options exercised................ 49 153 153
Net loss for the year ended December
31, 1996............................. (14,495) (14,495)
------ ---- ------- -------- ------ ------- --------
Balance at December 31, 1996........... 13,176 131 23,316 (29,484) (475) (1,044) (7,081)
Issuance of common stock -- conversion
of debentures........................ 643 7 1,529 1,536
Issuance of shares as payment of
interest............................. 69 1 224 225
Sale of treasury stock................. 25 45 35 55 100
Exercise of warrants of convertible
debentures........................... 22 72 72
Stock options exercised................ 95 1 303 304
Net loss for the year ended December
31, 1997............................. (15,013) (15,013)
------ ---- ------- -------- ------ ------- --------
Balance at December 31, 1997........... 14,030 140 25,489 (44,497) (440) (989) (19,857)
Issuance of common stock -- conversion
of notes payable..................... 110 1 213 214
Issuance of shares as payment of
interest............................. 263 3 592 595
Issuance of common stock -- settlement
of trade payables.................... 40 55 55
Deferred debt discount on warrants
issued with convertible debentures... 2,264 2,264
Net loss for the year ended December
31, 1998............................. (12,724) (12,724)
------ ---- ------- -------- ------ ------- --------
Balance at December 31, 1998........... 14,443 $144 $28,613 $(57,221) (440) $ (989) $(29,453)
====== ==== ======= ======== ====== ======= ========
|
The accompanying notes are an integral part of this statement.
F-5
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEAR ENDED DECEMBER 31,
--------------------------------
1998 1997 1996
-------- -------- --------
(IN THOUSANDS)
Cash flows from operating activities
Net loss................................................. $(12,724) $(15,013) $(14,495)
Adjustments to reconcile net loss to net cash used in
operating activities
Depreciation and amortization......................... 1,774 1,733 1,906
Provision for losses on accounts receivable........... (262) 118 144
Provision for loss on investment...................... 500
(Gain) loss on disposal of assets..................... 170 38 (1,000)
Changes in assets and liabilities
Accounts receivable................................. (1,115) 45 1,319
Inventories......................................... (3,898) 1,302 3,958
Prepaid insurance and other current assets.......... 126 165 (96)
Accounts payable.................................... (4,197) 1,851 1,029
Deferred gain....................................... (1,900)
Accrued expenses.................................... (2,665) 4,553 2,913
-------- -------- --------
Total adjustments..................................... (11,967) 9,805 10,673
-------- -------- --------
Net cash used in operating activities................. (24,691) (5,208) (3,822)
-------- -------- --------
Cash flows from investing activities
Capital expenditures..................................... (1,545) (85) (390)
Net proceeds from sale of assets......................... 96
Collection of notes receivable........................... 1,000
-------- -------- --------
Net cash (used in) provided by investing activities... (1,449) 915 (390)
-------- -------- --------
Cash flows from financing activities
Proceeds from issuance of notes payable.................. $ 6,495 $ 3,881 $ 25
Proceeds from issuance of common stock................... 318
Reissuance of treasury stock............................. 70
Payments to Department of Justice........................ (178)
Bank overdraft........................................... (159) (127) 73
Due to banks............................................. (2,476)
Payments to minority stockholders........................ (206)
Proceeds from issuance of convertible subordinated
debentures............................................ 25,800 2,500
Proceeds from exercise of stock options and warrants..... 305 153
Proceeds from exercise of warrants....................... 72 1,369
Deferred private offering costs.......................... (1,518) (255)
-------- -------- --------
Net cash provided by financing activities............. 27,964 4,201 3,977
-------- -------- --------
NET (DECREASE) INCREASE IN CASH AND CASH
EQUIVALENTS......................................... 1,824 (92) (235)
Cash and cash equivalents at beginning of year............. 26 118 353
-------- -------- --------
Cash and cash equivalents at end of year................... $ 1,850 $ 26 $ 118
======== ======== ========
|
F-6
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS -- (CONTINUED)
YEAR ENDED DECEMBER 31,
(IN THOUSANDS)
Supplemental disclosures of noncash activities:
Year ended December 31, 1998
1. The Company issued 262,836 shares of common stock as payment for
$593,313 in accrued interest.
2. The Company reissued 20,000 shares of common stock as payment for
$25,000 in legal fees and 20,000 shares of common stock as payment for
$30,000 in trade payables.
3. The Company issued 110,658 shares of common stock as payment of
outstanding notes payable in amounts of $214,000 and $1,782 in accrued
interest.
4. The Company issued approximately 4,202,020 warrants (Note A) and
1,009,909 warrants (Note A) valued and recorded in aggregate as
$3,118,000 of unamortized debt discount and a reduction in the related
amount of the obligation.
Year ended December 31, 1997
1. The Company issued 642,407 shares of common stock to Zatpack, Inc. as
payment for an outstanding note payable in the amount of $1,536,000.
2. The Company reissued 25,000 shares of treasury stock as payment for
$30,000 in consulting fees and the receipt of $70,000 in cash.
3. The Company issued 25,000 shares of common stock as payment for
$225,452 in accrued interest.
4. The Company recorded the satisfaction of $1,400,000 of subordinated
promissory notes, related accrued interest of $200,000 and accounts
payable of $300,000 due to Mallinckrodt, in lieu of Mallinckrodt paying
$1,900,000 owed to the Company as described in Note E.
Year ended December 31, 1996
1. The issuance of 3,504,000 shares of the Company's common stock upon
conversion of $6,759,000 of convertible subordinated debentures is
included in common stock and additional paid-in capital.
2. The valuation of the warrants issued in 1996 of $355,000 with
convertible subordinated debentures is included in additional paid-in
capital.
3. The issuance in 1996 of 59,550 shares of the Company's common stock is
valued at $318,000 in connection with litigation settlements.
The accompanying notes are an integral part of these statements.
F-7
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1998, 1997 AND 1996
NOTE A -- SUMMARY OF ACCOUNTING POLICIES
Halsey Drug Co., Inc. (the "Company"), a New York-based corporation
established in 1935, and its subsidiaries are engaged in the manufacture, sale
and distribution of generic drugs. The Company sells its generic drug products
under its Halsey label and under private-label arrangements with drug store
chains and drug wholesalers throughout the United States.
A summary of the significant accounting policies consistently applied in
the preparation of the accompanying consolidated financial statements follows.
1. Principles of Consolidation and Basis of Presentation
The consolidated financial statements include 100% of the accounts of the
Company and its wholly-owned subsidiaries, Blue Cross Products Co., Inc., Houba,
Inc., Halsey Pharmaceuticals, Inc., and Indiana Fine Chemicals Corporation, The
Medi-Gum Corporation (100% owned). The Medi-Gum Corporation and Halsey
Pharmaceuticals have not commenced operations. All material intercompany
accounts and transactions have been eliminated.
2. Liquidity Matters
As of December 31, 1998, the Company has a working capital deficiency of
approximately $6,665,000, has an accumulated deficit of approximately
$57,221,000 and has incurred a loss of approximately $12,724,000 for the year
then ended.
On March 10, 1998, the Company completed a private offering (the
"Offering") of securities to an investor group ("Galen") consisting of 5%
convertible senior secured debentures due March 15, 2003, and common stock
purchase warrants (with a 5 year life) exercisable for 2,101,010 shares of the
Company's common stock at an exercise price of $1.50 and 2,101,010 shares at an
exercise price of $2.375. The unamortized discount resulting from the issuance
of such warrants ($2,618,000) has Been recorded as a reduction of the related
obligation. The net proceeds to the Company from the Offering, after the
deduction of related offering expenses, was approximately $19.6 million. In
addition, in accordance with the terms of the private offering, during June
1998, Galen invested an additional $5 million in the Company in exchange for
debentures and warrants having terms identical to those issued in the Offering.
The net proceeds from the Offering and the additional investment have
primarily been used to satisfy a substantial portion of the Company's
liabilities and accounts payable. Such liabilities include the full satisfaction
of the Company's bank indebtedness and related fees, payment to the landlord of
the Brooklyn facility and satisfaction of outstanding judgments and liens.
Further, pursuant to agreements reached with other large creditors in
anticipation of the completion of the offering, including the Company's landlord
and the Department of Justice ("DOJ"), the Company has been able to bring these
creditors current and bring the Company in compliance with installment payment
agreements providing more favorable terms to the Company. The offering proceeds
also allowed the Company to satisfy its outstanding state and Federal payroll
tax obligations and meet current payroll tax obligations. The net proceeds from
the exercise of the option were used to fund working capital, including the
purchase of raw materials, payroll expenses and other Company expenses.
The Company secured bridge financing from Galen and certain investors in
the Offering in the aggregate amount of $9,504,111, funded through seven
separate bridge loan transactions between the period from August through and
including December 1998, as well as an additional bridge loan in March 1999
(collectively, the "Bridge Loans"). The Bridge Loans were consolidated on
December 2, 1998 pursuant to an Amended, Restated and Consolidated Bridge Loan
Agreement, as amended to permit the March 1999 bridge loan (the "Consolidated
Bridge Loan"). The Consolidated Bridge Loan bears interest at 10% per annum, is
F-8
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
secured by a first lien on all of the Company's assets and has a maturity date
of May 30, 1999. Approximately $9,120,000 in the principal amount of the
Consolidated Bridge Loan was advanced by Galen with the balance of approximately
$384,000 advanced by certain investors in the Offering. The Consolidated Bridge
Loan is evidenced by 10% convertible senior secured promissory notes which are
convertible at any time prior to maturity into shares of the Company's Common
Stock at a conversion price of approximately $1.368 per share with respect to
approximately $7,820,000 of such indebtedness, $1.331 per share with respect to
approximately $284,000 of such indebtedness, and $1.197 per share with respect
to approximately $1,400,000 of such indebtedness, for an aggregate of 7,099,338
shares of common stock (such conversion prices equal the fair market value of
the Common Stock at the date of issuance of the convertible promissory notes).
In addition, in consideration for the initial extension of the Bridge Loans and
the extension of the maturity dates of the Bridge Loans pursuant to the
consolidation of such loans on December 2, 1998, as amended to permit the March
1999 bridge loan, the Company issued common stock purchase warrants to Galen and
the other investors in the Consolidated Bridge Loan, to purchase an aggregate of
approximately 1,009,909 shares of the Company's common stock (representing
warrants to purchase 50,000 shares of Common Stock for each $1,000,000 in
principal amount of Bridge Loan having a term of 90 days from the date of the
making of the Bridge Loan). The unamortized discount resulting form the issuance
of such warrants ($500,000) has been recorded as a reduction of the related
obligation. The Bridge Loan warrants are substantially identical to those issued
by the Company in its Debenture and Warrant Offering completed on March 10,
1998.
The Consolidated Bridge Loan was obtained by the Company in order to
provide necessary working capital. In view of the Company's current cash
reserves and projections for revenues through May 30, 1999, the Company will be
unable to satisfy the Consolidated Bridge Loan in full at the stated maturity
date of May 30, 1999. Galen, the holder of approximately 96% of such
indebtedness, has indicated to the Company a willingness to cooperate in the
restructuring of the indebtedness evidenced by the Consolidated Bridge Loan to
extend the maturity date of such debt and/or convert the debt into common stock
or longer-term convertible indebtedness. The terms of such restructuring will
depend, to a large extent, on the terms and timing of any third-party
investment, as described below. Accordingly, the terms of any such restructuring
have yet to be agreed to by the parties and will be subject to the negotiation
and preparation of definitive agreements.
The Company is in preliminary discussions with an unaffiliated third party
concerning the terms of a proposed investment in the Company in an amount of up
to $15 million, to be funded in three equal increments based on the achievement
of certain milestones. The structure of the investment will likely take the form
of convertible debentures and common stock purchase warrants, similar in many
respects to the debentures and warrants issued by the Company in its March 10,
1998 offering. The discussions with this third-party investor are in the
preliminary stages and no assurance can be given that final terms acceptable to
the Company will result and/or that if consummated, that the Company will be
successful in achieving the milestones necessary to fund all or any portion of
the proposed investment.
In the event the Company is successful in restructuring the Consolidated
Bridge Loan and completing the third-party investment of the type and size
described above, the Company will have sufficient cash reserves to satisfy its
working capital requirements for at least the next twelve months. The Company is
also seeking to secure a senior revolving line of credit from a banking
institution. There can be no assurance, however, that the Company will be able
to obtain such third-party investment or a bank facility. If the Company is
unable to complete the third-party investment described above or obtain other
sources of working capital, including a bank line of credit or proceeds from the
issuance of debt and/or equity securities, the Company's cash reserves will be
sufficient to satisfy the Company's working capital requirements for
approximately two to three months. Failure to obtain a third-party investment of
the type described above, a bank line of credit or alternative sources of
financing of a comparable amount in the near term will materially adversely
affect the Company's working capital position and financial condition and
results of operations.
F-9
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
3. Inventories
Inventories are stated at the lower of cost or market; cost is determined
using the first-in, first-out method.
4. Property, Plant and Equipment
Property, plant and equipment are stated at cost less accumulated
depreciation and amortization. Depreciation and amortization are provided for in
amounts sufficient to relate the cost of depreciable assets to operations over
their estimated service lives, principally on a straight-line basis. The
estimated lives used in determining depreciation and amortization are:
Buildings................................................... 25 years
Machinery and equipment..................................... 5-10 years
Leasehold improvements...................................... 5-10 years
|
Leasehold improvements are amortized over the lives of the respective
leases or the service lives of the improvements, whichever is shorter.
5. Income Taxes
The Company accounts for income taxes utilizing an asset liability method
for financial accounting and reporting for income taxes. Under this method,
deferred tax assets and liabilities are determined based on differences between
financial reporting and tax bases of assets and liabilities and are measured
using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse.
6. Statements of Cash Flows
For purposes of the statements of cash flows, the Company considers all
highly liquid debt instruments purchased with an original maturity of three
months or less to be cash equivalents. The Company paid no substantial income
taxes for the years ended December 31, 1998, 1997 and 1996. In addition, the
Company paid interest of approximately $1,946,000, $1,113,000, $1,173,000,
respectively, for the years ended December 31, 1998, 1997 and 1996.
7. Use of Estimates in Consolidated Financial Statements
In preparing consolidated financial statements in conformity with generally
accepted accounting principles, management makes estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the consolidated financial
statements, as well as the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
8. Research and Development Costs
All research and development costs, including payments related to licensing
agreements on products under development and research consulting agreements are
expensed when incurred.
9. Impairment of Long-Lived Assets
The Company reviews long-lived assets and certain identifiable intangibles
held and used for possible impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable (Note I).
F-10
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
10. Stock-Based Compensation
The Company accounts for stock-based compensation under Statement of
Financial Accounting Standards No. 123 ("SFAS No. 123"), "Accounting for
Stock-Based Compensation," and continues to apply APB Opinion No. 25,
"Accounting for Stock Issued to Employees," and related interpretations in
accounting for its plans and does not recognize compensation expense for its
stock-based compensation plans other than for restricted stock (Note K).
Equity instruments issued to nonemployees in exchange for goods and/or
services are accounted for under the fair value method of SFAS No. 123.
11. New Pronouncements
Earnings (Loss) Per Share
In 1997, the Company adopted Statement of Financial Accounting Standards
No. 128 ("SFAS No. 128"), "Earnings Per Share," which requires public companies
to present basic earnings (loss) per share and, if applicable, diluted earnings
per share. All comparative periods have been restated in accordance with SFAS
No. 128.
The computation of basic earnings (loss) per share of common stock is based
upon the weighted average number of common shares outstanding during the period.
Diluted earnings per share is equal to basic earnings per share for all years
presented as the effect of other potentially dilutive securities would be
antidilutive.
Reporting Comprehensive Income
In June 1997, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards No. 130 ("SFAS No. 130"), "Reporting
Comprehensive Income," which is effective for the Company's year ended December
31, 1998. The statement addresses the reporting and displaying of comprehensive
income and its components. Earnings per share is only reported for net income
and not for comprehensive income and its components. At December 31, 1998, 1997
and 1996, the Company had no items of other comprehensive income.
12. Reclassifications
Certain reclassifications have been made to the 1997 and 1996 presentations
to conform to the 1998 presentation.
NOTE B -- FAIR VALUE OF FINANCIAL INSTRUMENTS
Long-term and Short-term Debt and Convertible Subordinated Debentures
The fair value of the Company's long-term and short-term debt and
convertible subordinated debentures is estimated based upon the quoted market
prices for the same or similar issues or on the current rates offered to the
Company for debt of the same outstanding maturities. Accordingly, the carrying
amount of these financial instruments approximates their fair value at December
31, 1998 and 1997.
F-11
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
NOTE C -- INVENTORIES
Inventories consist of the following:
DECEMBER 31,
----------------
1998 1997
------ ------
(IN THOUSANDS)
Finished goods.............................................. $2,675 $ 789
Work-in-process............................................. 1,166 263
Raw materials............................................... 2,513 1,404
------ ------
$6,354 $2,456
====== ======
|
NOTE D -- PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are summarized as follows:
DECEMBER 31,
------------------
1998 1997
------- -------
(IN THOUSANDS)
Machinery and equipment..................................... $12,278 $11,478
Leasehold improvements...................................... 6,103 5,967
Building.................................................... 747 997
Land........................................................ 44 265
------- -------
19,172 18,707
Less accumulated depreciation and amortization.............. 14,385 14,077
------- -------
$ 4,787 $ 4,630
======= =======
|
Depreciation expense for the years ended December 31, 1998, 1997 and 1996
was approximately $1,122,000, $1,640,000, and $1,562,000, respectively.
NOTE E -- DEBT
Due to Banks
At December 31, 1997 the Company had $2,476,000 under a line of credit
agreement with three participating banks for which the average borrowing rate
for the year then ended was 11.9 %. The agreement contained certain financial
covenants, for which the Company was not in compliance at December 31, 1997.
During March 1998, the Company completely satisfied its bank indebtedness and
terminated the line of credit agreement with its banks.
Notes Payable
At December 31, 1998 and 1997, notes payable consisted of the following:
DECEMBER 31,
-----------------
1998 1997
------- ------
(IN THOUSANDS)
Unsecured promissory demand notes........................... $ 2,817
Subordinated promissory notes............................... $4,825
Bridge Loans (Note A)....................................... 7,533
------- ------
$10,350 $4,825
======= ======
|
F-12
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
During 1997, the Company borrowed from and issued to several debenture
holders and shareholders unsecured, demand promissory notes in the amount of
$1,125,000, bearing interest at 12% per annum, with interest payable quarterly.
These notes were paid in full in 1998.
During the period from May 1997 through July 1997, the Company borrowed
approximately $3 million from Mylan Laboratories, Inc. ("Mylan") pursuant to
five unsecured, demand promissory notes. The advances made by Mylan
Laboratories, Inc. were part of a proposed investment by Mylan in the Company,
including the proposed purchase of the Company's Houba Indiana facility as well
as a partial tender offer for the Company's common stock. The Company used the
proceeds of these borrowings for working capital. To date, $236,000 has been
paid by the Company to Mylan against such indebtedness in the form of product
deliveries to Mylan. Pursuant to an agreement reached between the parties, the
Company is required to satisfy interest on the outstanding indebtedness on an
annual basis while the indebtedness remains outstanding and to satisfy the
principal amount of such indebtedness in the form of product deliveries to Mylan
until such time as the indebtedness is satisfied in full. In 1998, the Company,
in exchange for extending the loan, agreed to grant a warrant to purchase 50,000
shares of the Company's common stock at a price of $1.94 per share.
Additionally, the Company began reducing the loan by supplying product to Mylan.
At December 31, 1998, the loan balance was $2,817,000.
During the fourth quarter of 1997, the Company received $500,000 from an
investor of a proposed joint venture, a demand promissory note bearing interest
at 10% per annum which was secured by the property of Houba. In addition, as
part of a proposed financing agreement, the Company received $200,000 as a
promissory note bearing interest at 8% per annum during the fourth quarter of
1997. Both of these promissory notes were paid in full in 1998.
NOTE F -- CONVERTIBLE SUBORDINATED DEBENTURES AND STOCK WARRANTS
In connection with certain 1995 amendments to the line of credit agreement
described in Note E, the Company issued stock warrants to the bank, expiring
July 17, 2000, to purchase up to 699,696 shares of the Company's common stock at
exercise prices ranging from $1.98 to $2.07 per share. The fair value of the
warrants, $200,000, as determined by the Company's Board of Directors, was
recorded by the Company in 1994 as additional paid-in capital and a discount to
bank debt which was fully amortized through the maturity date, August 31, 1995.
On July 18, 1995, the Company issued 408 units, at $10,000 per unit, in a
private placement of its securities ("July Private Placement"). Each unit
consisted of: (i) a 10% convertible subordinated debenture due July 18, 2000 in
the principal amount of $10,000, interest payable quarterly, and convertible
into shares of the Company's common stock at a conversion price of $2.00 per
share, subject to antidilution provisions, and (ii) 750 redeemable common stock
purchase warrants ("warrants"). Each warrant entitled the holder to purchase one
share of common stock for $2.00, subject to adjustment during the five-year
period commencing July 18, 1995. The warrants were redeemable by the Company at
a price of $.01 per warrant at any time commencing July 18, 1996, provided that
at July 18, 1996, the fair market value of the Company's common stock equals or
exceeds $2.00 per share for the 20 consecutive trading days ending on the third
day prior to the notice of redemption to the holders of the warrant. The
debentures were converted into 2,040,000 shares of common stock in August 1996.
On November 29, 1995, the Company issued 366 units, at $10,000 per unit, in
a private placement of its securities ("November Private Placement"). Each unit
consisted of (i) a 10% convertible subordinated debenture due November 29, 2000
in the principal amount of $10,000, interest payable quarterly, and convertible
into shares of the common stock, at a conversion price of $2.50 per share,
subject to dilution, and (ii) 600 redeemable common stock purchase warrants. The
terms and conditions of the warrants issued in connection with the November
Private Placement are similar to those issued in the July Private Placement,
F-13
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
except that the exercise price of the warrant pursuant to the November Private
Placement is $2.50 per share. These debentures were converted into 1,464,000
shares of common stock in December 1996.
On August 6, 1996, the Company issued 250 units, at $10,000 per unit, in a
private placement of its securities ("August Private Placement"). Each unit
consisted of: (i) a 10% convertible subordinated debenture due August 6, 2001 in
the principal amount of $10,000, interest payable quarterly, and convertible
into shares of the Company's common stock at a conversion price of $3.25 per
share, subject to dilution, and (ii) 750 redeemable common stock purchase
warrants ("warrants"). Each warrant entitled the holder to purchase one share of
common stock for $3.25, subject to adjustment during the five-year period
commencing August 6, 1996. Pursuant to the agreement, the Company was required
to establish an escrow account to repay interest in the outstanding convertible
debenture, which was fully paid during 1997.
NOTE G -- ACCRUED EXPENSES
Accrued expenses are summarized as follows:
DECEMBER 31,
----------------
1998 1997
------ ------
(IN THOUSANDS)
Payroll taxes payable (Note H).............................. $1,714 $3,290
Interest.................................................... 619 1,018
Professional fees........................................... 539 537
Accrued pension and welfare................................. 15 501
Medicaid rebates payable.................................... 169 481
Accrued payroll............................................. 92 420
Directors' fees............................................. 126 90
New York State Department of Education...................... 140 134
Medical claims.............................................. 149
Commissions................................................. 30 42
Property taxes.............................................. 94
Accrued chargeback liability................................ 40
Accrued equipment purchase.................................. 56
Other....................................................... 189 719
------ ------
$3,972 $7,232
====== ======
|
At December 31, 1998, payroll taxes payable include approximately
$1,373,000 and $275,000 of delinquent payroll taxes (including penalties and
interest) due to the Internal Revenue Service and the State of New York,
respectively, all of which liability was incurred in 1997 and 1996. The Company
expects that the Federal liability will be substantially offset by income tax
refund claims which were filed and are pending before the IRS. Until such time
as the IRS completes its review, the Company has not recorded any expected tax
refund claims. The Company has negotiated a payment plan with the State of New
York and the balance will be paid by the end of 1999.
F-14
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
NOTE H -- INCOME TAXES
The actual income tax expense varies from the Federal statutory rate
applied to consolidated operations as follows:
YEAR ENDED DECEMBER 31,
--------------------------------------------------------
1998 1997 1996
---------------- ---------------- ----------------
AMOUNT % AMOUNT % AMOUNT %
------- ----- ------- ----- ------- -----
(IN THOUSANDS)
Federal statutory rate............... $(4,326) (34.0)% $(5,105) (34.0)% $(4,928) (34.0)%
Loss for which no tax benefit was
provided........................... 4,247 33.8 4,924 32.8 4,233 29.1
Losses of subsidiaries with no tax
benefit............................ 424 3.0
Amortization of Warrants............. 24 .2 32 .2
Goodwill amortization................ 12 .1 73 .5
Department of Justice settlement..... 42 .1 57 .4
Other................................ 37 .1 145 .9 109 .8
------- ----- ------- ----- ------- -----
Actual tax expense................... $ -- --% $ -- --% $ -- --%
======= ===== ======= ===== ======= =====
|
The Company has net operating loss carryforwards aggregating approximately
$45,572,700, expiring during the years 2011 through 2018. In addition, certain
of the Company's subsidiaries filed separate Federal income tax returns in prior
years and have separate net operating loss carryforwards aggregating
approximately $4,062,758 expiring during the years 1999 through 2018.
The tax loss carryforwards of the Company and its subsidiaries are subject
to limitation by Section 382 of the Internal Revenue Code with respect to the
amount utilizable each year. This limitation reduces the Company's ability to
utilize net operating loss carryforwards included above each year. The amount of
the limitation has not been quantified by the Company.
F-15
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The components of the Company's deferred tax assets (liabilities), pursuant
to SFAS No. 109, are summarized as follows:
DECEMBER 31,
--------------------
1998 1997
-------- --------
(IN THOUSANDS)
Deferred tax assets
Net operating loss carryforwards.......................... $ 21,831 $ 15,125
Allowance for doubtful accounts........................... 75 304
Research and development tax credit....................... 212 212
Reserve for inventory..................................... 169 886
Litigation settlement..................................... 73 195
Rent...................................................... 231 172
Reserve for Medicaid...................................... 71 209
Capital loss carryforwards................................ 210
Reserve for property, plant and equipment................. 111
Other..................................................... 15 24
-------- --------
Gross deferred tax assets.............................. 22,677 17,448
-------- --------
Deferred tax liabilities
Depreciation.............................................. (332) (828)
Installment sale gain..................................... (798)
Other..................................................... (42) (42)
-------- --------
(374) (1,668)
-------- --------
Net deferred tax assets before valuation allowance..... 22,303 15,780
Valuation allowance......................................... (22,303) (15,780)
-------- --------
Net deferred tax assets................................ $ -- $ --
======== ========
|
SFAS No. 109 requires a valuation allowance against deferred tax assets if,
based on the weight of available evidence, it is more likely than not that some
or all of the deferred tax assets may not be realized. The valuation allowance
at December 31, 1998 primarily pertains to uncertainties with respect to future
utilization of net operating loss carryforwards.
NOTE I -- OTHER INCOME (EXPENSE)
Cessation of California Operations
During 1997, management decided to shut down its California operations
which comprised two of its subsidiaries, Cenci Powder Products, Inc. and H.R.
Cenci Laboratories, Inc. The Company had not incurred any significant costs to
exit these operations other than minimal vacation compensation and salary paid
to a former plant employee to manage the exit process. Continuing operating
losses and the inability to leverage the manufacturing capacity were among
factors considered by the Board and Management in their determination to cease
such operations.
At December 31, 1997, the net assets of H.R. Cenci Laboratories, Inc.,
consisted primarily of building, equipment and land with a net carrying value of
$528,000 and inventory with a total net carrying value of $93,000. Accordingly,
during 1997 the Company recorded a charge of $264,000 to reduce the fixed assets
to their then estimated net realizable value, and a $93,000 charge to write off
the remaining inventory. In 1998,
F-16
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
the Company disposed of the remaining assets and recorded a charge of $191,000.
For the years ended December 31, 1998, 1997 and 1996, these subsidiaries, in
aggregate, accounted for revenues of approximately $160,000, $495,000, and
$290,000, respectively.
On March 30, 1998, the Company completed the sale of substantially all of
the non-real property assets of Cenci Powder Products to Zuellig Botanical. The
purchase price for the assets consisted of the forgiveness by Zuellig Botanical
of approximately $262,000 in indebtedness owed by Cenci Powder to Zuellig
Botanical related to the purchase of raw materials. The Agreement provided
further that Zuellig Botanical would satisfy the manufacture and delivery
requirements of Cenci Powder at its facility located at Fresno, California,
under an existing third party supply contract.
Sale of Assets
On March 21, 1995, the Company sold its Abbreviated New Drug Application
("ANDA") for 5mg Oxycodone HCL/325mg Acetaminophen Tablets ("Tablets") and
certain equipment used in the production of the Tablets for up to $5.4 million
to Mallinckrodt. The Company received $500,000 of the proceeds in July 1994,
which was recorded as deferred income on the Company's 1994 consolidated balance
sheet. Mallinckrodt also paid the Company $2,000,000 on March 21, 1995 and the
remainder was to be payable as follows: (i) $1,000,000 upon the Company
receiving general clearance from the FDA for unrestricted operations at its
Brooklyn facility and written notice from the FDA that it is in compliance with
certain provisions of the consent degree dated June 29, 1993 and (ii) $1,900,000
at the earlier of (a) Mallinckrodt receiving certain authorizations from the FDA
or (b) September 21, 1997. Mallinckrodt also agreed to defer $1,200,000 of the
Company's trade debt due to an affiliate of Mallinckrodt (Note E). Pursuant to
the release of the Company from the FDA's Application Integrity Policy list and
its Restrictions (collectively, the "AIP") by the FDA on December 19, 1996, the
Company recorded a gain of $1,000,000. On January 9, 1997, Mallinckrodt tendered
this amount to the Bank Group. Pursuant to the agreement of September 21, 1997,
the Company recorded $1,900,000 as a deferred gain which was recognized on March
21, 1998.
In connection with the agreement, the Company agreed to manufacture Tablets
for Mallinckrodt for a period of three years and Mallinckrodt agreed to order a
minimum number of Tablets from the Company for two years ending March 21, 1997.
The Company and Mallinckrodt entered into a noncompetition agreement pursuant to
which the Company agreed not to compete with Mallinckrodt and its affiliates
with respect to the Tablets until March 21, 2000.
NOTE J -- PENSION EXPENSE
1. Management Pension Plan
The Company had maintained a defined benefit plan covering substantially
all nonunion employees which was terminated in November 1996. Subsequently, all
Plan assets were converted to cash and held in a money market fund (to continue
the Trust) from which all vested participant interests were to be paid. Based on
information provided by the Company's actuary, the total liability of the Plan
as of the plan year ended November 30, 1997 was $398, 281. The actuary
determined that this amount was sufficient to pay the vested interests of all of
the participants who were in the Plan as of November 30, 1996, and for any
participants who had terminated with previously vested interests that had not
yet been paid. Included in the Plan's assets as of November 30, 1997, were
receivables from the Company and the Insurer for $54,631 and $57,468,
respectively, which were subsequently paid in March 1998. No additional
contributions were required to be paid to the Trust for the period ended
November 30, 1997.
In 1998 the Company received approval to terminate the Plan by the Pension
Benefit Guarantee Corporation, all assets were distributed to the vested
participants, the Trust was terminated and a final filing was made with the
Internal Revenue Service.
F-17
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
2. Employees' Pension Plan
The Company contributed approximately $421,000, $407,000, and $492,000 in
1998, 1997 and 1996, respectively, to a multiemployer pension plan for employees
covered by collective bargaining agreements. This plan is not administered by
the Company and contributions are determined in accordance with provisions of
negotiated labor contracts. Information with respect to the Company's
proportionate share of the excess, if any, of the actuarially computed value of
vested benefits over the total of the pension plan's net assets is not available
from the plan's administrator.
The Multiemployer Pension Plan Amendments Act of 1980 (the "Act")
significantly increased the pension responsibilities of participating employers.
Under the provision of the Act, if the plans terminate or the Company withdraws,
the Company could be subject to a "withdrawal liability."
NOTE K -- STOCK OPTION PLAN
In June 1998, the stockholders of the Company approved the adoption of a
stock option and restricted stock purchase plan (the "1998 Option Plan"). The
1998 Option Plan replaces the 1995 Option Plan which was terminated in 1998. The
1998 Option Plan provides for the granting of (i) nonqualified options to
purchase the Company's common stock at not less than the fair market value on
the date of the option grant, (ii) incentive stock options to purchase the
Company's common stock at not less than the fair market value on the date of the
option grant and (iii) rights to purchase the Company's common stock on a
"Restricted Stock" basis, as defined, at not less than the fair market value on
the date the right is granted. As of December 31, 1998, there was no exercise of
rights to purchase any common stock on a restricted stock basis. The total
number of shares which may be sold pursuant to options and rights granted under
the 1998 Option Plan is 2,600,000. No option can be granted under the 1998
Option Plan after April, 2008 and no option can be outstanding for more than ten
years after its grant.
The Company has adopted the disclosure provisions of Statement of Financial
Accounting Standards No. 123 ("SFAS No. 123"), "Accounting for Stock-Based
Compensation." It applies APB Opinion No. 25, "Accounting for Stock Issued to
Employees," and related interpretations in accounting for its plans and does not
recognize compensation expense for its stock-based compensation plans other than
for restricted stock. If the Company had elected to recognize compensation
expense based upon the fair value at the grant date for awards under these plans
consistent with the methodology prescribed by SFAS No. 123, the Company's net
income and earnings per share would be reduced to the pro forma amounts
indicated below:
YEAR ENDED DECEMBER 31,
--------------------------------------
1998 1997 1996
---------- ---------- ----------
(THOUSANDS, EXCEPT PER SHARE AMOUNTS)
Net loss
As reported...................................... $(12,724) $(15,013) $(14,495)
Pro forma........................................ (13,663) (15,323) (14,180)
Loss per share
As reported...................................... $ (.92) $ (1.12) $ (1.49)
Pro forma........................................ (.98) (1.14) (1.46)
|
These pro forma amounts may not be representative of future disclosures
because they do not take into effect pro forma compensation expenses related to
grants made before 1995. The fair value of these options was estimated at the
date of grant using the Black-Scholes option-pricing model with the following
weighted average assumptions for the years ended December 31, 1998, 1997 and
1996, respectively: expected volatility of 67%, 65%, and 82% ; risk-free
interest rates of 5.6%, 6.0%, and 6.6% ; and expected lives of 10 years, 4 years
and 4.6 years. At the date of grant, all exercise prices equaled the market
value of the stock.
F-18
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options which have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected stock price
volatility. Because the Company's employee stock options have characteristics
significantly different from those of traded options, and because changes in the
subjective input assumptions can materially affect the fair market estimate, in
management's opinion, the existing models do not necessarily provide a reliable
single measure of the fair value of its employee stock options.
Transactions involving stock options are summarized as follows:
WEIGHTED WEIGHTED
STOCK AVERAGE AVERAGE
OPTIONS EXERCISE FAIR
OUTSTANDING PRICE VALUE
----------- -------- --------
Balance at January 1, 1996........................... 600,500 $3.49
Granted.............................................. 126,000 4.77
Exercised............................................ (49,159) 3.12
Cancelled............................................ (21,334) 4.39
---------
Balance at December 31, 1996......................... 656,007 3.53
Exercised............................................ (89,300) 3.22 $3.39
Cancelled............................................ (84,968) 5.16 3.39
---------
Balance at December 31, 1997......................... 481,739 3.60
=========
Granted.............................................. 2,254,850 2.37 1.71
Cancelled............................................ (511,303) 3.16 2.08
---------
Balance at December 31, 1998......................... 2,225,286 2.46
=========
|
The following table summarizes information concerning currently outstanding
and exercisable stock options:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
--------------------------------------- -------------------------
WEIGHTED
NUMBER AVERAGE WEIGHTED NUMBER WEIGHTED
OUTSTANDING AT REMAINING AVERAGE EXERCISABLE AT AVERAGE
RANGES OF DECEMBER 31, CONTRACTUAL EXERCISE DECEMBER 31, EXERCISE
EXERCISE PRICES 1998 LIFE PRICE 1998 PRICE
--------------- -------------- ----------- -------- -------------- --------
$1.19 - $2.00 70,000 8.10 $1.55 20,000 $1.97
2.01 - 3.00 2,025,350 9.19 2.40 348,750 2.38
3.01 - 4.88 129,936 7.32 3.86 80,036 3.74
--------- -------
2,225,286 448,786
========= =======
|
NOTE L -- COMMITMENTS
The Company occupies plant and office facilities under noncancellable
operating leases which expire in December 2005. These operating leases provide
for scheduled base rent increases over the term of the lease, however, the total
amount of the base rent payments will be charged to operations using the
straight-line method over the term of the lease. The leases provide for payment
of real estate taxes based upon a percentage of the annual increase. In
addition, the Company rents certain equipment under operating leases, generally
for terms of four years. Total rent expense for the years ended December 31,
1998, 1997 and 1996 was approximately $1,243,000, $884,000 and $659,000,
respectively.
F-19
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
As of December 31,1998, the approximate minimum rental commitments under
these operating leases are as follows:
(IN THOUSANDS)
Twelve months ending December 31,
1999......................................... $1,023
2000......................................... 1,075
2001......................................... 1,128
2002......................................... 1,186
2003 and thereafter.......................... 3,921
------
Total minimum payments required........... $8,333
======
|
Employment Contracts
During March 1998, the Company entered into employment contracts with each
of two new officers/employees of the Company which cover a five-year and a
three-year period, respectively. The contracts provide for, among other things:
(i) annual salaries of $170,000 and $140,000 to be paid over the five-year and
three-year periods, respectively and (ii) an aggregate of 1,300,000 options
(included in the 1998 grants -- Note K) to purchase the Company's stock at an
exercise price of $2.38 per common share that vest evenly over a
three-to-five-year service period and expire in ten years.
NOTE M -- CONTINGENCIES
The Company currently is a defendant in several lawsuits involving product
liability and other claims. The Company's insurance carriers have assumed the
defense for all product liability and other actions involving the Company. None
of the lawsuits is brought as a class action. The ultimate outcome of these
lawsuits cannot be determined at this time, and accordingly, no adjustment has
been made to the consolidated financial statements.
On October 23, 1996, the Company withdrew four of its Abbreviated New Drug
Applications ("ANDAs") including its ANDA for acetaminophen/oxycodone capsules
(the "Capsule ANDA"), and halted sales of the affected products. The Company
instituted the withdrawal at the suggestion of the FDA and in anticipation of
its release from the FDA's Application Integrity Policy ("AIP"). The FDA has
placed the Company on the AIP, in October 1991, in connection with its
investigation of the Company's operations which culminated in the 1993 consent
decree. Under the AIP, the FDA suspended all of the parent company's (i.e.,
Halsey Drug Co.'s) applications for new drug approvals, including ANDAs and
supplements to ANDAs. At the FDA's suggestion, the Company retained outside
consultants to perform validity assessments of its drug applications.
Thereafter, in October 1996, the FDA recommended that several applications,
including the Capsule ANDA, be withdrawn. As a basis of its decision, the FDA
cited questionable and incomplete data submitted in connection with the
applications. The FDA indicated that withdrawal of the four ANDAs was necessary
for the release of the Company from the AIP. The FDA further required submission
by the Company of a Corrective Action Plan. Said Plan was prepared and submitted
by the Company and accepted by the FDA during 1997.
On December 19, 1996, the FDA released the Company from the AIP. As a
consequence, for the first time since October 1991, the Company was permitted to
submit ANDAs to the FDA for review. Since its release from the AIP in December
1996, through the fiscal year ended December 31, 1998, the Company submitted
thirteen ANDAs for review by the FDA, including a new ANDA with respect to the
Capsules. During the period from the Company's release from the AIP to March 15,
1999, the Company received six ANDA approvals, all of which relate to ANDA
filings made with the FDA subsequent to the Company's release from the AIP.
As of March 15, 1999, the Company had submitted one additional ANDA for
review by the FDA in fiscal 1999 and anticipates the submission of five
additional ANDAs during the balance of fiscal 1999.
F-20
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Although the Company has been successful in receiving the ANDA approvals
described above since its release from the AIP in December 1996, there can be no
assurance that any of its newly submitted ANDAs, or those contemplated to be
submitted, will be approved by the FDA. The Company will not be permitted to
market any new product unless and until the FDA approves the ANDA relating to
such product. Failure to obtain FDA approval for the Company's pending ANDAs, or
a significant delay in obtaining such approval, would adversely affect the
Company's business operations and financial condition.
On June 21, 1993, the Company entered into a Plea Agreement with the DOJ to
resolve the DOJ's investigation into the manufacturing and record keeping
practices of the Company's Brooklyn plant. Under the terms of the Plea
Agreement, the Company agreed to plead guilty to five counts of adulteration of
drug products shipped in interstate commerce. Each count involved product
adulteration, and record keeping deficiencies relating to a single drug product,
Quinidine Gluconate (324mg tablets), manufactured at the Brooklyn plant. The
Plea Agreement also required the Company to pay a fine of $2,500,000 over five
years in quarterly installments of $125,000, commencing on or about September
15, 1993. The Company's plea was entered and the terms of the Plea Agreement
were approved by the United States District Court for the District of Maryland
on July 13, 1993. As of February 28, 1998, the Company was in default of the
payment terms of the Plea Agreement and had made payments aggregating $350,000.
On March 27, 1998, the Company and the DOJ signed the Letter Agreement serving
to amend the Plea Agreement relating to the terms of the Company's satisfaction
of the fine assessed under the Plea Agreement Specifically, the Letter Agreement
provided that the Company will satisfy the remaining $2,150,000 of the fine
through the payment of $25,000 on a monthly basis commencing June 1, 1998, plus
interest on such outstanding balance (at the rate calculated pursuant to 28
U.S.C Section 1961)(currently 5.319%). Such payment schedule will result in the
full satisfaction of the DOJ fine in December, 2005. The Letter Agreement also
provides certain restrictions on the payment of salary or compensation to any
individual in excess of $150,000 without the written consent of the United
States District Court for the District of Maryland, subject to certain
exceptions. In addition, the Letter Agreement requires the repayment of the
outstanding fine to the extent of 25% of the Company's after-tax profit or the
remaining balance owed and 25% of the net proceeds received by the Company on
any sale of a capital asset for a sum in excess of $10,000. If, at any time, the
Company does not make the payments required under the Letter Agreement in a
timely fashion, the United States will be free to declare that the fine is
delinquent and/or in default, and exercise all legal process to immediately
collect the full amount of the fine, interest and applicable penalties.
By letter dated October 23, 1995, the Company was notified by the New York
State Education Department (the "Department") that the Professional Conduct
Officer of the Office of Professional Discipline had determined that there was
sufficient evidence of professional misconduct on the Company's part to warrant
a disciplinary proceeding pursuant to New York law. Upon contacting the Deputy
Director of the Office of Professional Discipline, counsel for the Company was
advised that the alleged misconduct related to the same activities that were the
subject of the DOJ investigation, indictment and plea. The Company submitted a
written response on November 16, 1995. The Company and the Department have
agreed to the entry of a Consent Order concluding any disciplinary proceedings.
The Company will pay $175,000 in fines over five years. In addition, the
Company's registration as a manufacturer of drugs in New York State is revoked,
but such revocation is stayed and the Company has been placed on probation for a
maximum of five years. The Company has the right to apply for removal from
probation after two years. At December 31, 1998, the Company is current in its
payment obligations with a remaining obligation of $140,000.
The Company's Common Stock is listed on the American Stock Exchange (the
"Exchange") under the symbol "HDG."
The Company does not meet certain of the Exchange's criteria for continued
listing. Accordingly, there can be no assurance that the Company's common stock
will remain listed on the Exchange or that the Exchange will not commence a
review of the Company's continued listing eligibility. If the Common Stock
should become delisted from the Exchange, trading, if any, in the Common Stock
would continue on the OTC
F-21
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Bulletin Board, an NASD-sponsored inter-dealer quotation system, or in what is
commonly referred to as the "Pink Sheets." In such event, a shareholder may find
it more difficult to dispose of, or to obtain accurate quotations as to the
market value of the Common Stock.
Immediately prior to the completion of the Offering, the Company was in
default under the consent order with the Department for failure to satisfy two
of the monthly installments of the fine as provided in the consent order. Prior
to the completion of the Offering, the Company advised the Department as to the
existence of the default and that such deficiencies would be corrected upon the
completion of the Offering. The Company has satisfied these outstanding amounts
and is now current under the consent order with the Department. Based on
discussions between representatives of the Department and the Company's outside
counsel handling this matter, the Company has been advised that the revocation
of the Company's registration as a manufacturer of drugs in the State of New
York will remain stayed and that the Company continues to have the right to
apply for removal from probation after two years from the effective date of the
consent order.
Other Legal Proceedings
Beginning in 1992, actions were commenced against the Company and numerous
other pharmaceutical manufacturers in the Pennsylvania Court of Common Pleas,
Philadelphia Division, in connection with the alleged exposure to
diethylstilbestrol ("DES"). The defense of all of such matters was assumed by
the Company's insurance carrier, and a substantial number have been settled by
the carrier. Currently, five actions remain pending with the Company as a
defendant, and the insurance carrier is defending each action. Similar actions
were brought in Ohio, and have been dismissed based on Ohio law. The Company and
its legal counsel do not believe any of such actions will have a material impact
on the Company's financial condition.
The Company has been named as a defendant in four additional actions, each
of which has been referred to the Company's carrier and has been accepted for
defense. The first action, Alonzo v. Halsey Drug Co., Inc. and K-Mart Corp., No.
64DOT-95111-CT-2736 (Indiana Superior Court, Porter County), was commenced on
November 5, 1995 and involves a claim for unspecified damages relating to the
alleged ingestion of "Doxycycline 100." At this early stage of the proceedings,
the Company is unable to predict with any degree of certainty the likely outcome
of these claims and whether they will have a material adverse effect on the
Company's financial condition. The second action, Files v. Halsey Drug Co.,
Index No. 198787193 (New York Supreme Court, Suffolk County), commenced on
September 16, 1993, seeking $10,000,000 in damages for wrongful death allegedly
caused by the ingestion of Isoniazid. Halsey has been dismissed from this action
on motion for summary judgment. The third and fourth actions, entitled Hunt v.
Halsey Drug Co., Inc., and McCray v. Halsey Drug Co., Inc. (New York State
Supreme Court, Kings County), were commenced on October 21, 1993, seeking the
recovery of $8,000,000 for alleged personal injuries suffered by two Wells Fargo
security guards who responded to an alarm and were shot, resulting in the death
of one and the injury to the other. The Company's insurance carrier and the
plaintiffs in these matters have agreed in principle to a settlement providing
for the payment by the Company's insurance carrier of the sum of $600,000 to the
estate of John McCray and the sum of $150,000 to Joseph Hunt in full and final
settlement of all their respective claims against the Company.
The Company has been named as a defendant in a complaint filed with the
United States District Court, Eastern District of New York, on June 30, 1998
(the "Complaint") by Quality Products and Services, L.L.C. The Complaint alleges
the existence of a Joint Venture Agreement between the Plaintiff and the Company
concerning the development, manufacture and marketing of a single product. The
Complaint also alleges that the Company has breached the Agreement by failing to
satisfy its respective obligations defined in the Agreement. The Complaint seeks
monetary damages of approximately $20 million. The Company believes that the
allegations contained in the Complaint are without basis in fact, and that it
has meritorious defenses to each of the allegations. The Company has retained
counsel and intends to vigorously defend this action. This matter is currently
in discovery. The Company has filed a third-party complaint against Rosendo
Ferran, the Company's former President, in connection with the Complaint.
F-22
HALSEY DRUG CO., INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The Company has been named as a defendant in an action in Suffolk County,
New York, by Designed Laboratories, Inc., for construction work allegedly
performed at the Company's facilities in Brooklyn. Plaintiff is seeking
approximately $148,000. The Company has no records of work being performed by
this entity, and is therefore defending the action.
The Company's former President, Rosendo Ferran, has instituted an
arbitration against the Company, seeking sums alleged due under his employment
contract in the amount of $225,000, deferred salary in the approximate amount of
$100,000, and unspecified damages upon allegations of age, ethnic and religious
discrimination. The Company believes it has meritorious defenses to the
allegations claimed in the arbitration. The Company and its legal counsel do not
believe this claim will have a material adverse effect on the Company's
financial condition.
NOTE N -- SIGNIFICANT CUSTOMERS AND SUPPLIERS
The Company sells its products to a large number of customers who are
primarily drug distributors, drugstore chains and wholesalers and are not
concentrated in any specific region. The Company performs ongoing credit
evaluations of its customers and generally does not require collateral. During
1998, the Company had net sales to one customer in excess of 10% of total sales,
aggregating 11.5% of total sales. During 1997, the Company had net sales to two
customers in excess of 10% of total sales. One customer (Mallinckrodt) accounted
for 22.1% of total sales and another customer (Warner Chilcott) accounted for
10% of total sales. During 1996, the Company had net sales to one customer
aggregating 10% of total sales.
During 1998 and 1997, the Company purchases approximated $2,583,000 and
$1,187,000, respectively, representing approximately 29% and 25%, respectively,
of total purchases for those years.
NOTE O -- SUBSEQUENT EVENTS
Lease of Congers, New York Facility
Effective March 22, 1999, the Company leased, as sole tenant, a
pharmaceutical manufacturing facility located in Congers, New York (the "Congers
Facility") from Par Pharmaecutical, Inc. ("Par") pursuant to an Agreement to
Lease (the "Lease"). The Congers Facility contains office, warehouse and
manufacturing space and is approximately 35,000 square feet. The Lease provides
for a term of three years, with a two-year renewal option and provides for
annual fixed rent of $500,000 per year during the primary term of the Lease and
$600,000 per year during the option period. The Lease also covers certain
manufacturing and related equipment previously used by Par in its operations at
the Congers Facility (the "Leased Equipment"). In connection with the execution
of the Lease, the Company and Par entered into a certain Option Agreement
pursuant to which the Company may purchase the Congers Facility and the Lease
Equipment at any time during the lease term for $5 million.
As part of the execution of the Lease, the Company and Par entered into a
certain Manufacturing and Supply Agreement (the "M&S Agreement") having a term
of two years. The M&S Agreement provides for the Company's contract manufacture
of certain designated products manufactured by Par at the Congers Facility prior
to the effective date of the Lease. The M&S Agreement also provides that Par
will purchase a minimum of $1,150,000 in product during the initial 18 months of
the Agreement. The M&S Agreement further provides that the Company will not
manufacture, supply, develop or distribute the designated products to be
supplied by the Company to Par under the M&S Agreement to or for any other
person for a period of three years.
F-23
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
We have issued our report dated March 5, 1999, accompanying the
consolidated financial statements included in the Annual Report of Halsey Drug
Co., Inc. on Form 10-K for the year ended December 31, 1998. We hereby consent
to the incorporation by reference of said report in the Registration Statements
of Halsey Drug Co., Inc. on Form S-8 (File No. 33-98396, effective October 19,
1995).
GRANT THORNTON LLP
New York, New York
March 5, 1999
F-24
EXHIBIT INDEX
Exhibit 3.1
Certificate of Incorporation and amendments
Exhibit 3.3
Restated By-Laws
Exhibit 10.45
[Amended, Restated and Consolidated Bridge Loan Agreement dated as of
December 2, 1998 between the Company, Galen Partners III, L.P., Galen
Partners International III, L.P., Galen Employee Fund III, L.P.
and the other signatures thereto]
Exhibit 10.46
[First Amendment to Amended, Restated and Consolidated Bridge Loan Agreement
dated December 7, 1998 between the Company and the lenders listed
on the signature page thereto]
Exhibit 10.47
[Second Amendment to Amended, Restated, Consolidated Bridge Loan
Agreement dated March 8, 1999 between the Company and the
lenders listed on the signature pages thereto]
Exhibit 10.48
[Form of 10% Convertible Secured Note due May 30, 1999]
Exhibit 10.49
[Form of Common Stock Purchase Warrant issued pursuant to the Amended,
Restated and Consolidated Bridge Loan Agreement]
Exhibit 10.50
[Amended and Restated General Security Agreement dated December 2, 1998
between the Company and Galen Partners III, L.P., as Agent]
Exhibit 10.51
[Subordination Agreement dated December 2, 1998 between the Registrant
and Galen Partners III, L.P., as Agent]
Exhibit 10.52
[Agency Letter Agreement dated December 2, 1998 by and among the lenders a party
to the Amended, Restated and Consolidated Bridge Loan Agreement, as amended]
Exhibit 10.53
[Lease Agreement dated March 17, 1998 between the
Registrant and Par Pharmaceuticals Inc.]
Exhibit 10.54
[Lease Agreement dated September 1, 1998 between the Registrant and Crinson
Ridge Partners]
Exhibit 10.55
[Manufacturing and Supply Agreement dated March 17, 1999 between
the Company and Par Pharmaceuticals Inc.]
Exhibit 10.56
[Halsey Drug Co., Inc. 1998 Stock Option Plan]
Exhibit 23.1
[Consent of Grant Thornton LLP, independent certified public accountants]
Exhibit 27
[Financial Data Schedule, which is submitted electronically to the Securities
and Exchange Commission for informational purposes only and not filed]
Exhibit 3.1
[Amendments to Certificate of Incorporation]
CERTIFICATE OF AMENDMENT
OF THE CERTIFICATE OF INCORPORATION
OF
HALSEY DRUG CO., INC.
UNDER SECTION 805 OF THE NEW YORK BUSINESS CORPORATION LAW
* * * * *
WE, THE UNDERSIGNED, Michael K. Reicher and Peter Clemens, being
respectively the President and the Secretary of Halsey Drug Co., Inc., hereby
certify:
1. The name of the corporation is Halsey Drug Co., Inc. The corporation
was originally incorporated under the name of Halsey Drug Co. Inc.
2. The certificate of incorporation of said corporation was filed with the
Department of State on the 10th day of April, 1935, amended on June 16, 1952,
restated on February 23, 1962, amended on March 12, 1984, amended on February 7,
1986, amended on August 20, 1986, amended on May 24, 1989, and further amended
on August 27, 1998.
3. (a) The certificate of incorporation is amended to increase the
number of directors to not more than eight (8).
(b) To effect the foregoing, Article SIXTH relating to the number
of directors is amended to read as follows:
SIXTH: The number of directors shall be not less than
three (3) nor more than eight (8) none of whom need be
stockholders of the Corporation.
4. The amendment was authorized in the following manner:
By a unanimous written consent of the Board of Directors followed by
an affirmative vote of the holders of a majority of the outstanding
shares of Common Stock of the corporation entitled to vote thereon.
IN WITNESS WHEREOF, we have signed this certificate on the 28 day of
January, 1999 and we affirm the statements contained herein as true under
penalties of perjury.
_/S/_________________________________
Michael K. Reicher
President and Chief Executive Officer
_/S/_________________________________
Peter Clemens
Secretary
|
CERTIFICATE OF AMENDMENT
OF THE CERTIFICATE OF INCORPORATION
OF
HALSEY DRUG CO., INC.
Please forward the filing receipt for this document to:
ST. JOHN & WAYNE, L.L.C.
Attn: John P. Reilly, Esq.
2 Penn Plaza East, 10th Floor
Newark, New Jersey 07105
CERTIFICATE OF AMENDMENT
OF THE CERTIFICATE OF INCORPORATION
OF
HALSEY DRUG CO., INC.
UNDER SECTION 805 OF THE NEW YORK BUSINESS CORPORATION LAW
* * * * *
WE, THE UNDERSIGNED, Michael K. Reicher and Peter Clemens, being
respectively the President and the Secretary of Halsey Drug Co., Inc., hereby
certify:
1. The name of the corporation is Halsey Drug Co., Inc. The corporation
was originally incorporated under the name of Halsey Drug Co. Inc.
2. The certificate of incorporation of said corporation was filed with the
Department of State on the 10th day of April, 1935, amended on June 16, 1952,
restated on February 23, 1962, amended on March 12, 1984, amended on February 7,
1986, amended on August 20, 1986 and further amended on May 24, 1989.
3. (a) The certificate of incorporation is amended to increase
the number of authorized shares of Common Stock available from
20,000,000 to 40,000,000 Shares.
(b) To effect the foregoing, Article THIRD relating to the amount
of authorized capital stock of the Corporation is amended to
read as follows:
THIRD: The amount of the authorized capital
stock of the Corporation shall be Four
Hundred Thousand ($400,000) Dollars
consisting of 40,000,000 shares of Common
Stock, each share having a par value of $.01
per share.
4. The amendment was authorized in the following manner:
By a unanimous written consent of the Board of Directors followed by
an affirmative vote of the holders of a majority of the outstanding
shares of Common Stock of the corporation entitled to vote thereon.
IN WITNESS WHEREOF, we have signed this certificate on the 21st day of
July and we affirm the statements contained herein as true under penalties of
perjury.
_/S/_________________________________
Michael K. Reicher
President and Chief Executive Officer
_/S/_________________________________
Peter Clemens
Secretary
|
CERTIFICATE OF AMENDMENT
OF THE CERTIFICATE OF INCORPORATION
OF
HALSEY DRUG CO., INC.
Please forward the filing receipt for this document to:
ST. JOHN & WAYNE, L.L.C.
Attn: B. Knochenmus
2 Penn Plaza East, 10th Floor
Newark, New Jersey 07105
Exhibit 3.3
[Amended and Restated Bylaws]
As Amended: April 24, 1998
RESTATED
BY-LAWS
of
HALSEY DRUG CO., INC.
ARTICLE I.
STOCKHOLDERS.
SECTION 1. Annual Meeting. The annual meeting of the stockholders shall be
held at such time and place in the City and State of New York as the Board of
Directors may from time to time designate on a day not later than one hundred
fifty (150) days from the end of the Corporation's last fiscal year, each year
for the purpose of electing directors and of transacting such other business as
may properly come before the meeting. The directors shall be chosen by a
plurality of the votes at such election.
SECTION 2. Special Meetings. Special meetings of the stockholders may be
called by a majority of the members of the Board of Directors or the President
and shall be called at any time by the President, any Vice President or the
Secretary upon the written request of stockholders owning a majority of the
outstanding shares of the Corporation entitled to vote at the meeting, and shall
be hold at such time and place in the City and State of New York as may be fixed
in the call and stated in the notice.
SECTION 3. Notice of Meetings. Notice of each meeting of stockholders
shall be in writing and signed by the President or a Vice President or the
Secretary or an Assistant Secretary. Such notice shall state the purpose or
purposes for which the meeting is called and the time when and the place where
it is to be held, and copy thereof shall be served, either personally or by
mail, upon each stockholder of record entitled to vote at such meeting, and upon
each stockholder of record who, by reason of any action proposed at such
meeting, would be entitled to have his stock appraised if such action were
taken, not less than ten nor more than forty days before the meeting. If mailed,
it shall be directed to a stockholder at his address as it appears on the
stockbook unless he shall have filed with the Secretary of the Corporation a
written request that notices intended for him be mailed to some other address,
in which case it shall be mailed to the address designated in such request.
A meeting of stockholders may be held without notice, and any action
proper to be taken by the stockholders may be taken thereat, if at any time
before or after such action be completed the requirements for notice be waived
in writing by all the stockholders of record entitled to notice of such meeting
or by their attorneys thereunto authorized.
SECTION 4. Qualification of Voters. Unless otherwise provided in a
certificate filed pursuant to law, every stockholder of record of the
Corporation shall be entitled at every meeting of the stockholders to one vote
for every share of stock standing in his name on the books of the Corporation.
Shares of its own stock belonging to the Corporation at the time of the
meeting or at the time a voting record therefor, as hereafter provided, is
taken, shares retired before the meeting and no longer deemed to be issued and
outstanding at the time of the meeting although outstanding at the time a voting
record therefor is taken, and shares issued before the meeting but after a
voting record therefor is taken, shall not be voted, directly or indirectly, and
shall not be counted in determining a quorum or the number of shares necessary
to constitute a quorum or to take any action contemplated, unless otherwise
provided by law.
The books and papers containing the list of stockholders shall be produced
at any meeting of the stockholders upon the request of any stockholder. If the
right to vote at any such meeting shall be challenged, the inspectors of
election, or other person presiding thereat, shall require such books to be
produced as evidence of the right of the person challenged to vote at such
meetings and all persons who may appear from such books to be stockholders of
the Corporation entitled to vote may vote at such meeting in person or by proxy,
subject to the provisions of the law.
SECTION 5. Determination of Stockholders of Record for Certain Purposes.
The Board of Directors may prescribe a period not exceeding forty days prior to
any meeting of the stockholders or prior to the last day on which the consent or
dissent of stockholders may be effectively expressed for any purpose without a
meeting, or prior to the payment of any dividend, or the making of any
distribution, or the delivery of evidence of rights or evidences of interests
arising out of any change, conversion or exchange of capital stock, during which
no transfer of stock on the books of the corporation may be made. In lieu of
prohibiting the transfer of stock as aforesaid, the Board of Directors may fix a
day and hour, not more than forty days prior to any such meeting, or to any such
last day for the expression of consent or dissent, or to any such dividend
payment, distribution or delivery, as the time as of which stockholders entitled
to notice of and to vote at such meeting, or to express such consent or dissent
or to the receipt of such dividend payment, distribution or delivery, as the
case may be, shall be determined, and all persons who were stockholders of
record at such time and no others shall be entitled to notice of and to vote at
such meeting, to express such consent or dissent, or to the receipt of such
dividend payment, distribution or delivery, as the case may be.
SECTION 6. Quorum. The amount of stock which must be represented at a
meeting of the stockholders to constitute a quorum, unless otherwise provided by
law, shall be a majority of the shares of the Corporation which are entitled to
be voted at such meeting, represented by holders of record entitled to vote
thereat, present in person or by proxy.
If at any meeting of the stockholders the amount of stock so represented
shall not constitute a quorum or shall be less than the amount required by
statute to take the action then contemplated, the holders of a majority of the
shares of stock so represented may adjourn the meeting from time to time during
the period of not more than forty days thereafter, without notice other than
announcement at the meeting, until the required amount of stock shall be
represented at the meeting, when such action may be taken as was contemplated by
the notice of the meeting.
SECTION 7. Proxies. Every stockholder of the Corporation entitled to vote
at any meeting thereof may vote by proxy. Every proxy must be executed in
writing by the stockholder or by his duly authorized attorney. No proxy shall be
valid after the expiration of eleven months from the date of execution unless
the stockholder executing it shall have specified therein its duration.
SECTION 8. Inspectors of Election. Two inspectors of election to serve at
each election of directors by stockholders or in any other case in which
inspectors may act shall be appointed by the chairman at the meeting. The
inspectors so appointed, before entering upon the discharge of their duties,
shall be sworn faithfully to execute the duties of inspectors at such meeting
with strict impartiality, and according to the best of their ability, and the
oath so taken shall be subscribed by them. Thereupon the inspectors shall take
charge of the polls and after the balloting shall make a certificate of the
result of the vote taken. No director or candidate for the office of director
shall be appointed such inspector.
SECTION 9. Form of Stock Certificates. The stock of the Corporation shall
be represented by certificates, in such forms as the Board of Directors may from
time to time prescribe, signed by the President or a Vice President and the
Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer,
and sealed with the seal of the Corporation. Such seal may be a facsimile,
engraved or printed. Where any such certificate in signed by a transfer agent or
transfer clerk, the signatures of any such President, Vice-President, Secretary,
Assistant Secretary, Treasurer and Assistant Treasurer upon such certificate may
be facsimiles, engraved or printed. In case any such officer who has signed or
whose facsimile signature has been placed upon such certificate shall have
ceased to be such before such certificate is issued, it may be issued by the
Corporation with the same effect as if such officer had not ceased to be such at
the date of its issue.
Every certificate of stock issued by the Corporation shall plainly state
upon the face thereof the number, kind and class of shares, including series, if
any, which it represents.
SECTION 10. Transfers of Stock. Shares of the stock of the Corporation
shall be transferable on the books of the Corporation, by the holder thereof in
person or by his attorney, upon surrender or cancellation of certificates for
the same number of shares, with a written assignment of
the certificate or a power of attorney to sell, assign or transfer the same or
the shares represented thereby, signed by the person appearing by the
certificate to be the owner of the shares represented thereby, either indorsed
thereon or attached thereto, with such proof of the authenticity of the
signature as the Corporation or its agents may reasonably require. Such
assignment or power of attorney may be either in blank or to a specified person,
and shall have affixed thereto all stock transfer stamps required by law.
No share shall be transferable until all previous calls thereon shall have
been fully paid in.
SECTION 11. Lost, Stolen or Destroyed Stock Certificates. No certificate
for shares of stock of the Corporation shall be issued in place of any
certificate alleged to have been lost, stolen or destroyed, except upon
production of such evidence of the loss, theft or destruction, and upon such
indemnification of the Corporation and its agents to such extent and in such
manner as the Board of Directors may from time to time prescribe.
ARTICLE II.
BOARD OF DIRECTORS.
SECTION 1. Power of Board and Qualification of Directors. The business of
the Corporation shall be managed by its Board of Directors, all of whom shall be
of full age and need not be stockholders. Directors shall be elected at the
annual meetings of the stockholders and each director shall be elected to serve
for one year and until his successors shall be elected and shall qualify.
SECTION 2. Number. The number of directors of the Corporation shall be not
less than three nor more than eleven as fixed from time to time within said
limits by the Board of Directors.
SECTION 3. Meetings or the Board. The annual meeting of the Board of
Directors shall be held in each year after the adjournment of the annual
stockholders' meeting and on the same day. If a quorum of the directors are not
present on the day appointed for the annual meeting, the meeting shall be
adjourned to some convenient day. No notice need be given of the annual meeting
of the Board.
Meetings of the Board of Directors shall be held at such place as may from
time to time be specified in the call of any meeting.
Regular meetings of the Board of Directors shall be held at such times as
may from time to time be fixed by resolution of the Board, and no notice need be
given of regular meetings.
Special meetings of the Board may be called at any time by the President
and shall be called by the President, any Vice President or the Secretary upon
the written request of any two members of the Board, to be held not more than
five days after receipt of the said request. Notice of special
meetings say be oral, telegraphic or written and shall be served on or sent or
mailed to each director not less than forty-eight hours before such meeting.
A special meeting of the Board of Directors may be held without notice,
and any action proper to be taken by the Board of Directors may be taken
thereat, if every member of the Board of Directors is present or if at any time
before or after such action be completed the requirement for notice be waived in
writing by every director entitled to notice of such meeting.
SECTION 4. Quorum and Power of a Majority. A majority of the Board of
Directors at a meeting duly assembled shall be necessary to constitute a quorum
for the transaction of business and the act of a majority of the directors
present at such meeting shall be the act of the Board of Directors.
SECTION 5. Resignations. Any director of the Corporation may resign at any
time by giving written notice to the Board of Directors or to the President or
to the Secretary of the Corporation. Such resignation shall take effect at the
time specified therein; and unless otherwise Specified therein the acceptance of
such resignation shall not be necessary to make it effective.
SECTION 6. Vacancies. Vacancies in the Board of Directors, whether caused
by death, resignation, increase in the number of directors, or otherwise, may be
filled by a vote of a majority of the directors in office at the time. However,
in case the number of directors be increased by action of the stockholders, the
additional directors may be elected by vote of the stockholders at the meeting
at which the increase is effected.
SECTION 7. Compensation. Directors, as such, shall not receive any stated
salary for their services, but by resolution of the Board of Directors a fixed
sum and expenses of attendance, if any may be allowed for attendance at each
meeting of the Board. However, this by-law shall not be construed to preclude
any director from serving the Corporation in any other capacity and receiving
compensation therefor. Members of the Executive Committee and of other
committees may be allowed like compensation for attending committee meetings.
SECTION 8. Executive Committee. The Board of Directors may, by vote of a
majority of the Board, designate an Executive Committee, to consist of the
President and such other member or members of the Board of Directors as may be
designated by the Board of Directors. The Executive Committee shall have and may
exercise, so far as may be permitted by law, all the powers of the Board of
Directors in the management of the business, affairs and property of the
Corporation during the intervals between meetings of the Board of Directors and
shall have power to authorize the seal of the Corporation to be affixed to all
papers which may require it; but the Executive Committee shall not have power to
fill vacancies in the Board of Directors or to change the membership of, or to
fill vacancies in, the Executive Committee, or to make or amend the by-laws of
the Corporation. The Board of Directors shall have the power at any time to fill
vacancies in, to change the membership of, or to dissolve the Executive
Committee. The Executive Committee may hold meetings and make rules for the
conduct of its business and appoint such committees and assistants
as it shall from time to time deem necessary. A majority of the members of the
Executive Committee shall constitute a quorum determine its action. All action
of the Executive Committee shall be reported at the meeting or the Board of
Directors next succeeding such action.
SECTION 9. Other Committees. The Board of Directors may in its discretion
appoint other committees which shall have such powers and perform such duties as
from time to time may be prescribed by the Board of Directors. A majority of the
members of any such committee may determine its action and fix the time and
place of its meetings, unless the Board shall otherwise provide. The Board of
Directors shall have power at any time to change the membership of any such
committee, to fill vacancies, and to discharge any such committee.
SECTION 10. Telephonic Meetings. Unless otherwise restricted by the
Certificate of Incorporation or these By-Laws, members of the Board of Directors
or any committee thereof may participate in a meeting of such Board or committee
by means of a conference telephone or similar communications equipment allowing
all persons participating in the meeting to hear each other at the same time,
and participation in a meeting pursuant to such means shall constitute presence
in person at such meeting.
ARTICLE III.
OFFICERS.
SECTION 1. Officers. The Board of Directors, as soon as may be after the
annual election of directors, shall elect a President, one or more Vice
Presidents, a Secretary and a Treasurer, and from time to time may appoint such
other officers (including among others, an Executive Vice President, one or more
Assistant Secretaries and one or more Assistant Treasurers), agents and
employees as it may deem proper. More than one office may be hold by the same
person. The President shall be chosen from among the directors but no other
officer need be a director.
SECTION 2. Salaries of Officers. The salaries of all officers of the
Corporation shall be fixed by the Board of Directors.
SECTION 3. Term of Office. The term of office for all officers shall be
for one year and until their respective successors are chosen and qualified.
SECTION 4. Powers and Duties.
(a) The President
The President shall preside at all meetings of the directors and shall
generally oversee the management of the business of the Corporation. He shall be
the chief executive officer of the Corporation and shall have the management of
the business of the Corporation. He shall preside at all meetings of
stockholders. Except as the Board of Directors may otherwise direct and except
as
otherwise expressly provided in these by-laws or by law, the President shall
execute any action on behalf of the Corporation as may from time to time be
taken by the Board of Directors.
(b) Vice Presidents
The Vice Presidents, in the order designated by the Board of Directors,
during the absence or disability of the President, shall perform the duties and
exercise the powers of the President, and shall perform such other duties as the
Board of Directors shall prescribe.
(c) Secretary
The Secretary shall attend all sessions of the Board and all meetings of
the stockholders and record all votes and the minutes of all proceedings in a
book to be kept for that purpose. He shall give or cause to be given notice of
all meetings of stockholders and special meetings of the Board of Directors and
shall Perform such other duties as may be prescribed by the Board of Directors.
He shall keep in safe custody the seal of the Corporation and affix it to any
instrument when authorized by the Board of Directors.
(d) Treasurer
The Treasurer shall have the custody of the corporate funds and securities
and shall keep full and accurate accounts of receipts and disbursements in books
belonging to the Corporation and shall deposit all moneys and other valuable
effects in the name and to the credit of the Corporation in such depositories as
may be designated by the Board of Directors. He shall disburse the funds of the
Corporation as may be ordered by the Board of Directors, taking proper vouchers
for such disbursements, and shall render to the President and directors at the
regular meetings of the Boards or whenever they may require it, an account of
all his transactions as Treasurer and of the financial condition of the
Corporation.
The Treasurer shall, if required by the Board of Directors, give the
Corporation a bond in such sum or sums and with such surety or sureties as shall
be satisfactory to tho Board of Directors, conditioned upon the faithful
performance of his duties and for the restoration to the Corporation in case of
his death, resignation, retirement or removal from office of all books, papers,
vouchers, money and other property of whatever kind in his possession or under
his control belonging to the Corporation.
SECTION 5. Books to be Kept. The officers shall keep at the office of the
Corporation correct books of account of all its business and transactions, and a
book to be known as the stockbook, containing the names, alphabetically
arranged, of all persons who are stockholders of the Corporation, showing their
places of residence, the number of shares of stock held by them respectively,
the time when they respectively became the owners thereof, and the amount paid
thereon.
SECTION 6. Checks, Notes, etc. All checks and drafts on the Corporation's
bank accounts and all bills of exchange and promissory notes and all
acceptances, obligations and other instruments for the payment of money, shall
be signed by such officer or officers or agent or agents as shall be thereunto
authorized from time to time by the Board of Director.
ARTICLE IV.
OTHER MATTERS.
SECTION 1. Corporate Seal. The corporate seal shall have inscribed thereon
the name of the Corporation and such other appropriate legend as the Board of
Directors may from time to time determine. In lieu of the corporate seal, when
so authorized by the Board of Directors or a duly empowered committee thereof, a
facsimile thereof may be affixed or reproduced.
SECTION 2. Fiscal Year. The fiscal year of the Corporation shall be
determined by the Board of Directors.
SECTION 3. Amendments. The by-laws of the Corporation may be amended,
added to or repealed at any meeting of the stockholders by the vote of the
holders of record of a majority of the outstanding shares of the Corporation
entitled to vote at the meeting, provided that notice of the proposed change
shall have been given in the notice of the meeting. The by-laws may also be,
amended or Added to or repealed at any meeting of the Board of Directors by the
vote of a majority of all members of the Board, provided that notice of the
proposed change shall have been given in the notice of the meeting. However, any
by-laws hereafter duly adopted at a meeting of the stockholders shall control
action of the directors except as therein otherwise provided.
SECTION 4. Reliance Upon Reports. Each Director, each officer and each
member of any committee designated by the Board of Directors shall in the
performance of his duties be fully protected in relying in good faith upon the
books of account or reports made to the Corporation by any of its officials, or
by an independent certified public accountant, or by an appraiser selected with
reasonable care by the Board of Directors, or by such officer or by such
committee, or in relying in good faith upon other records of the Corporation.
SECTION 5. Removals.
(a) The stockholders may, at any meeting called for the purpose, by vote
of a majority of the capital stock issued and outstanding and entitled to vote
thereon, remove any director from office. The Board of Directors may, at any
meeting called for the purpose, by an affirmative vote of two-thirds of their
entire number holding office at the time, and for good cause shown, remove any
director from office.
(b) The-Board of Directors may, at any meeting called for the purpose, by
a vote of a majority of their entire number holding office at the time, remove
from office any officer or agent
of the Corporation or any member of any committee appointed by the Board of
Directors or by any committee appointed by the Board of Directors or by any
officer or agent of the Corporation.
SECTION 6. Indemnification . It is expressly provided that any and every
person made a party to any action, suit, or proceeding by or in the right of the
corporation to procure a judgment in its favor by reason of the fact that he,
his testator or intestate, is or was a director or officer of this corporation
or of any corporation which be served as such at the request of this
corporation, may be indemnified by the corporation to the full extent permitted
by law, against any and all reasonable expenses, including attorneys' fees,
actually and necessarily incurred by him in connection with the defense of such
action or in connection with any appeal therein, except in relation to matters
as to which it shall be adjudged in such action, suit or proceeding that such
officer or director has breached his duty to the corporation.
It is further expressly provided that any and every person made a party to
any action, suit, or proceeding other than one by or in the right of the
corporation to procure a judgment in its favor, whether civil or criminal,
including an action by or in the right of any other corporation of any type or
kind, domestic or foreign, which any director or officer of the corporation
served in any capacity at the request of the corporation, by reason of the fact
that he, his testator or interstate, was a director or officer of the
corporation, or served such other corporation in any capacity, may be
indemnified by the corporation, to the full extent permitted by law, against
judgments, fines, amounts paid in settlement, and reasonable expenses, including
attorneys' fees; actually and necessarily incurred as a result of such action,
suit or proceeding, or any appeal therein, if such person acted in good faith
for a purpose which he reasonably believed to be in the best interests of the
corporation and, in criminal actions or proceedings, in addition, had no
reasonable cause to believe that his conduct was unlawful.
Exhibit 10.45
[Amended, Restated and Consolidated Bridge Loan Agreement dated as of
December 2, 1998 between the Company, Galen Partners III, L.P., Galen
Partners International III, L.P., Galen Employee Fund III, L.P. and the
other signatures thereto]
AMENDED, RESTATED AND CONSOLIDATED
BRIDGE LOAN AGREEMENT
for
$8,500,000
among
HALSEY DRUG CO., INC., as Borrower,
and
GALEN PARTNERS III, L.P.
GALEN PARTNERS INTERNATIONAL III, L.P.
GALEN EMPLOYEE FUND III, L.P.
and OTHERS, as Lenders,
and
GALEN PARTNERS III, L.P., as Agent for Lenders
Dated as of December 2, 1998
Wolf, Block, Schorr and Solis-Cohen LLP
250 Park Avenue
New York, New York 10177
TABLE of CONTENTS
SECTION 1. DEFINITIONS, TERMS AND HEADINGS..................................2
1.1. General Definitions..............................................2
1.2. Accounting Terms and Determinations..............................9
1.3. Other Terms; Headings............................................9
SECTION 2. TERMS OF THE CONSOLIDATED BRIDGE LOAN............................9
2.1. Commitment.......................................................9
2.2. Consolidated Bridge Loan.........................................9
2.3. Amended, Restated and Consolidated Notes........................10
(a) The Amount................................................10
(b) General Terms ............................................10
(c) Adjustment of Conversion Price............................10
(d) Payment...................................................10
(e) Interest..................................................10
(f) Prepayments of Notes......................................11
(g) Interest After Event of Default...........................11
(h) Exchange or Replacement...................................11
(i) Transfer..................................................12
2.4. Warrants........................................................12
2.5. Security; Subordination of the Existing Credit Facility.........12
2.6. Registration Rights.............................................12
2.7. Consent and Waiver..............................................12
2.8. Agency Agreement ...............................................13
2.9. Miscellaneous...................................................13
SECTION 3. CONDITION PRECEDENT.............................................13
3.1. Conditions Precedent to Consolidated Bridge Loan................13
3.2. No Liens........................................................13
3.3. Representations and Warranties Correct..........................14
3.4. Legal Opinion of Counsel to Borrower............................14
3.5. Officer's Certificate...........................................14
3.6. Closing Fees....................................................14
SECTION 4. REPRESENTATIONS AND WARRANTIES..................................14
4.1. Representations and Warranties of Borrower......................14
(a) Organization and Qualification............................14
(b) Authority; Consents and Filings...........................14
(c) Enforceability............................................15
(d) No Conflict...............................................15
(e) Government Regulation.....................................15
i
|
(f) Indebtedness; Rights in Collateral........................15
(g) Locations of Offices, Records and Inventory...............16
(h) Inventory.................................................16
(i) No Judgments or Litigation................................16
(j) No Defaults...............................................16
(k) Financial Information, SEC Documents......................16
(l) Compliance with Law.......................................16
(m) Intellectual Property.....................................16
(n) Licenses and Permits......................................17
(o) Taxes.....................................................18
(p) Labor Disputes and Acts of God............................18
(q) Partnerships..............................................18
(r) Solvency..................................................18
(s) Forfeiture Proceeding.....................................18
(t) Offering..................................................18
(u) No Discrimination.........................................19
(v) ERISA.....................................................19
(w) Registration Rights.......................................19
(x) Accuracy and Completeness of Information..................19
4.2. Representations and Warranties of Lenders.......................19
SECTION 5. CHANGE OF CONTROL PURCHASE ORDER;
CONVERSION RIGHTS...............................................20
5.1. Change of Control...............................................20
SECTION 6. AFFIRMATIVE COVENANTS...........................................22
(a) Financial Reporting and Projections.......................22
(b) Discharge Taxes and Indebtedness..........................22
(c) Notification Requirements.................................23
(d) Notice of Default.........................................23
(e) Proceedings or Adverse Changes............................23
(f) Corporate Existence, Charter and By-Laws; Corporate Name..23
(g) Books and Records; Inspections............................23
(h) Compliance with Laws; Compliance with Agreements..........23
(i) Use of Proceeds...........................................24
(j) Maintenance of Insurance..................................24
(k) Further Assurances........................................24
(l) Payment of Note...........................................24
(m) Reporting Requirements....................................24
(n) Authorization of Shares of Common Stock for Issuance
Upon Conversion of Note and Exercise of Warrants and
Voting Rights for Note Holders............................24
ii
|
(o) Listing of Common Stock...................................25
(p) HSR Act Filing............................................25
(q) Year 2000 Computer Capability.............................25
SECTION 7. NEGATIVE COVENANTS..............................................25
(a) Additional Indebtedness...................................25
(b) No Guarantee..............................................25
(c) Liens.....................................................26
(d) No Transfer of Asset......................................26
(e) Extraordinary Transactions and Disposal of Asset..........26
(f) Restricted Payments.......................................26
(g) Investments...............................................26
(h) Affiliate Transactions; Intercompany Transfers; Diversion
of Corporate Assets ......................................26
(i) Mergers...................................................27
(j) No Activities Leading to Forfeiture.......................27
(k) Corporate Documents; Fiscal Year..........................27
(l) Capital Expenditure.......................................27
SECTION 8. REGISTRATION RIGHTS.............................................27
8.1. Restrictive Legend..............................................27
8.2. Certain Definitions.............................................28
8.3. Requested Registration..........................................28
8.4. Piggyback Registrations.........................................29
8.5. Holdback Agreements.............................................30
8.6. Registration Procedures.........................................31
8.7. Expenses of Registration........................................32
8.8. Indemnification.................................................32
8.9. Information by Holders..........................................34
8.10. Limitations on Registration of Issues of Securities.............34
8.11. Rule 144 Reporting..............................................34
8.12. Participation in Underwritten Registrations.....................35
8.13. Selection of Underwriters.......................................35
8.14. Termination of Registration Rights..............................35
SECTION 9. EVENTS OF DEFAULT AND REMEDIES..................................35
9.1. Events of Default...............................................35
9.2. Acceleration....................................................36
9.3. Remedies........................................................37
9.4. Application of Proceeds; Surplus; Deficiencies..................37
SECTION 10. GENERAL PROVISIONS..............................................37
10.1. GOVERNING LAW...................................................37
iii
|
10.2. SUBMISSION TO JURISDICTION.....................................37
10.3. SERVICE OF PROCESS.............................................38
10.4. JURY TRIAL.....................................................38
10.5. LIMITATION OF LIABILITY........................................38
10.6. Notices........................................................38
10.7. Indemnification................................................39
10.8. Amendments and Waivers.........................................40
10.9 Construction...................................................40
10.10. Counterparts and Effectiveness.................................41
10.11. Severability...................................................41
10.12. Entire Agreement; Successors and Assigns.......................41
10.13. Assignments and Participations.................................41
10.14. No Brokers.....................................................41
10.15. No Novation....................................................42
Exhibits
Exhibit A List of Lenders, Their Contributions, Their Notes and Their
Warrants
Exhibit B Amended, Restated and Consolidated Notes
Exhibit C Warrants
Exhibit D Consent and Waiver
Exhibit E Agency Letter
Exhibit F Amended and Restated General Security Agreement
Exhibit G Subordination Agreement
|
iv
AMENDED, RESTATED AND CONSOLIDATED
BRIDGE LOAN AGREEMENT
THIS AMENDED, RESTATED AND CONSOLIDATED BRIDGE LOAN AGREEMENT is entered
into as of December 2, 1998 among HALSEY DRUG CO., INC., a New York corporation
("Borrower"), GALEN PARTNERS III, L.P. ("Galen" or a "Lender"), GALEN PARTNERS
INTERNATIONAL III, L.P. and GALEN EMPLOYEE FUND III, L.P., each a Delaware
limited partnership (each a "Lender", and collectively, with Galen, the "Galen
Entities"), THOSE PERSONS WHOSE NAMES ARE SET FORTH ON THE SIGNATURE PAGE HERETO
(each a "Lender", and collectively, with the Galen Entities, the "Lenders") and
GALEN, as agent for the Lenders (in such capacity, the "Agent").
WHEREAS, Borrower and the Galen Entities entered into a Bridge Loan
Agreement dated as of August 12, 1998 (as amended through the date hereof, the
"Original Bridge Loan Agreement"), pursuant to which the Galen Entities made a
loan to Borrower in the amount of $1,000,000 (the "Initial Bridge Loan"), as
evidenced by a promissory note ("Bridge Note 1") in such amount;
WHEREAS, Borrower and the Galen Entities entered into a First Amendment to
Bridge Loan Agreement dated as of September 17, 1998 (the "First Amendment"),
pursuant to which the Galen Entities made a loan to Borrower in the amount of
$500,000 (the "First Amendment Loan"), as evidenced by a promissory note
("Bridge Note 2") in such amount;
WHEREAS, Borrower and the Galen Entities entered into a Second Amendment
to Bridge Loan Agreement dated as of October 2, 1998 (the "Second Amendment"),
pursuant to which the Galen Entities made a loan to Borrower in the amount of
$500,000 (the "Second Amendment Loan"), as evidenced by a promissory note
("Bridge Note 3") in such amount;
WHEREAS, Borrower, the Galen Entities and Michael Weisbrot and Susan
Weisbrot (each, a "Lender" and collectively, the "Weisbrots") entered into a
Third Amendment to Bridge Loan Agreement dated as of October 19, 1998 (the
"Third Amendment"), pursuant to which the Galen Entities made a loan to Borrower
in the amount of $150,000 (the "Third Amendment Galen Loan"), as evidenced by a
promissory note ("Bridge Note 4") in such amount, and, pursuant to which the
Weisbrots made a loan to Borrower in the amount of $100,000 (the "Third
Amendment Weisbrot Loan", as evidenced by a promissory note ("Bridge Note 5") in
such amount (the Third Amendment Galen Loan and the Third Amendment Weisbrot
Loan, collectively the "Third Amendment Loan");
WHEREAS, Borrower and the Galen Entities entered into a Fourth Amendment
to Bridge Loan Agreement dated as of October 29, 1998 (the "Fourth Amendment"),
pursuant to which the Galen Entities made a loan to Borrower in the amount of
$750,000 (the "Fourth Amendment Loan"), as evidenced by a promissory note
("Bridge Note 6") in such amount;
1
WHEREAS, Borrower and the Galen Entities entered into a Fifth Amendment to
Bridge Loan Agreement dated as of November 6, 1998, pursuant to which the Galen
Entities made a loan to Borrower in the amount of $1,500,000 (the "Fifth
Amendment Loan"), as evidenced by a promissory note ("Bridge Note 7") in such
amount (the Initial Bridge Loan, the First Amendment Loan, the Second Amendment
Loan, the Third Amendment Loan, the Fourth Amendment Loan and the Fifth
Amendment Loan, collectively, the "Original Bridge Loan" and Bridge Note 1,
Bridge Note 2, Bridge Note 3, Bridge Note 4, Bridge Note 5, Bridge Note 6 and
Bridge Note 7, collectively, the "Original Notes");
WHEREAS, Borrower has requested that some or all Lenders consider making
an additional $3,250,000 bridge loan to Borrower ("Additional Bridge Loan");
WHEREAS, to induce such Lenders to extend to Borrower the Additional
Bridge Loan, Borrower has agreed to execute this Amended, Restated and
Consolidated Bridge Loan Agreement (the "Agreement");
WHEREAS, some or all of the Lenders, as signatories to a certain Debenture
and Warrant Purchase Agreement dated as of March 10, 1998 (the "Debenture and
Warrant Purchase Agreement") and as holders of certain 10% convertible
subordinated debentures issued and dated August 6, 1996 (the "1996 Debentures")
desire to participate in this Agreement by exercising certain first refusal or
preemptive rights granted under Section 16.1 of the Debenture and Warrant
Purchase Agreement and under Article 8A of the 1996 Debentures;
WHEREAS, Borrower and Lenders desire to amend and restate the Original
Bridge Loan Agreement and consolidate the Original Bridge Loan with the
Additional Bridge Loan, such that the terms of such Original Bridge Loan as set
forth in the Original Bridge Loan Agreement, as so amended and restated, the
terms of such Additional Bridge Loan and the terms of such consolidation, are
set forth in this Agreement;
NOW, THEREFORE, in consideration of the mutual promises contained herein,
and for other good and valuable consideration, the recipient and sufficiency of
which are hereby acknowledged, the parties hereto hereby agree as follows:
2
SECTION 1.
DEFINITIONS, TERMS AND HEADINGS
1.1. General Definitions.
Additional Bridge Loan has the meaning set forth in the Recitals to
this Agreement.
Additional Bridge Loan Commitment means the commitment of each
Lender to fund the dollar amount of its share of the Additional Bridge Loan in
the amount set forth opposite such Lender's name on Exhibit A, copy of which is
attached hereto and made a part hereof.
Affiliate of a Person means another Person who directly or
indirectly controls, is controlled by, is under common control with or is a
director or officer of, such Person. For purposes of this definition, "control"
means the possession, directly or indirectly, of the power to vote five percent
(5%) or more of the securities having ordinary voting power for the election of
directors or the direct or indirect power to direct the management and policies
of a business.
Agency Agreement means the Agency Agreement by and among the Agent
and each Lender dated as of the date hereof and entered into simultaneously
herewith, substantially in the form of Exhibit E attached hereto
Agreement means this Agreement, as the same may be amended,
extended, modified, restated or supplemented from time to time.
Authorizations means all filings, recordings and registrations with,
and all validations or exemptions, approvals, orders, authorizations, consents,
licenses, certificates and permits from any Governmental Authority.
Bridge Loan Documents mean, collectively, this Agreement, the Notes,
the Warrants, the Consent and Waiver, the Agency Agreement, each of the
Collateral Documents and all other documents, agreements, instruments, opinions
and certificates now or hereafter executed and delivered in connection herewith
or therewith, as amended, extended, modified, restated or supplemented from time
to time.
Business Day means any day other than a Saturday, Sunday or other
day on which commercial banks in New York City are authorized or required by law
to close.
Closing Date means the date upon which the last of the events, the
fulfillment of each of which is condition precedent to the effectiveness of this
Agreement, as set forth in Section 3 of this Agreement, shall have occurred.
Code has the meaning set forth in Section 1.3.
3
Collateral means all property of Borrower, of whatever kind or
nature whether now owned or hereafter acquired or created, wherever located,
including, without limitation, all property identified as security for the
Obligations under the Collateral Documents.
Collateral Documents means the General Security Agreement, the
Subordination Agreement and all other contracts, instruments and other documents
pursuant to which Liens are now or hereafter granted to Agent, for the benefit
of Lenders, or to Lenders, to secure the Obligations, as any of such documents
may be amended, extended, modified, restated or supplemented from time to time.
Common Stock means the common stock of Borrower, par value $.01 per
share.
Consent and Waiver means the Consent and Waiver executed by Majority
Holders simultaneously herewith as of the date hereof, substantially in the form
of Exhibit D attached hereto.
Consolidated Bridge Loan has the meaning set forth in Section 2.2.
Conversion Shares has the meaning set forth in Section 2.3(b) of
this Agreement.
Debenture and Warrant Purchase Agreement means the Debenture and
Warrant Purchase Agreement by and among Borrower, the Galen Entities, the
Weisbrots and others, dated as of March 10, 1998.
Default means an event, condition or default which, with the giving
of notice, the passage of time, or, both, would be an Event of Default.
Equipment means all present and future machinery, equipment, tenant
improvements, furniture, fixtures, vehicles, tools, parts and attachments in
which Borrower has any interest.
Event(s) of Default has the meaning set forth in Section 9.1.
Existing Credit Facility/ies means the 5% Convertible Senior Secured
Debentures in the aggregate principal amount of $25,800,000 issued pursuant to
the Debenture and Warrant Purchase Agreement.
Expenses means (i) all reasonable costs and expenses of Lenders, or
Agent, on behalf of Lenders, incurred in connection with, arising under or
relating to the Bridge Loan Documents and the transactions contemplated therein
and (ii) all reasonable costs and expenses (including the reasonable fees and
expenses of legal counsel and other professionals) paid or incurred by Lenders,
or Agent, on behalf of Lenders, (a) during the continuance of an Event of
Default, (b) in enforcing or defending its rights under or with respect to this
Agreement, the other Bridge Loan Documents, the Collateral Documents or any
other document or instrument now or hereafter
4
executed and delivered in connection herewith, (c) in collecting the
Consolidated Bridge Loan, (d) in foreclosing or otherwise collecting upon the
Collateral or any part thereof and (e) in obtaining any legal, accounting or
other advice in connection with any of the foregoing.
Forfeiture Proceeding means the commencement of any action or
proceeding affecting Borrower before any court, Governmental Authority,
commission, board, bureau, agency or instrumentality, domestic or foreign which
may result in the seizure or forfeiture of any of its property which would cause
a Material Adverse Effect upon the operations, business, properties or financial
condition of Borrower or on the ability of Borrower to perform its obligations
hereunder.
GAAP means generally accepted accounting principles in the United
States as in effect from time to time.
General Security Agreement means the Amended and Restated General
Security Agreement by and between Borrower and Agent dated the date hereof and
executed simultaneously herewith, substantially in the form of Exhibit F
attached hereto.
Governing Documents means certificates or articles of incorporation,
by-laws and other organizational or governing documents.
Governmental Authority means any nation or government, any state or
other political subdivision thereof and any entity exercising executive,
legislative, judicial, regulatory or administrative functions of or pertaining
to government.
Indebtedness of a Person means (a) indebtedness for borrowed money
or for the deferred purchase price of property or services (other than trade
liabilities incurred in the ordinary course of business and payable in
accordance with customary practices), whether on open account or evidenced by a
note, bond, debenture or similar instrument, (b) obligations under capital
leases, (c) reimbursement obligations for letters of credit, banker's
acceptances or other credit accommodations, (d) any direct, indirect, contingent
or non-contingent guaranty or obligation for the indebtedness of another Person,
except endorsements in the ordinary course of business and (e) indebtedness
secured by any Lien on that Person's property, even if that Person has not
assumed such Indebtedness.
Investment means all expenditures made and all liabilities incurred
(contingently or otherwise) for or in connection with the acquisition of stock
or Indebtedness of, or for loans, advances, capital contributions or transfers
of property to, or acquisition of substantially all the assets of, a Person. In
determining the aggregate amount of Investments outstanding at any particular
time, (i) the amount of any Investment represented by a guaranty shall be taken
at not less than the principal amount of the obligations guaranteed and
outstanding; (ii) there shall be deducted in respect of each such Investment any
amount received as a return of capital (but only by repurchase, redemption,
retirement, repayment, liquidating dividend or liquidating distribution); (iii)
there shall not be deducted in respect of any Investment any amounts received as
earnings on such Investment,
5
whether as dividends, interest or otherwise; and (iv) there shall not be
deducted from the aggregate amount of Investments any decrease in the market
value thereof.
Lien means any lien, claim, charge, pledge, security interest,
assignment, hypothecation, deed of trust, mortgage, capitalized lease,
conditional sale, retention of title, or other preferential arrangement having
substantially the same economic effect as any of the foregoing, whether
voluntary or imposed by law.
Majority Holders has the meaning set forth in Section 6.1(p).
Material Adverse Effect means a material adverse effect on (i) the
business, prospects, operations, results of operations, assets, liabilities or
condition (financial or otherwise) of Borrower, (ii) the ability of Borrower to
perform its obligations under the Bridge Loan Documents, (iii) the ability of
Agent or Lenders to enforce the Obligations or realize upon the Collateral, or
(iv) the value of the Collateral or the amount which Lenders would be likely to
receive (after giving consideration to delays in payment and costs of
enforcement) in a liquidation of such Collateral.
Maturity Date means May 30, 1999.
1998 Debentures mean the 5% convertible senior secured debentures
issued pursuant to the Debenture and Warrant Purchase Agreement.
1996 Debentures mean the 10% convertible subordinated debentures
issued and dated August 6, 1996.
Notes has the meaning set forth in Section 2.3.
Obligations means the unpaid principal and interest hereunder,
Expenses and all other obligations and liabilities of Borrower to Lenders under
this Agreement, the Notes, or any other Bridge Loan Document and includes, but
is not limited to, any and all indebtedness of Borrower to Lenders, whether now
existing or hereafter incurred, of every kind and character, direct or indirect,
and whether such indebtedness is from time to time reduced and thereafter
increased, or entirely extinguished and thereafter reincurred, including,
without limitation: (a) indebtedness not yet outstanding, but contracted for, or
with respect to which any other commitment by Lenders exists; (b) all interest
provided in any instrument, document, or agreement (including this Agreement)
which accrues on any indebtedness until payment of such indebtedness in full;
and (c) any moneys payable as hereinabove provided.
Permitted Investments mean (i) marketable direct obligations issued
or unconditionally guaranteed by the United States of America or any agency or
any State thereof maturing within one (1) year from the date of acquisition
thereof, (ii) commercial paper maturing no more than one (1) year from the date
of creation thereof and currently having the highest rating
6
obtainable from either Standard & Poor's Corporation or Moody's Investors
Service, Inc., and (iii) certificates of deposit maturing no more than one (1)
year from the date of investment therein issued by Bank.
Permitted Liens mean:
(a) Liens (i) upon or in any Equipment acquired or held by
Borrower or any of its Subsidiaries to secure the purchase price of such
Equipment or indebtedness incurred solely for the purpose of financing the
acquisition of such Equipment, or (ii) existing on such Equipment at the time of
its acquisition, provided that the Lien is confined solely to the property so
acquired and improvements thereon, and the proceeds of such Equipment.
(b) Liens on Equipment leased by Borrower or any Subsidiary
pursuant to an operating lease in the ordinary course of business (including
proceeds thereof and accessions thereto) incurred solely for the purpose of
financing the lease of such Equipment and Liens arising from UCC financing
statements regarding leases permitted by this Agreement.
(c) Liens incurred in connection with the extension, renewal
or refinancing of the indebtedness secured by Liens of the type described in
clauses (a) through (b) above, provided that any extension, renewal or
replacement Lien shall be limited to the property encumbered by the existing
Lien and the principal amount of the indebtedness being extended, renewed or
refinanced does not increase.
(d) Liens securing the obligation arising out of the Debenture
and Warrant Purchase Agreement.
(e) Liens for taxes, assessments and other governmental
charges, if payment thereof shall not at the time be required to be made, and
provided such reserve as shall be required by GAAP consistently applied shall
have been made therefor;
(f) Liens of workmen, materialmen, vendors, suppliers,
mechanics, carriers, warehouseman and landlords or other like Liens, incurred in
the ordinary course of business for sums not then due or being contested in good
faith, if an adverse decision in which contest would not materially affect the
business of Borrower;
(g) Liens securing indebtedness of Borrower or any
Subsidiaries which (i) relates to a working capital line of credit in an amount
not to exceed $10,000,000 or (ii) is in an aggregate principal amount not
exceeding $500,000;
(h) Statutory Liens of landlords, statutory Liens of banks and
rights of set-off, and other Liens imposed by law, in each case incurred in the
ordinary course of business (i) for amounts not yet overdue or (ii) for amounts
that are overdue and that are being contested in good
7
faith by appropriate proceedings, so long as such reserves or other appropriate
provisions, if any, as shall be required by GAAP shall have been made for any
such contested amounts;
(i) Liens incurred or deposits made in the ordinary course of
business in connection with workers' compensation, unemployment insurance and
other types of social security, or to secure the performance of tenders,
statutory obligations, surety and appeal bonds, bids, leases, government
contracts, trade contracts, performance and return-of-money bonds and other
similar obligations (exclusive of obligations for the payment of borrowed
money);
(j) Any attachment or judgment Lien not constituting an Event
of Default;
(k) Easements, rights-of-way, restrictions, encroachments, and
other minor defects or irregularities in title, in each case which do not and
will not interfere in any material respect with the ordinary conduct of the
business of Borrower or any of its Subsidiaries;
(l) Any (i) Interest or title of a lessor or sublessor under
any lease, (ii) Restriction or encumbrance that the interest or title of such
lessor or sublessor may be subject to, or (iii) Subordination of the interest of
the lessee or sublessee under such lease to any restriction or encumbrance
referred to in the preceding clause (ii), So long as the holder of such
restriction or encumbrance agrees to recognize the rights of such lessee or
sublessee under such lease;
(m) Liens in favor of customs and revenue authorities arising
as a matter of law to secure payment of customs duties in connection with the
importation of goods;
(n) Any zoning or similar law or right reserved to or vested
in any governmental office or agency to control or regulate the use of any real
property;
(o) Liens securing obligations (other than obligations
representing debt for borrowed money) under operating, reciprocal easement or
similar agreements entered into in the ordinary course of business of Borrower
and its Subsidiaries;
(p) The liens listed in the Permitted Lien Schedule of the
Schedule of Exceptions; and
(q) The replacement, extension or renewal of any Lien
permitted by under Section 10.4 of the Debenture and Warrant Purchase Agreement
upon or in the same property theretofore subject or the replacement, extension
or renewal (without increase in the amount or change in any direct or contingent
obligor) of the indebtedness secured thereby.
Person means any individual, sole proprietorship, partnership, joint
venture, trust, unincorporated organization, association, corporation,
institution, entity, party or government (including any division, agency or
department thereof), and its successors, heirs and assigns.
8
Prime Rate means the rate of interest quoted in the "Money Rates"
column of The Wall Street Journal as published in the City of New York from time
to time as the then prevailing prime rate, provided, however, that if no such
rate can be finally determined on any Business Day by reference to such column
or newspaper then the Prime Rate in effect on such day shall mean the rate of
interest then announced by Morgan Guaranty Trust Company as its "prime rate",
"base rate" or "reference rate".
Requirement of Law means any law, treaty, rule or regulation or
determination of an arbitrator, court or other Governmental Authority.
Solvent, when used with respect to any Person on a particular date,
means that on such date: (a) the fair saleable value of its assets is in excess
of the total amount of its liabilities, including, without limitation, the
reasonably expected amount of such Person's obligations with respect to
contingent liabilities, (b) the present fair saleable value of the assets of
such Person is not less than the amount that will be required to pay the
probable liability of such Person on its debts as they become absolute and
matured, (c) such Person does not intend to, and does not believe that it will,
incur debts or liabilities beyond such Person's ability to pay as such debts and
liabilities mature and (d) such Person is not engaged in business or a
transaction for which such Person's property would constitute an unreasonably
small capital.
Subordination Agreement means the subordination agreement by and
among the Borrower, the Agent and the agent acting on behalf of the purchasers
under the Debenture and Warrant Purchase Agreement dated the date hereof and
executed simultaneously herewith, substantially in the form of Exhibit G
attached hereto.
Subsidiary means, with respect to any Person, any corporation,
association or other business entity of which more than fifty percent (50%) of
the total voting power of shares of stock (or equivalent ownership or
controlling interest) entitled (without regard to the occurrence of any
contingency) to vote in the election of directors, managers or trustees thereof
is at the time owned or controlled, directly or indirectly, by that Person or
one or more of the other Subsidiaries of that Person or a combination thereof.
Total Commitment means the commitment of each Lender to fund the
aggregate dollar amount of its share of the Consolidated Bridge Loan, in the
amount set forth opposite such Lender's name on Exhibit A. For purposes of
calculating such Total Commitment, the Total Commitment of the Weisbrots shall
be treated as a single joint and several commitment.
Warrant Shares has the meaning set forth in Section 2.4 of this
Agreement.
Warrants mean the warrants to purchase 689,722 shares, in the
aggregate, of the Common Stock, dated the date hereof, substantially in the form
of Exhibit C hereto.
9
1.2. Accounting Terms and Determinations. Unless otherwise defined or
specified herein, all accounting terms used in this Agreement shall be construed
in accordance with GAAP, applied on a consistent basis. The Financial Statements
required to be delivered hereunder from and after the Closing Date, and all
financial records, shall be maintained in accordance with reasonable accounting
standards and practices, consistently applied.
1.3. Other Terms; Headings. Terms used herein that are defined in the
Uniform Commercial Code in effect in the State of New York (the "Code") shall
have the meanings given in the Code. Each of the words "hereof," "herein," and
"hereunder" refer to this Agreement as a whole. An Event of Default shall
"continue" or be "continuing" until it shall have been cured or until Lenders
shall have agreed in writing to waive such Event of Default. References to
Sections, Articles, Annexes, Schedules, and Exhibits are internal references to
this Agreement, and to its attachments, unless otherwise specified. The headings
and the Table of Contents are for convenience only and shall not affect the
meaning or construction of any provision of this Agreement.
SECTION 2.
TERMS OF THE CONSOLIDATED BRIDGE LOAN
2.1. Commitment. Subject to the terms and conditions of this Agreement:
(i) each Lender hereby agrees to amend and restate the Original Notes and the
Original Bridge Loan Agreement; (ii) each Lender hereby agrees to fund the
amount of its Additional Bridge Loan Commitment and (iii) each Lender hereby
agrees to consolidate the Original Bridge Loan, together with all interest
accrued thereon, with the Additional Bridge Loan.
2.2. Consolidated Bridge Loan. Borrower warrants, represents and confirms
that, as of the Closing Date, (i) the aggregate outstanding principal balance of
the Original Bridge Loan equals $4,500,000, (ii) the aggregate accrued interest
on such principal balance equals $71,111 and (iii) the aggregate outstanding
principal balance of the Additional Bridge Loan equals $3,250,000. Borrower and
Lenders agree that effective on the Closing Date, upon the consolidation of the
outstanding principal balances of the Original Bridge Loan and the Additional
Bridge Loan, and the addition to principal of the accrued interest on the
Original Bridge Loan, Lenders shall be deemed to have made a single loan to
Borrower in the aggregate principal amount of $7,721,111 (the "Consolidated
Bridge Loan").
2.3 Amended, Restated and Consolidated Notes.
(a) The Amount. The Consolidated Bridge Loan is evidenced by
Amended, Restated and Consolidated Notes payable by Borrower to the order of
each Lender, each such Note in the form of Exhibit B attached hereto and each
such Note in the original principal amount equal to such Lender's Total
Commitment (each a "Note" and collectively, "Notes").
10
(b) General Terms. The Notes are 10% Convertible Senior Secured
Notes due on May 30, 1999. Each Note is convertible, in whole or in part, from
time to time, into a number of shares of Common Stock, initially at the rate of
one share of Common Stock for each $1.3688 in principal amount of the Note to be
converted. For purposes of this Agreement, the term "Conversion Shares" shall
mean the shares of Common Stock which may be issued upon conversion of all or a
portion of the principal amount of the Notes.
(c) Adjustment of Conversion Price. The price at which the
Conversion Shares may be acquired upon conversion of the Notes is subject to
adjustment as set forth in Section 3.7 of each Note.
(d) Payment. So long as a Lender shall be the holder of any Note,
Borrower will make payments of principal and interest to such Lender no later
than 11 a.m. Eastern Standard Time on the date when such payment is due.
Payments shall be made by delivery to such Lender at such Lender's address,
furnished to Borrower in accordance with this Agreement, of a certified or
official bank check drawn upon or issued by a bank which is a member of the New
York Clearinghouse for banks or by wire transfer to such Lender's (or such
Lender's nominee's) account at any bank or trust company in the United States of
America, or with respect to the payment of accrued interest on the Notes, shares
of Common Stock, as provided in Section 2.3(e) below. Each Lender further agrees
that, before a Note is assigned or transferred, such Lender will make or cause
to be made a notation thereon of principal payments previously made thereof and
of the date to which interest thereon has been paid and will notify Borrower of
the name and address of the transferee of such Note.
(e) Interest.
(i) Payment of Interest. Borrower shall pay interest to
Lenders on the aggregate unpaid principal amount of the Consolidated Bridge Loan
at the fixed rate of ten percent (10%) per annum at Maturity Date, as further
set forth in each Note. Interest shall be calculated on the basis of a year of
360 days for the actual number of days elapsed. Each Lender shall have the
option of (i) having the accrued interest on the principal of such Lender's Note
paid at the Maturity Date in immediately available funds, or, alternatively,
having the accrued interest on the principal of such Lender's Note converted
into shares of Common Stock, the conversion price to be based on the average
closing price of the Common Stock for the twenty (20) days prior to the payment
date of the interest payment or as reported by the American Stock Exchange.
Interest on the Consolidated Bridge Loan shall be paid in arrears on the date of
any prepayment (on the amount prepaid), and on the Maturity Date (whether by
acceleration or otherwise).
(ii) Excessive Interest. Notwithstanding any provision
contained in this Agreement or any other Bridge Loan Document to the contrary,
Lenders shall not be entitled to receive, collect or apply, as interest on the
Consolidated Bridge Loan under this Agreement, any amount in excess of the
maximum rate of interest permitted to be charged by applicable law, and, if
Lenders shall have received, collected or applied as interest any such excess,
such amount which
11
would be excessive interest shall be applied first to the reduction of principal
then outstanding, and second, if such principal amount is paid in full, any
remaining excess shall forthwith be returned to Borrower.
(f) Prepayments of Notes. Borrower may not, without having received
the prior written consent of the Majority Holders ("Majority Approval") prepay
any Note, in whole or in part. Upon receipt of Majority Approval, Borrower may,
upon at least three (3) Business Days' prior written notice to the Lenders,
prepay the Notes, in whole or in part, with accrued interest to the date of such
prepayment on the amount prepaid, provided that each such partial prepayment
shall be in a principal amount of not less than $100,000. Prepayment of all or
any portion of the Notes shall not entitle the Borrower to reborrow the amount
so prepaid.
(g) Interest After Event of Default. From the date of occurrence of
an Event of Default until the earlier to occur of the date upon which (i) all
Obligations shall have been paid and satisfied in full or (ii) such Event of
Default shall have been waived, interest on the Consolidated Bridge Loan shall
be payable on demand at a rate per annum equal to the Prime Rate plus five and
three-quarter percent (5-3/4%).
(h) Exchange or Replacement.
(i) Notice of Exchange or Replacement. Subject to Sections 2.3
(d); 2.3(g)(ii)and 10.13 below, at any time at the request of any holder of one
or more of the Notes to Borrower at its office provided under Section 10.6 (the
Notice Provision), Borrower, at its expense (except for any transfer tax or any
other tax arising out of the exchange) will issue in exchange therefor new
Notes, in such denomination or denominations ($100,000 or any larger multiple of
$100,000, plus one Note in a lesser denomination, if required) as such holder
may request, in the aggregate principal amount equal to the unpaid principal
amount of the Note or Notes surrendered and substantially in the form thereof,
dated as of the date to which interest has been paid on the Note or Notes
surrendered (or, if no interest has yet been so paid thereon, then dated the
date of the Note or Notes so surrendered) and payable to such person or persons
or order as may be designated by such holder.
(ii) Actual Exchange or Replacement. Upon receipt of evidence
satisfactory to Borrower of the loss, theft, destruction or mutilation of any
Note and, in the case of any such loss, theft, or destruction, upon delivery of
a bond of indemnity satisfactory to Borrower (provided that if the holder is a
Lender or a financial institution, its own agreement will be satisfactory), or
in the case of any such mutilation, upon surrender and cancellation of such
Note, Borrower will issue a new Note of like tenor as if the lost, stolen,
destroyed or mutilated Note were then surrendered for exchange in lieu of such
lost, stolen, destroyed or mutilated Note.
12
(i) Transfer.
(i) Notification of Proposed Sale. Subject to Sections 2.3
(h)(ii) and 10.13 below, each holder of a Note, by acceptance thereof, agrees
that it will give Borrower ten (10) days written notice prior to selling or
otherwise disposing of such Note. No such sale or other disposition shall be
made unless:
(a) the holder shall have supplied to Borrower an
opinion of counsel to the holder, reasonably acceptable to Borrower, to the
effect that no registration under the Securities Act of 1933, as amended (the
"Securities Act") is required with respect to such sale or other disposition, or
(b) an appropriate registration statement with respect
to such sale or other disposition shall have been filed by Borrower and declared
effective by the Securities and Exchange Commission (the "Commission").
(ii) Transfer without Notification. If the holder of a Note
has obtained an opinion of counsel reasonably acceptable to Borrower to the
effect that the sale of its Note may be made without registration under the
Securities Act pursuant to compliance with Rule 144 (or any successor rule under
the Securities Act), the holder need not provide Borrower with the notice
required in Section 2.3 (h)(i) above.
2.4 Warrants. Subject to the terms of this Agreement and the terms of the
Warrants substantially in the form of Exhibit C, Borrower will issue Warrants to
purchase in the aggregate, 689,722 shares of the Common Stock, initially, at a
price per share equal to the average closing price of a share of the Common
Stock for the twenty (20) trading days immediately preceding the Closing Date,
as reported the price of each share is reported by the American Stock Exchange.
The Warrants shall be issued to each of Lenders in the amounts set forth
opposite their names on Exhibit A. For purposes of this Agreement, the term
"Warrant Shares" shall mean the shares of Common Stock that may be issued from
time to time pursuant to the exercise of the Warrants.
2.5 Security; Subordination of the Existing Credit Facility. All of the
Obligations of Borrower under this Agreement will be secured by the General
Security Agreement, substantially in the form of Exhibit F. The indebtedness and
Liens granted by Borrower pursuant to the Debenture and Warrant Purchase
Agreement are subordinate to the indebtedness and Liens granted by Borrower
pursuant to this Agreement, in accordance with the terms of the Subordination
Agreement, substantially in the form of Exhibit G.
2.6 Registration Rights. The Conversion Shares and the Warrant Shares are
entitled to the registrations rights set forth in Section 8 of this Agreement.
13
2.7 Consent and Waiver. The lien, indebtedness and registration right
restrictions and limitations have been waived by the holders of the 1998
Debentures pursuant to the Consent and Waiver, substantially in the form of
Exhibit D.
2.8 Agency Agreement. In connection with the acts contemplated under this
Agreement, the Bridge Loan Documents, the Collateral Documents or any other
document relating hereto or thereto, the rights, powers, duties and obligations
of Agent are set forth in the Agency Agreement, substantially in the form of
Exhibit E.
2.9 Miscellaneous.
(a) Expenses. Borrower shall reimburse the Expenses of Lenders
and Agent promptly upon demand. Payment of Expenses shall be made not later than
2:00 P.M. Eastern Standard Time on the day when due, in immediately available
funds, to the offices of the Agent, at its offices located at the address set
forth on Exhibit A, or as Agent may otherwise direct Borrower.
(b) Distribution and Application of Payments. Unless an Event
of Default has occurred and is continuing, all payments received by Agent shall
be applied against the Obligations in the following order: first, to the payment
of any Expenses due and payable to Agent under any of the Bridge Loan Documents;
second, to the ratable payment of any Expenses or Obligations due and payable to
Lenders under any of the Bridge Loan Documents, other than those Obligations
specifically referred to in the two clauses below; third, to the ratable payment
of interest due on the Consolidated Bridge Loan; and, finally, to the ratable
payment of principal due on the Consolidated Bridge Loan.
SECTION 3
CONDITIONS PRECEDENT
3.1. Conditions Precedent to Consolidated Bridge Loan. The obligation of
each Lender to fund its ratable portion of the Additional Bridge Loan is subject
to the satisfaction or waiver of the following conditions precedent:
(a) Each Lender shall have received duly executed originals
of:
(i) this Agreement;
(ii) its Note;
(iii) its Warrant;
(iv) the General Security Agreement;
(v) the Subordination Agreement;
(vi) the Agency Agreement; and
(vii) the Waiver and Consent;
14
each conforming to the requirements hereof and executed as of the date of this
Agreement by a duly authorized representative of Borrower, the Agent and each
Lender, as the case may require.
3.2. No Liens. From the date of effectiveness of the Fifth Amendment to
the Closing Date of this Agreement, no Liens shall have arisen or been recorded
against the Collateral.
3.3. Representations and Warranties Correct. The representations and
warranties in Section 4 hereof shall be true and correct in all material
respects when made, and shall be true and correct in all material respects on
the Closing Date with the same force and effect as if they had been made on and
as of the Closing Date.
3.4. Legal Opinion of Counsel to Borrower. Agent and Lenders shall have
received an opinion of St. John & Wayne, L.L.C., counsel to Borrower, which
opinion shall be dated as of the Closing Date and shall be reasonably
satisfactory to Agent and Lenders and their respective counsel.
3.5. Officer's Certificate. Agent shall have received an Officer's
Certificate of Borrower dated as of the Closing Date, certifying as to the (i)
Borrower's Certificate of Incorporation and all amendments thereto, (ii)
accuracy and completeness of all By-Laws attached thereto, (iii) updated
Certificates of Good Standing with respect to the Borrower from the Secretaries
of State of New York and Illinois, (iv) resolutions of the Borrower's Board of
Directors approving the transactions relating to this Agreement and (v)
incumbency and signature of the Borrower's duly authorized officers signing this
Agreement and each of the Bridge Loan Documents to which it or they are a party
and any other certificate or other document to be delivered pursuant thereto,
together with evidence of the incumbency of such officer signing the same.
3.6. Closing Fees. All Expenses outstanding as of the date of this
Agreement, including legal fees, relating to this Agreement and any and all
documents relating thereto shall have been paid on or prior to the Closing Date.
SECTION 4
REPRESENTATIONS AND WARRANTIES
4.1. Representations and Warranties of Borrower. To induce Lenders to
enter into this Agreement and make the Additional Bridge Loan, Borrower hereby
represents and warrants to Lenders that the representations and warranties
contained in this Section 4 are true, correct and complete. Such representations
and warranties, and all other representations and warranties made by Borrower in
any other Bridge Loan Documents, shall survive the execution and delivery of
this Agreement and such other Bridge Loan Documents.
(a) Organization and Qualification. Borrower (i) is a corporation
duly organized, validly existing and in good standing under the laws of the
state of its incorporation,
15
(ii) has the power and authority to own its properties and assets and to
transact the businesses in which it presently is, or proposes to be, engaged and
(iii) is duly qualified and is authorized to do business and is in good standing
in each jurisdiction where it presently is, or proposes to be, engaged in
business, except where the failure to so qualify would not have a Material
Adverse Effect.
(b) Authority; Consents and Filings. Borrower has the requisite
corporate power and authority to execute and deliver each of the Bridge Loan
Documents. Subject to: (a) compliance with the terms of the right of first
refusal provided (i) in Section 16.1 of the Debenture and Warrant Purchase
Agreement and (ii) in Article 8A of the 10% convertible subordinated debentures
issued and dated August 6, 1996 and (b) the receipt of shareholder approval (i)
to amend Borrower's certificate of incorporation to increase its authorized
shares of Common Stock and (ii) to the extent required under Section 713 of the
American Company Stock Exchange Guide, to authorize the issuance of the
Conversion Shares and the Warrant Shares in the event a dilution adjustment to
the Warrants results in an issuances of the Conversion Shares or the Warrant
Shares at less than fair market value, no consent, authorization, permit or
filing is required in connection with the execution, delivery and performance of
this Agreement or any Bridge Loan Document, or the continuing operations of
Borrower, except (i) those that have been obtained or made and (ii) filings
necessary to create, perfect or retain the perfection of Liens against the
Collateral. Except as otherwise set forth in this Section, all corporate action
necessary for the execution, delivery and performance of any of the Bridge Loan
Documents has been taken, provided however, that the listing of the Conversion
Shares and the Warrant Shares on the American Stock Exchange is subject to the
consent of the American Stock Exchange.
(c) Enforceability. This Agreement and each Bridge Loan Document is
the legal, valid and binding obligation of Borrower, enforceable in accordance
with its terms, except as such enforceability may be limited by (i) bankruptcy,
insolvency or similar laws affecting creditors' rights generally, and (ii)
general principles of equity.
(d) No Conflict. The execution, delivery and performance of each
Bridge Loan Document by Borrower is not in contravention of (i) the Governing
Documents of Borrower, or (ii) any Requirement of Law, or (iii) any franchise,
license, permit, indenture, contract, lease, agreement (other than the loan
agreements or security agreements executed in connection with the Existing
Credit Facilities), instrument or other commitment to which it is a party or by
which it or any of its properties are bound and will not, except as contemplated
herein, result in the such imposition of any Liens upon any of its properties.
No order, consent, approval, license, authorization, or validation of, or
filing, recording or registration with, or completion by, any Governmental
Authority, or any subdivision thereof, is required to authorize, or is required
in connection with the execution, delivery and performance of, or the legality,
validity, binding effect or enforceability of, this Agreement or any of the
other Bridge Loan Documents.
(e) Government Regulation. Borrower is not subject to regulation
under the Public Utility Holding Company Act of 1935, the Federal Power Act, the
Interstate Commerce Act, the Investment Company Act of 1940, or any other
Requirement of Law, other than the
16
Bankruptcy Code, that limits its ability to incur indebtedness or its ability to
consummate the transactions contemplated in this Agreement and the other Bridge
Loan Documents.
(f) Indebtedness; Rights in Collateral. Borrower is not obligated or
liable with respect to any Indebtedness, other than Indebtedness described on
Borrower's Form 10-Q for the quarter ended September 30, 1998. All Collateral is
owned or leased by Borrower, free and clear of any and all Liens in favor of
third parties, other than the Permitted Liens, those Liens permitted in the
Existing Credit Facilities and the Lien in favor of Lenders. Upon the proper
filing of the UCC financing statements executed by Borrower in favor of the
Agent, the security interests granted pursuant to the Bridge Loan Documents
constitute valid and enforceable and perfected Liens on the Collateral, to the
extent such Liens can be perfected by the filing of such financing statements.
(g) Locations of Offices, Records and Inventory. The address of the
principal place of business and chief executive office of Borrower is set forth
on Borrower's Form 10-Q for the quarter ended September 30, 1998. The books and
records of Borrower, and all its chattel paper and records of Accounts, are
maintained exclusively at such locations. There is no jurisdiction in which
Borrower has any Collateral (except for vehicles and Inventory in transit for
processing) other than those jurisdictions identified on Borrower's Form 10-Q
for the quarter ended September 30, 1998.
(h) Inventory. All inventory of Borrower consists of a quality and
quantity usable and salable in the ordinary course of business, except for
obsolete items and items of below-standard quality, all of which have been or
will be written off or written down to net realizable value on the unaudited
consolidated balance sheet of Borrower and its Subsidiaries as of September 30,
1998. The quantities of each type of inventory (whether raw materials,
work-in-process, or finished goods) are not excessive, but are reasonable and
warranted in the present circumstances of Borrower.
(i) No Judgments or Litigation. No judgments, orders, writs or
decrees are outstanding against Borrower nor is there now pending or, to the
best of Borrower's knowledge after diligent inquiry, threatened, any litigation,
contested claim, investigation, arbitration, or governmental proceeding by or
against Borrower, other than those which, either singly or in the aggregate,
would not have a Material Adverse Effect other than those identified on
Borrower's Form 10-Q for the quarter ended September 30, 1998 and at its
Brooklyn facility located at 1827 Pacific Street, Brooklyn, New York 11233.
(j) No Defaults. Borrower is not in default in any material respect
under any term of any indenture, contract, lease, agreement, instrument or other
commitment to which it is a party or by which it is bound. Except as otherwise
described on Borrower's Form 10-Q for the quarter ended September 30, 1998,
Borrower knows of no dispute regarding any such indenture, contract, lease,
agreement, instrument or other commitment.
17
(k) Financial Information, SEC Documents. None of the documents
filed by Borrower with the Commission since December 31, 1995 contain any untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements contained therein
not false or misleading in light of the circumstances in which they were made.
There is no fact known to Borrower which Borrower has not disclosed to Lenders
prior to or as of the date of this Agreement which materially and adversely
affects, or in the future is likely to materially and adversely affect, the
business, properties, condition (financial or otherwise) or business prospects
of Borrower and its Subsidiaries, taken as a whole.
(l) Compliance with Law. Borrower has not violated or failed to
comply in any material respect with any Requirement of Law, including without
limitation (a) applicable rules and regulations of any Governmental Authority
having jurisdiction over its activities, (b) environmental laws, the consequence
of which violation or failure has or is reasonably likely to have a Material
Adverse Effect.
(m) Intellectual Property. Borrower possesses such assets, licenses,
patents, patent applications, copyrights, service marks, trademarks, trade
names, New Drug Applications, Investigatory New Drug Applications, Abbreviated
New Drug Applications, Alternative New Drug Applications, registrations and
quotas as issued by the Drug Enforcement Agency or the Attorney General of the
United States pursuant to the Controlled Substances Act, as are necessary or
advisable to continue to conduct its present and proposed business activities.
(n) Licenses and Permits
(i) Generally. Borrower and its Subsidiaries possesses such
franchises, licenses, permits and other authority as are necessary for the
conduct of its business as now being conducted and proposed to be conducted
(except where the failure to possess such franchises, licenses, permits or other
authority would not have a Material Adverse Effect on Borrower and its
Subsidiaries taken as a whole) and Borrower and its Subsidiaries are not in
default under any of such franchises, licenses, permits or other authority.
Other than the approval required under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended (the "HSR Act"); other than as set forth in
Schedule 4.10 of the Schedule of Exceptions or [Selected Reports] to the
Debenture and Warrant Purchase Agreement; and other than those consents that
have been obtained; no approval, consent, authorization or other order of, and
no designation, filing, registration, qualification or recording with, any
governmental authority or any other person or entity is required in connection
with Borrower's valid execution, delivery and performance of this Agreement or
the offer, issuance and sale of the Notes, Warrants, the Conversion Shares or
the Warrant Shares by Borrower to Lenders or the consummation of any other
transaction contemplated on the part of Borrower hereby.
(ii) The FDC, FDA, DEA and Controlled Substances Act, etc.
Without limiting the generality of the representations and warranties made in
Section 4.1(n)(i) above, Borrower represents and warrants that (1) it and its
Subsidiaries are in compliance in all material
18
respects with all applicable provisions of the Federal Food, Drug, and Cosmetic
Act (the "FDC Act"), (2) its products and those of its Subsidiaries are not
adulterated or misbranded and are in lawful distribution, and (3) it and its
Subsidiaries are in compliance with the following specific requirements:
Borrower and its Subsidiaries have registered all facilities with the United
States Food and Drug Administration (the "FDA"); Borrower and its Subsidiaries
have listed all drug products with the FDA; each drug product marketed by
Borrower or any Subsidiary is the subject of an application approved by the FDA;
all marketed drug products comply with any conditions of approval and the terms
of the application submitted to the FDA; all drug products are manufactured in
compliance with the FDA's good manufacturing practice regulations; all products
are labeled and promoted in accordance with the terms of the marketing
application and the provisions of the FDC Act; all adverse events that were
required to be reported to the FDA have been reported to the FDA in a timely
manner; each of Borrower and its Subsidiaries is in compliance in all material
respects with the terms of the consent agreement entered into by Borrower with
the United States Attorney for the Eastern District of New York on behalf of the
FDA on June 29, 1993, as modified by the Joint Motion for Modification of
Sentence dated May 8, 1998; to Borrower's knowledge, neither Borrower nor any
Subsidiary is employing or utilizing the services of any individual who has been
debarred under the FDC Act; all stability studies required to be performed for
products distributed by Borrower or a Subsidiary have been completed or are
ongoing in accordance with the applicable FDA requirements; any products
exported by Borrower or a Subsidiary have been exported in compliance with the
FDC Act; and each of Borrower and its Subsidiaries is in compliance in all
material respects with the provisions of the Prescription Drug Marketing Act, to
the extent applicable. Without limiting the generality of the representations
and warranties made in Section 4(q)(i), Borrower also represents and warrants
that it and its Subsidiaries are in compliance in all material respects with all
applicable provisions of the Controlled Substances Act (the "CSA") and that
Borrower and its Subsidiaries are in compliance with the following specific
requirements: Borrower and its Subsidiaries are registered with the Drug
Enforcement Administration (the "DEA") at each facility where controlled
substances are exported, imported, manufactured or distributed; all controlled
substances are stored and handled pursuant to DEA security requirements; all
records and inventories of receipt and distributions of controlled substances
are maintained in the manner and form as required by DEA regulations; all
reports, including, but not limited to, ARCOS, manufacturing quotas, production
quotas, and disposals, have been submitted to DEA in a timely manner; all
adverse events, including thefts or significant losses of controlled substances,
have been reported to DEA in a timely manner; to Borrower's knowledge, neither
Borrower nor any Subsidiary is employing any individual, with access to
controlled substances, who has previously been convicted of a felony involving
controlled substances; and any imports or exports of controlled substances have
been conducted in compliance with the CSA and DEA regulations.
(o) Taxes. Except as set forth on Schedule A to the General Security
Agreement, Borrower has filed all tax returns (federal, state and local)
required to be filed by it and Borrower has paid all taxes, assessments and
governmental charges and levies thereon that are due, including interest and
penalties, other than taxes, assessments and governmental charges and levies
being contested in good faith by appropriate proceedings and with respect to
which adequate
19
reserves, in conformity with GAAP, consistently applied, shall have been
provided on the books of Borrower.
(p) Labor Disputes and Acts of God. Neither the business nor the
properties of Borrower are affected by any fire, explosion, accident, strike,
lockout or other labor dispute, drought, storm, hail, earthquake, embargo, act
of God or of the public enemy or other casualty (whether or not covered by
insurance), materially and adversely affecting such business or properties or
the operations of Borrower or the ability of Borrower to perform its
obligations.
(q) Partnerships. Borrower is not a partner in any partnership.
(r) Solvency. Borrower is solvent.
(s) Forfeiture Proceeding. Borrower is not engaged in or does not
propose to be engaged in the conduct of any business or activity which could
result in a Forfeiture Proceeding and no Forfeiture Proceeding against Borrower
is pending, or to the best knowledge of Borrower, threatened.
(t) Offering. Subject in part to the truth and accuracy of Lenders'
representations and the compliance by Lenders with its covenants set forth in
this Agreement and any subscription agreement executed and delivered by Lenders,
the issuance of the Notes, the Warrants, the Conversion Shares and the Warrant
Shares as contemplated by this Agreement are not subject to the registration
requirements of the Securities Act, and, Borrower, or anyone acting on its
behalf, will not take any action hereafter that would cause such registration
requirements to be applicable.
(u) No Discrimination. Borrower does not in any manner or form
discriminate, foster discrimination or permit discrimination against any person
on the grounds of age, color, handicap, mental status, national origin, race,
religion or sex.
(v) ERISA. Borrower has not received any notice indicating that it
is not in compliance with any of the requirements of the Employee Retirement
Income Security Act, as amended ("ERISA") and the regulations promulgated
thereunder. With respect to the Borrower, there exists no event described in
Section 4043 of ERISA.
(w) Registration Rights. Except as provided for in this Agreement,
the Debenture and Warrant Purchase Agreement, and as set forth in Schedule 4.14
of the Debenture and Warrant Purchase Agreement, the Borrower is not under any
binding obligation to register any of its currently outstanding securities or
any of its securities which may hereafter be issued.
(x) Accuracy and Completeness of Information. All factual
information furnished by or on behalf of Borrower in writing to Lenders for
purposes of or in connection with this Agreement or any Bridge Loan Documents,
or any transaction contemplated hereby or thereby
20
is or will be true and accurate in all material respects on the date as of which
such information is dated or certified and not incomplete by omitting to state
any material fact necessary to make such information not misleading at such
time.
4.2. Representations and Warranties of Lenders. Each Lender represents and
warrants that:
(a) Investment Intent. The Warrants and the Notes being acquired
hereunder and the Conversion Shares and Warrant Shares that may be acquired upon
conversion or of any of the Notes or Warrants, as the case may be, would be
acquired for its own account and not with the view to, or the resale in
connection with, any distribution or public offering thereof within the meaning
of the Securities Act by reason of their issuance in a transaction exemption
from the registration and prospectus delivery requirements of the Securities Act
pursuant to Section 4(2) thereof, that they must be held indefinitely unless
they are registered under the Securities Act or are exempt from registration and
that the reliance of Borrower and others upon this exemption is predicated in
part upon this representation and warranty.
(b) Acts and Proceedings. This Agreement has been duly authorized by
all necessary action on the part of each Lender, has been executed and delivered
by it and is a valid and binding agreement upon its part, enforceable in
accordance with its terms, except as such enforceability may be limited by (i)
bankruptcy, insolvency or similar laws affecting creditors' rights generally,
and (ii) general principles of equity.
SECTION 5.
CHANGE OF CONTROL
PURCHASE OFFER; CONVERSION RIGHTS
5.1. Change of Control.
(a) Upon the occurrence of a Change of Control (as hereinafter
defined), Borrower shall make an offer to all holders of Notes to purchase (a
"Change of Control Offer") all outstanding Notes and will purchase, on a day not
more than thirty (30) days after the occurrence of the Change of Control (such
purchase date being the "Change of Control Purchase Date"), all Notes properly
tendered pursuant to such offer to purchase for a cash price (the "Change of
Control Purchase Price") equal to 150% of the outstanding principal amount of
the Notes, plus accrued and unpaid interest, if any, to the Change of Control
Purchase Date.
(b) In order to effect a Change of Control Offer, Borrower shall,
within ten (10) days after the occurrence of a Change of Control, in accordance
with Section 10.6 (the Notice Provision), provide a Change of Control Offer to
each Note holder. The Change of Control Offer shall remain open from the time of
receipt thereof for at least fifteen (15) calendar days. The notice,
21
which shall govern the terms of the Change of Control Offer, shall include such
disclosures as are required by law and shall state:
(i) the date of such Change of Control and, briefly, the
events causing such Change of Control;
(ii) that the Change of Control Offer is being made pursuant
to this Section 5.1 and that all Notes properly tendered pursuant to the Change
of Control Offer will be accepted for payment;
(iii) the Change of Control Purchase Price for each Note, the
Change of Control Purchase Date, the date on which the Change of Control Offer
expires, that if the holder desires to accept the Change of Control Offer, the
Note held by such holder must be surrendered to Borrower or any designated
paying agent of Borrower prior to 5:00 p.m. Eastern Standard Time on the Change
of Control Purchase Date, and the name and address of any such paying agent, if
any;
(iv) that any Note not tendered for payment will continue to
accrue interest in accordance with the terms thereof;
(v) that, unless Borrower shall default in the payment of the
Change of Control Purchase Price, any Note accepted for payment pursuant to the
Change of Control Offer shall cease to accrue interest after the Change of
Control Purchase Date;
(vi) that holders will be entitled to withdraw their
acceptance of the Change of Control Offer election if Borrower or paying agent
of Borrower receives, not later than 5:00 p.m. Eastern Standard Time on the day
preceding the Change of Control Purchase Date a telex or facsimile transmission
(confirmed by overnight delivery of the original thereof) or letter setting
forth the name of the holder, the principal amount of Notes the holder delivered
for purchase, and a statement that such holder is withdrawing its election to
have such Notes purchased;
(vii) that holders whose Notes are purchased only in part will
be issued Notes equal in principal amount to the unpurchased portion of the
Notes surrendered; and
(viii) any other instructions that holders must follow in
order to tender their Notes and the procedures for withdrawing an election to
accept a Change of Control Offer.
(c) On the Change of Control Purchase Date, Borrower shall accept
for payment Notes or portions thereof tendered pursuant to the Change of Control
Offer and deposit with the paying agent, if any, money in United States dollars,
in immediately available funds, sufficient to pay the Change of Control Purchase
Price of all Notes or portions thereof so tendered and accepted. Borrower shall,
or cause any paying agent to, promptly disburse or deliver to the holders of
Notes so accepted payment in an amount equal to such Change of Control Purchase
Price,
22
and mail or deliver to such holders a new Note equal in principal amount to any
unpurchased portion of each Note surrendered.
(d) Borrower shall comply, to the extent applicable, with the
requirements of Section 14(e) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and any other securities laws or regulations, in
connection with the repurchase of Notes pursuant to a Change of Control Offer.
To the extent that the provision of any securities laws or regulations conflict
with the provisions of this Section 5.1, Borrower shall comply with the
applicable securities laws and regulations and shall not be deemed to have
breached its obligations under this Section 5.1 by virtue thereof.
(e) For purposes of this Section:
(i) the term "Change of Control" means the occurrence of any
of the following: the consummation of any transaction the result of which is
that any person or group (as such term is used in Section 13(d)(3) of the
Exchange Act), other than any of the Galen Entities, the Lenders or any
Affiliate thereof or any group comprised of any of the foregoing, owns, directly
or indirectly, 51% of the Common Equity (as hereinafter defined) of Borrower,
Borrower consolidates with, or merges with or into, another person (other than a
direct or indirect wholly-owned Subsidiary) or sells, assigns, conveys,
transfers, leases or otherwise disposes of all or substantially all of
Borrower's assets or the assets of Borrower and its Subsidiaries taken as a
whole to any person, or any person consolidates with, or merges with or into,
Borrower, in any such event pursuant to a transaction in which the outstanding
Voting Stock (as hereinafter defined) of the Borrower, as the case may be, is
converted into or changed for cash, securities or other property, other than any
such transaction where the outstanding Voting Stock of Borrower, as the case may
be, is converted into or exchanged for Voting Stock of the surviving or
transferee corporation and the beneficial owners of the Voting Stock of Borrower
immediately prior to such transaction own, directly or indirectly, not less than
a majority of the Voting Stock of the surviving or transferee corporation
immediately after such transaction, Borrower, either individually or in
conjunction with one or more Subsidiaries sells, assigns, conveys, transfers,
leases or otherwise disposes of, or the Subsidiaries sell, assign, convey,
transfer, lease or otherwise dispose of, all or substantially all of the
properties and assets of Borrower and its Subsidiaries, taken as a whole (either
in one transaction or a series of related transactions), including capital stock
of the Subsidiaries, to any person (other than Borrower or a wholly owned
Subsidiary of Borrower), or during any two (2) year period commencing subsequent
to the date of this Agreement, individuals who at the beginning of such period
constituted the Board of Directors of Borrower (together with any new directors
whose election by such Board of Directors or whose nomination for election by
the stockholders of Borrower was approved by a vote of two-thirds of the
directors then still in office) who were either directors at the beginning of
such period or whose election or nomination for election was previously so
approved cease for any reason to constitute a majority of the Board of Directors
then in office; provided, however, that a person shall not be deemed to have
ceased being a director for such purpose if such person shall have resigned or
died or if the involuntary removal of such person was made at the direction the
Galen Entities or of persons holding a majority in principal amount of the
outstanding Notes;
23
(ii) the term "Common Equity" of Borrower means all capital
stock of Borrower that is generally entitled to vote on the election of members
of the board of directors and (iii) the term "Voting Stock" of Borrower means
securities of any class of capital stock of Borrower entitling the holders
thereof to vote in the election of members of the board of directors of
Borrower.
SECTION 6.
AFFIRMATIVE COVENANTS
6.1. Until termination of this Agreement and payment and satisfaction of
all Obligations due hereunder, Borrower agrees as follows:
(a) Financial Reporting and Projections. Borrower shall keep
adequate records and books of account with respect to its business activities in
which true, proper and accurate entries are made in accordance with reasonable
accounting standards and practices, reflecting all its financial transactions.
In addition, Borrower shall cause to be prepared and furnished to Lenders the
financial information required to be delivered by it pursuant to the Debenture
and Warrant Purchase Agreement and the documents ancillary thereto, at the times
and in the manner set forth therein, provided, however, that in the event
Borrower is no longer obligated to comply with such financial reporting
requirements, then Borrower shall cause to be prepared and furnished to Lenders
(a) not later than (i) thirty (30) days after the end of each month after the
Closing Date, (ii) forty-five (45) days after the end of each fiscal quarter
after the Closing Date and (iii) 120 days after the end of each fiscal year
after the Closing Date, unaudited Financial Statements as of the end of such
month, quarter and year and of the portion of Borrower's fiscal year then
elapsed, each certified by the chief financial officer of Borrower as prepared
in accordance with GAAP, consistently applied and fairly presenting the
financial position, results of operations and statement of cash flows of
Borrower for such month, quarter and year, and (b) such other data and
information (financial and otherwise) as Lenders, from time to time, may
reasonably request, bearing upon or related to Borrower's financial condition or
results of operations.
(b) Discharge Taxes and Indebtedness. The Borrower will pay and
discharge, as they become due, all taxes, assessments, debts, claims and other
governmental or non-governmental charges lawfully imposed upon or incurred by it
or the properties and assets of the Borrower, except taxes, assessments, debts,
claims and charges contested in good faith in appropriate proceedings for which
the Borrower shall have set aside adequate reserves for the payment of such tax,
assessment, debt, claim or charge. The Borrower shall provide each Lender, upon
Lender's request, evidence of payment of such taxes, assessments, debts, claims
and charges satisfactory to Lender.
(c) Notification Requirements. Borrower shall timely give Lenders
the following notices:
(d) Notice of Defaults. Promptly, and in any event within two (2)
Business Days after becoming aware of the occurrence of a Default or Event of
Default, a certificate of the chief
24
executive officer or chief financial officer of Borrower specifying the nature
thereof and Borrower's proposed response thereto, each in reasonable detail.
(e) Proceedings or Adverse Changes. Promptly, and in any event
within five (5) Business Days after Borrower becomes aware of (i) any proceeding
being instituted or threatened to be instituted by or against Borrower in any
federal, state, local or foreign court or before any commission or other
regulatory body (federal, state, local or foreign) which, if adversely
determined, could result in the entry of an order, judgment or decree against
Borrower; (ii) any order, judgment or decree being entered against Borrower or
any of its properties or assets or (iii) any actual or prospective change,
development or event which has had or could reasonably be expected to have a
Material Adverse Effect, a written statement describing such proceeding, order,
judgment, decree, change, development or event and any action being taken with
respect thereto by Borrower.
(f) Corporate Existence, Charter and By-Laws; Corporate Name.
Borrower shall (i) maintain its corporate existence, (ii) maintain in full force
and effect all licenses, bonds, franchises, leases, trademarks and
qualifications to do business, and, all patents, New Drug Applications,
Investigatory Drug Applications, Abbreviated New Drug Applications, Alter New
Drug Applications, registrations and quotas as issued by the Drug Enforcement
Agency or the Attorney General of the United States, pursuant to the Controlled
Substances Act, contracts and other rights necessary or advisable to the
profitable conduct of its business, and (iii) continue in, and limit its
operations to, the same general lines of business as presently conducted by it.
(g) Books and Records; Inspections. Borrower agrees to maintain
books and records pertaining to the Collateral in such detail, form and scope as
is consistent with good business practice. Borrower agrees that Lenders or its
agents may enter upon the premises of Borrower at any time and from time to
time, during normal business hours and upon reasonable notice under the
circumstances, and at any time at all on and after the occurrence of a Default
which continues beyond the expiration of any grace or cure period applicable
thereto, and which has not otherwise been waived by Lenders, for the purposes of
(i) inspecting and verifying the Collateral, (ii) inspecting and/or copying (at
Borrower's expense) any and all records pertaining thereto, and (iii) discussing
the affairs, finances and business of Borrower with any officers, managerial
employees and directors of Borrower.
(h) Compliance with Laws; Compliance with Agreements. Borrower
agrees to comply in all material respects with all Requirements of Law
applicable to the Collateral or any part thereof, or to the operation of its
business or its assets generally, unless Borrower contests any such Requirements
of Law in a reasonable manner and in good faith. Borrower agrees to maintain in
full force and effect its licenses and permits granted by any Governmental
Authority as may be necessary or advisable for Borrower to conduct its business
in all material respects. Borrower shall comply with the terms and conditions of
all material agreements, commitments, or instruments to which Borrower is a
party or by which it may be bound, including, without limitation, this Agreement
and the Debenture and Warrant Purchase Agreement.
25
(i) Use of Proceeds. Proceeds of the Consolidated Bridge Loan made
hereunder shall be used by Borrower solely for its ongoing working capital
requirements and other general corporate purposes. Borrower shall not use any
portion of the proceeds of the Consolidated Bridge Loan for the purpose of
purchasing or carrying any "margin stock" (as defined in Regulation U of the
Board of Governors of the Federal Reserve System) in any manner which violates
the provisions of Regulation T or X of said Board of Governors or for any other
purpose in violation of any applicable statute or regulation, or of the terms
and conditions of this Agreement.
(j) Maintenance of Insurance. Borrower shall maintain insurance with
financially sound and reputable insurance companies or associations in such
amounts and covering such risks as are usually carried by companies engaged in
the same or a similar business and similarly situated. Borrower shall (i)
deliver to Agent, upon its request, a detailed list of insurance then in effect,
stating (A) the names of the insurance companies, (B) the amounts and rates of
the insurance, (C) dates of expiration thereof and the properties and risks
covered thereby; (ii) within fifteen (15) days after notice from Agent, obtain
such additional insurance as Agent may reasonably request; and (iii) upon
request, provide to Agent copies of all insurance policies. All such policies
shall name Agent for Lenders as an additional insured and shall be part of the
Collateral securing the Notes.
(k) Further Assurances. Borrower shall take all such further actions
and execute all such further documents and instruments as Lenders may at any
time reasonably determine in their sole discretion to be necessary or desirable
to further carry out and consummate the transactions contemplated by the
Consolidated Bridge Loan Documents and any documentation relating thereto, to
cause the execution, delivery and performance of the Bridge Loan Documents to be
duly authorized and to perfect or protect the Liens (and the priority status
thereof) of Lenders on the Collateral.
(l) Payment of Notes. Borrower shall pay the principal of and
interest on the Notes in the time, the manner and the form provided therein.
(m) Reporting Requirements. Borrower shall comply with its reporting
and filing obligations pursuant to Section 13 or 15(d) of the Exchange Act.
Borrower shall provide copies of such reports, including, without limitation,
reports on Form 10-K, 10-Q, 8-K and Schedule 14A promulgated under the Exchange
Act, or substantially the same information required to be contained in any
successor form, to each Lender promptly upon filing with the Commission.
(n) Authorization of Shares of Common Stock for Issuance Upon
Conversion of Note and Exercise of Warrants and Voting Rights for Note Holders.
Borrower will present to its shareholders for consideration at the next annual
meeting of Borrower's shareholders, to occur on or prior to May 30, 1999, a
proposal to amend Borrower's Certificate of Incorporation to increase the number
of authorized shares of Borrower's common stock available for issuance from
40,000,000 to 75,000,000 shares in order to provide for a sufficient number of
authorized shares to be available and reserved for issuance upon conversion of
the Notes and exercise of the Warrants. Upon receipt of approval from Borrower's
shareholders to increase Borrower's authorized shares from 40,000,000 to
75,000,000 shares, Borrower will at all times cause there to be reserved for
26
issuance a sufficient number of Conversion Shares and Warrant Shares upon
conversion of the Notes and exercise of the Warrants.
(o) Listing of Common Stock. As promptly as practicable after the
filing of a Certificate of Amendment to Borrower's Certificate of Incorporation
to increase its Shares of Common Stock in accordance with Section 6.1(o) above,
Borrower shall file the appropriate applications for listing with the American
Stock Exchange the Conversion Shares and Warrant Shares. Borrower shall use its
best efforts and work diligently to accomplish such listings as promptly as
practicable after the annual meeting of the stockholders of the Company to take
place on or prior to May 30, 1999.
(p) HSR Act Filing. Borrower hereby agrees to file all the
Pre-Merger Notifications and reports, if any, required to be filed by it under
the HSR Act with forty-five (45) days after its receipt of a written request to
do so by the holder or holders of at least a majority of the aggregate principal
amount of the Notes, then outstanding ("Majority Holders"). Such request shall
be made in accordance with Section 10.6 below.
(q) Year 2000 Computer Capability. Borrower shall take all action
necessary to assure that at all times the computer-based systems utilized by
Borrower and each of its Subsidiaries are able to effectively interpret, process
and manipulate data, including dates before, on and after December 31, 1999. At
Agent's request, Borrower shall provide to Agent assurance that is reasonably
satisfactory to Agent that the computer-based systems utilized by Borrower and
each of its Subsidiaries are able to recognize and perform without error
functions involving dates before, on and after December 31, 1999.
SECTION 7.
NEGATIVE COVENANTS
7.1. Until the termination of this Agreement and the payment and
satisfaction in full of all Obligations due hereunder, neither the Borrower, nor
any of its Subsidiaries, will, either directly or indirectly, do or permit to be
done, absent the prior written consent of the Majority Holders, the following:
(a) Additional Indebtedness. Borrower shall not directly or
indirectly incur, create, assume or suffer to exist any Indebtedness other than
(a) Indebtedness under the Bridge Loan Documents, (b) Indebtedness permitted
under the Existing Credit Facility, but not any increase in the outstanding
principal amount thereof and (c) Indebtedness relating to a working capital line
of credit in an amount not to exceed $10,000,000.
(b) No Guarantees. Except for obligations owing to Lenders under
this Agreement and owing under the Existing Credit Facilities, Borrower will not
assume, endorse or become liable for or guarantee the obligations of any
corporation, partnership, individual or other
27
entity excluding the endorsement of negotiable instruments for deposit or
collection in the ordinary course of business.
(c) Liens. Except for Permitted Liens, Borrower shall not directly
or indirectly create, incur, assume, or suffer to exist any Lien on any of its
property now owned or hereafter acquired except Liens granted to Lenders under
the Bridge Loan Documents and Liens described or permitted under the Existing
Credit Facility.
(d) No Transfer of Assets. Borrower will not (a) enter into any
acquisition, merger, consolidation, reorganization, or recapitalization, or
reclassify its capital stock, or liquidate, wind up, or dissolve itself (or
suffer any liquidation or dissolution), (b) convey, sell, assign, lease,
transfer, or otherwise dispose of, in one transaction or a series of
transactions, all or any substantial part of the business, property, or assets,
whether now owned or hereafter acquired, of Borrower, or (c) acquire by purchase
or otherwise all or substantially all of the property, assets, stock, or other
evidence of beneficial ownership of any person or entity, except where the
purchase price for such acquisition is less than $10,000 and the aggregate
purchase price for all acquisitions made within any period of twelve months is
less than $25,000.
(e) Extraordinary Transactions and Disposal of Assets. Borrower will
not enter into any transaction not in the ordinary and usual course of
Borrower's business, including the sale, lease, or other disposition of, moving,
relocation, or transfer, whether by sale or otherwise, of any of Borrower's
properties or assets (other than sales of inventory to buyers in the ordinary
course of Borrower's business as currently conducted).
(f) Restricted Payments. Borrower shall not directly or indirectly
(a) declare or pay any dividend (other than dividends payable solely in Common
Stock) on, or make any payment on account of, or set apart assets for a sinking
or other analogous fund for, the purchase, redemption, defeasance, retirement or
other acquisition of, any shares of any class of capital stock of Borrower or
any warrants, options or rights to purchase any such capital stock, whether now
or hereafter outstanding, or make any other distribution in respect thereof,
either directly or indirectly, whether in cash or property or in obligations of
Borrower; or (b) make any optional payment or prepayment on or redemption
(including, without limitation, by making payments to a sinking or analogous
fund) or repurchase of any Indebtedness (other than Indebtedness pursuant to
this Agreement and in accordance with this Agreement).
(g) Investments. Except for Permitted Investments, Borrower shall
not directly or indirectly make any Investment in any Person, whether in cash,
securities, or other property of any kind.
(h) Affiliate Transactions; Intercompany Transfers; Diversion of
Corporate Assets. Borrower shall not directly or indirectly (a) Enter into any
transaction with, including, without limitation, the purchase, sale or exchange
of property or the rendering of any service to, any Subsidiary or Affiliate of
Borrower, unless any such transaction is at arm's length, on fair and reasonable
terms to Borrower, and on terms which are no more onerous to Borrower as
28
could be obtained from a Person unrelated to Borrower; (b) Make any intercompany
transfers of monies or other assets in any single transaction or series of
transactions, except as otherwise permitted in this Agreement; or (c) Divert (or
permit anyone to divert) any business or opportunity of Borrower to any other
corporate or business entity.
(i) Mergers. Borrower shall not merge or consolidate with any Person
or sell, assign, lease or otherwise dispose of (whether in one transaction or in
a series of transactions) all or substantially all of its assets (whether now
owned or hereafter acquired) or acquire all or substantially all of the assets
or the business of any Person (or enter into any agreement to do any of the
foregoing).
(j) No Activities Leading to Forfeiture. Borrower shall not engage
in the conduct of any business or activity which could result in a Forfeiture
Proceeding.
(k) Corporate Documents; Fiscal Year. Borrower shall not amend,
modify or supplement its certificate or articles of incorporation or by-laws in
any way which would adversely affect the ability of Borrower to perform its
obligations hereunder. Borrower shall not change its fiscal year.
(l) Capital Expenditures. Other than for a capital expenditure
contained in any budget approved by the Board of Directors, including a majority
of the directors designated by the purchasers pursuant to the terms and
conditions of Debenture and Warrant Purchase Agreement, or capital expenditures
not contained in any such budget, but which do not exceed $100,000 in the
aggregate during any fiscal year of Borrower, make or commit to make any capital
expenditures.
SECTION 8.
REGISTRATION RIGHTS
8.1. Restrictive Legend. Each certificate representing
(a) any Note, the Warrants or any Conversion Shares, any Warrant
Shares or other securities issued with respect to the Notes, Warrants,
Conversion Shares or Warrant Shares, upon any stock split, stock dividend,
recapitalization, merger, consolidation or similar event or upon the exercise of
the Warrants or conversion of the Notes, shall be stamped or otherwise imprinted
with a legend in the following form (in addition to any legend required under
applicable state securities laws):
"THIS [NAME OF SECURITY] [AND THE COMMON STOCK ISSUABLE UPON [CONVERSION]
[EXERCISE] HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, NOR ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED,
SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNTIL (1)
29
A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT
AND ANY APPLICABLE STATE SECURITIES LAW OR (2) BORROWER RECEIVES AN
OPINION OF COUNSEL TO BORROWER OR OTHER COUNSEL TO THE HOLDER OF SUCH
[NAME OF SECURITY] REASONABLY SATISFACTORY TO BORROWER THAT SUCH [NAME OF
SECURITY] [AND/OR COMMON STOCK] MAY BE PLEDGED, SOLD, ASSIGNED,
HYPOTHECATED OR TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS."
8.2. Certain Definitions As used in this Section 8, the following terms
shall have the following respective meanings:
"Holders" shall mean Lenders or any person to whom a Lender or
transferee of a Lender has assigned any Note, Warrants, Conversion Shares or
Warrant Shares.
"Initiating Holders" shall mean any persons who in the aggregate are
Holders of at least a majority of the Conversion Shares and the Warrant Shares.
"Registrable Securities" shall mean any Conversions Shares and
Warrant Shares issued upon exercise of the Warrants, conversion of any Note or
in respect of the Conversion Shares and Warrant Shares issued upon exercise of
the Warrants or conversion of any Note upon any stock split, stock dividend,
recapitalization or similar event.
"Requesting Stockholders'" shall mean holders of securities of
Borrower entitled to have securities included in any registration pursuant to
Section 8.3 and who shall request such inclusion.
The terms "register," "registered" and "registration" shall refer to
a registration effected by preparing and filing a registration statement in
compliance with the Securities Act and applicable rules and regulations
thereunder, and the declaration or ordering of the effectiveness of such
registration statement.
"Registration Expenses" shall mean all expenses incurred by Borrower
in compliance with Sections 8.3 and 8.4 hereof, including, without limitation,
all registration and filing fees, printing expenses, fees and disbursements of
counsel for Borrower, blue sky fees and expenses, reasonable fees and
disbursements of one counsel for all the selling Holders for a "due diligence"
examination of Borrower, and the expense of any special audits incident to or
required by any such registration (but excluding the compensation of regular
employees of Borrower, which shall be paid in any event by Borrower), exclusive
of Selling Expenses.
"Restricted Securities" shall mean the securities of Borrower
required to bear or bearing the legend set forth in Section 8.1 hereof.
30
"Selling Expenses" shall mean all underwriting discounts and selling
commissions applicable to the sale of Registrable Securities and all fees and
disbursements of counsel for any Holder, except as otherwise provided herein.
8.3. Requested Registration.
(a) Requests for Registration. The Initiating Holders may request
registration under the Securities Act of all or part of their Registrable
Securities. Within ten (10) days after receipt of any such request, Borrower
will give written notice of such requested registration to all other Holders of
Registrable Securities and any other stockholder having registration rights
which entitle it to participate in such registration. Borrower will include in
such registration all Registrable Securities with respect to which it has
received written requests for inclusion therein within fifteen (15) days after
receipt of Borrower's notice. Borrower shall cause its management to cooperate
fully and to use its best efforts to support the registration of the Registrable
Securities and the sale of the Registrable Securities pursuant to such
registration as promptly as is practicable. Such cooperation shall include, but
not be limited to, management's attendance and reasonable presentations in
respect of Borrower at road shows with respect to the offering of Registrable
Securities. The registration requested under this Section 8.3(a) is referred to
herein as a "Demand Registration."
(b) Number of Registrations. The Holders of Registrable Securities
will be entitled to request one (1) Demand Registration for which Borrower will
pay all Registration Expenses. A registration will not count as a Demand
Registration until it has become effective; provided, however, that whether or
not it becomes effective, Borrower will pay all Registration Expenses in
connection with any registration so initiated.
(c) Priority on Demand Registrations. If a Demand Registration is an
underwritten offering, and the managing underwriters advise Borrower in writing
that in their opinion the number of Registrable Securities requested to be
included exceeds the number which can be sold in such offering, Borrower will
include in such registration such number of Conversion Shares and Warrant
Shares, which in the opinion of such underwriters, may be sold, allocated among
the Holders electing to participate pro rata in accordance with the amounts of
securities requested to be so included by the respective Holders. Borrower will
not include in any Demand Registration any securities which are not Registrable
Securities without the written consent of the Holders of a majority of the
Registrable Securities requesting such registration. Any persons other than
Holders of Registrable Securities who participate in a Demand Registration which
is not at Borrower's expense must pay their share of the Registration Expenses.
A registration shall not count as a Demand Registration if some or all of the
Conversion Shares and Warrant Shares which any Holder desires to include therein
are not included due to the determination of the managing underwriters referred
to in the first sentence of this Section 8.3(c).
(d) Restrictions on Demand Registrations. Borrower will not be
obligated to effect any Demand Registration within six (6) months after the
effective date of a previous registration in which the Holders of Registrable
Securities were given piggyback rights pursuant to Section 8.4 other than a
registration of Registrable Securities intended to be offered on a continuous
31
or delayed basis under Rule 415 or any successor rule under the Securities Act
(a "Shelf Registration").
8.4. Piggyback Registrations.
(a) Right to Piggyback. Whenever Borrower proposes to register any
of its securities under the Securities Act (other than pursuant to a Demand
Registration or pursuant to a registration on Forms S-4 or S-8 or any successors
to such forms) and the registration form to be used may be used for the
registration and contemplated disposition of Registrable Securities (a
"Piggyback Registration"), Borrower will give prompt written notice to all
Holders of Registrable Securities of its intention to effect such a
registration. Borrower will include in such registration all Registrable
Securities with respect to which Borrower has received written requests for
inclusion therein within thirty (30) days after the receipt of Borrower's
notice.
(b) Piggyback Expenses. The Registration Expenses of the Holders of
Registrable Securities will be paid by Borrower.
(c) Priority on Primary Registrations. If a Piggyback Registration
is an underwritten primary registration on behalf of Borrower, and the managing
underwriters advise Borrower in writing that in their opinion the number of
securities requested to be included in such registration exceeds the number
which can be sold in such offering, Borrower will include in such registration
first, the securities Borrower proposes to sell, second, the Registrable
Securities and securities of Borrower with respect to which similar registration
rights have been granted and requested to be included in such registration, pro
rata in accordance with the amounts of Registrable Securities and such
securities requested to be so included by the respective Holders and holders of
such securities of Borrower; and third, any other securities requested to be
included in such registration.
(d) Priority on Secondary Registrations. If a Piggyback Registration
is an underwritten secondary registration on behalf of holders of Borrower's
securities, and the managing underwriters advise Borrower in writing that in
their opinion the number of securities requested to be included in such
registration exceeds the number which can be sold in such offering, Borrower
will include in such registration first, the securities requested to be included
therein by the holders requesting such registration, second, the Registrable
Securities and securities of Borrower with respect to which similar registration
rights have heretofore been granted and requested to be included in such
registration, pro rata in accordance with the amounts of Registrable Securities
and such securities requested to be so included by the respective Holders and
holders of such securities of Borrower, and third, other securities requested to
be included in such registration.
(e) Other Restrictions. Borrower hereby agrees that if it has
previously filed a registration statement with respect to Registrable Securities
pursuant to Section 8.3 or pursuant to this Section 8.4, and if such previous
registration has not been withdrawn or abandoned, Borrower will not file or
cause to be effected any other registration of any of its equity securities or
securities
32
convertible or exchangeable into or exercisable for its equity securities under
the Securities Act (except on Form S-8 or any other similar form for employee
benefit plans), whether on its own behalf or at the request of any holder or
holders of such securities, until a period of at least six (6) months has
elapsed from the effective date of such previous registration or, if sooner,
until all Registrable Securities included in such previous registration have
been sold.
8.5. Holdback Agreements.
(a) Each Holder of Registrable Securities which is a party to this
Agreement agrees not to effect any public sale or distribution of equity
securities of Borrower, or any securities convertible into or exchangeable or
exercisable for such securities, during the seven (7) days prior to and the
90-day period beginning on the effective date of any underwritten Demand
Registration or any underwritten Piggyback Registration (except as part of such
underwritten registration) or, if sooner, until all Registrable Securities
included within such registration have been sold.
(b) Borrower agrees (i) not to effect any public sale or
distribution of its equity securities, or any securities convertible into or
exchangeable or exercisable for such securities, during the seven (7) days prior
to and the 90-day period beginning on the effective date of any underwritten
Demand Registration or any underwritten Piggyback Registration (except as part
of such underwritten registration or pursuant to registrations on Form S-8 or
any other similar form for employee benefit plans) or, if sooner, until all
Registrable Securities included within such registration have been sold, and
(ii) to use its reasonable best efforts to cause each holder of its equity
securities, or any securities convertible into or exchangeable or exercisable
for such securities, purchased from Borrower at any time after the date of this
Agreement (other than in a registered public offering) to agree not to effect
any public sale or distribution of any such securities during such period
(except as part of such underwritten registration, if otherwise permitted) or,
if sooner, until all Registrable Securities included within such registration
have been sold.
8.6. Registration Procedures. Whenever the Holders of Registrable
Securities have requested that any Registrable Securities be registered pursuant
to this Section 8, Borrower will use its reasonable best efforts to effect the
registration and the sale of such Registrable Securities in accordance with the
intended method of disposition thereof, and pursuant thereto Borrower will as
expeditiously as possible:
(a) prepare and file with the Commission a registration statement
with respect to such Registrable Securities, which registration statement will
state that the Holders of Registrable Securities covered thereby may sell such
Registrable Securities either under such registration statement or, at any
Holder's proper request, pursuant to Rule 144 (or any similar rule then in
effect), and use its best efforts to cause such registration statement to become
effective (provided that before filing a registration statement or prospectus or
any amendments or supplements thereto, Borrower will furnish to the counsel
selected by the Holders of a majority of the Registrable Securities covered
33
by such registration statement copies of all such documents proposed to be
filed, which documents will be subject to the review of such counsel);
(b) prepare and file with the Commission such amendments and
supplements to such registration statement and the prospectus used in connection
therewith as may be necessary to keep such registration statement effective for
the period set forth in Section 8.6(j) hereof and comply with the provisions of
the Securities Act with respect to the disposition of all securities covered by
such registration statement during such period in accordance with the intended
methods of disposition by the sellers thereof set forth in such registration
statement;
(c) furnish to each seller of Registrable Securities such number of
copies of such registration statement, each amendment and supplement thereto,
the prospectus included in such registration statement (including each
preliminary prospectus) and such other documents as such seller may reasonably
request in order to facilitate the disposition of the Registrable Securities
owned by such seller;
(d) use its best efforts to register or qualify such Registrable
Securities under such other securities or blue sky laws of such jurisdictions as
any seller reasonably requests and do any and all other acts and things which
may be reasonably necessary or advisable to enable such seller to consummate the
disposition in such jurisdictions of the Registrable Securities owned by such
seller (provided that Borrower will not be required to qualify generally to do
business in any jurisdiction where it would not otherwise be required to qualify
but for this subsection, subject itself to taxation in any such jurisdiction, or
consent to general service of process in any such jurisdiction);
(e) notify each seller of such Registrable Securities, at any time
when a prospectus relating thereto is required to be delivered under the
Securities Act, of the happening of any event as a result of which the
prospectus included in such registration statement contains an untrue statement
of a material fact or omits to state any fact necessary to make the statements
therein not misleading, and, at the request of any such seller, Borrower will
prepare a supplement or amendment to such prospectus so that, as thereafter
delivered to the Lenders of such Registrable Securities, such prospectus will
not contain an untrue statement of a material fact or omit to state any fact
necessary to make the statements therein not misleading;
(f) cause all such Registrable Securities to be listed on each
securities exchange on which similar securities issued by Borrower are then
listed;
(g) provide a transfer agent and registrar for all such Registrable
Securities not later than the effective date of such registration statement;
(h) enter into such customary agreements (including an underwriting
agreement in customary form) and take all such other actions as the Holders of a
majority of the Registrable Securities being sold or the underwriters, if any,
reasonably request in order to expedite or facilitate
34
the disposition of such Registrable Securities (including, without limitation,
using its best efforts to effect a stock split or a combination of shares);
(i) make available for inspection by any seller of Registrable
Securities, any underwriter participating in any disposition pursuant to such
registration statement, and any attorney, accountant or other agent retained by
any such seller or underwriter, all financial and other records, pertinent
corporate documents and properties of Borrower, and cause Borrower's officers,
directors and employees to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant or agent in connection with such
registration statement; and
(j) keep each registration statement effective until the earlier to
occur of (i) the Holder or Holders have completed the distribution described in
the registration statement relating thereto (including a Shelf Registration) and
(ii) two (2) years.
8.7. Expenses of Registration. All Registration Expenses incurred in
connection with a registration, qualification or compliance pursuant to this
Section 8 shall be borne by Borrower, and all Selling Expenses shall be borne by
the Holders and the Requesting Stockholders of the securities so registered pro
rata on the basis of the number of their shares so registered; provided,
however, that Borrower shall not be required to pay any Registration Expenses
if, as a result of the withdrawal of a request for registration by Initiating
Holders, the registration statement does not become effective, in which case the
Holders and Requesting Stockholders requesting registration shall bear such
Registration Expenses pro rata on the basis of the number of their shares so
included in the registration request, and, further, that such registration shall
not be counted as a Demand Registration pursuant to Section 8.3.
8.8. Indemnification.
(a) Borrower will indemnify each Holder, each Holder's officers,
directors and partners, and each person controlling such Holder, with respect to
which registration, qualification or compliance of such Holder's securities has
been effected pursuant to this Section 8, and each underwriter, if any, and each
person who controls any underwriter, against all claims, losses, damages and
liabilities (or actions in respect thereof) arising out of or based on any
untrue statement (or alleged untrue statement) of a material fact contained in
any registration statement, prospectus, offering circular or other document
(including any related registration statement notification or the like) incident
to any such registration, qualification or compliance, or based on any omission
(or alleged omission) to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, or any
violation by Borrower of the Securities Act or any rule or regulation thereunder
applicable to Borrower and relating to action or inaction required of Borrower
in connection with any such registration, qualification or compliance, and will
reimburse each such Holder, each Holder's officers, directors and partners, and
each person controlling such Holder, each such underwriter and each person who
controls any such underwriter, for any legal and any other expenses reasonably
incurred in connection with investigating or defending any such claim, loss,
damage, liability or action, provided, that Borrower will not be liable in any
such case
35
to the extent that any such claim, loss, damage, liability or action arises out
of or is based on any untrue statement or omission of material fact based upon
written information furnished to Borrower by such Holder or underwriter and
stated to be specifically for use therein.
(b) Each Holder and Requesting Stockholder will, if Registrable
Securities held by it are included in the securities as to which such
registration, qualification or compliance is being effected, indemnify Borrower,
each of Borrower's directors and officers and each underwriter, if any, of
Borrower's securities covered by such registration statement, each person who
controls Borrower or such underwriter within the meaning of the Securities Act
and the rules and regulations thereunder, each other Holder and Requesting
Stockholder and each of their officers, directors and partners, and each person
controlling such Holder or Requesting Stockholder, against all claims, losses,
damages and liabilities (or actions in respect thereof) arising out of or based
on any untrue statement (or alleged untrue statement) of a material fact
contained in any such registration statement, prospectus, offering circular or
other document incident to any such registration, qualification or compliance,
or based on any omission (or alleged omission) to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading, and will reimburse Borrower, its officers and directors, each
underwriter, each person controlling Borrower or such underwriter, each other
Holder and Requesting Stockholders, their officers, directors, partners and
control persons for any legal or any other expenses reasonably incurred in
connection with investigating or defending any such claim, loss, damage,
liability or action, in each case to the extent, but only to the extent, that
such untrue statement (or alleged untrue statement) or omission (or alleged
omission) is made in such registration statement, prospectus, offering circular
or other document in reliance upon and in conformity with written information
furnished to Borrower by such Holder or Requesting Stockholder and stated to be
specifically for use therein; provided, however, that the obligations of each
Holder and Requesting Stockholders hereunder shall be limited to an amount equal
to the proceeds to each such Holder or Requesting Stockholder of securities sold
as contemplated herein.
(c) Each party entitled to indemnification under this Section 8.8
(the "Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any
litigation resulting therefrom, provided, that counsel for the Indemnifying
Party, who shall conduct the defense of such claim or any litigation resulting
therefrom, shall be approved by the Indemnified Party (whose approval shall not
be unreasonably withheld and for such purpose approval is hereby given for Wolf,
Block, Schorr and Solis-Cohen LLP ("Wolf, Block") to be such counsel), and the
Indemnified Party may participate in such defense at such party's expense, and
provided, further, that the failure of any Indemnified Party to give notice as
provided herein shall not relieve the Indemnifying Party of its obligations
under this Section 8 unless such failure has had a Material Adverse Effect on
such claim. The parties to this Agreement reserve any rights to claim under this
Agreement for damages actually incurred by reason of any failure of the
Indemnified Party to give prompt notice of a claim. To the extent counsel for
the Indemnifying Party shall in such counsel's reasonable judgment, have a
conflict in representing an Indemnified Party in conjunction with the
36
Indemnifying Party or other Indemnified Parties, such Indemnified Party shall be
entitled to separate counsel at the expense of the Indemnifying Party subject to
the approval of such counsel by the Indemnified Party (whose approval shall not
be unreasonably withheld and for such purpose approval is hereby given for Wolf,
Block to be such counsel). No Indemnifying Party, in the defense of any such
claim or litigation, shall, except with the consent of each Indemnified Party,
consent to entry of any judgment or enter into any settlement which does not
include as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party of a release from all liability with respect to such
claim or litigation. Each Indemnified Party shall furnish such information
regarding itself or the claim in question as an Indemnifying Party may
reasonably request in writing and as shall be reasonably required in connection
with the defense of such claim and any litigation resulting therefrom.
8.9. Information by Holders. Each Holder of Registrable Securities, and
each Requesting Stockholder holding securities included in any registration,
shall furnish to Borrower such information regarding such Holder or Requesting
Stockholder and the distribution proposed by such Holder or Requesting
Stockholder as Borrower may reasonably request in writing and as shall be
reasonably required in connection with any registration, qualification or
compliance referred to in this Section 8.
8.10. Limitations on Registration of Issues of Securities. From and after
the date of this Agreement, Borrower shall not enter into any agreement with any
holder or prospective holder of any securities of Borrower giving such holder or
prospective holder the right to require Borrower to register any securities of
Borrower equal to or more favorable than the rights granted under this Section
8. Any right given by Borrower to any holder or prospective holder of Borrower's
securities in connection with the registration of securities shall be
conditioned such that it shall be consistent with the provisions of this Section
8 and with the rights of the Holders provided in this Agreement and such holder
or prospective holder agrees to be bound by the terms of this Section 8.
8.11. Rule 144 Reporting. With a view to making available the benefits of
certain rules and regulations of the Commission which may permit the sale of the
Restricted Securities to the public without registration, Borrower agrees to:
(a) make and keep public information available, as those terms are
understood, defined and interpreted in and under Rule 144 under the Securities
Act, at all times from and after ninety (90) days following the effective date
of the first registration under the Securities Act filed by Borrower for an
offering of its securities to anyone other than its employees;
(b) use its best efforts to file with the Commission in a timely
manner all reports and other documents required of Borrower under the Securities
Act and the Exchange Act at any time after it has become subject to such
reporting requirements; and
(c) so long as Lender owns any Restricted Securities, furnish to
Lender forthwith, upon request, a written statement by Borrower as to its
compliance with the reporting requirements of Rule 144 (at any time from and
after ninety (90) days following the effective date of the first
37
registration statement filed by Borrower for an offering of its securities to
anyone other than its employees), and of the Securities Act and the Exchange Act
(at any time after it has become subject to such reporting requirements), a copy
of the most recent annual or quarterly report of Borrower, and such other
reports and documents so filed as Lender may reasonably request in availing
itself of any rule or regulation of the Commission allowing Lender to sell any
such securities without registration.
8.12. Participation in Underwritten Registrations. No person may
participate in any underwritten registration hereunder unless such person agrees
to sell such person's securities on the basis provided in any underwriting
arrangements approved by the persons entitled hereunder to approve such
arrangements and completes and executes all reasonable questionnaires, powers of
attorney, indemnities, underwriting agreements and other documents required
under the terms of such underwriting arrangements.
8.13. Selection of Underwriters. If any Demand Registration is an
underwritten offering, the Holders of a majority of the Registrable Securities
included in such registration have the right to select the investment banker(s)
and manager(s) to administer the offering, subject to the approval of Borrower
(which approval will not be unreasonably withheld). If any registration other
than a Demand Registration is an underwritten offering, Borrower will have the
right to select the investment banker(s) and manager(s) to administer the
offering, subject to the approval of the Holders of a majority of the
Registrable Securities included in such registration (which approval will not be
unreasonably withheld).
8.14. Termination of Registration Rights. The rights of Holders to request
a Demand Registration or participate in a Piggyback Registration shall expire on
May 30, 2003.
SECTION 9.
EVENTS OF DEFAULT AND REMEDIES
9.1. Events of Default. The occurrence of any of the following events
shall constitute an Event of Default hereunder:
(a) Failure to Pay. Borrower shall fail to pay any of its
Obligations when the same shall become due and payable.
(b) Breach of Certain Covenants. Borrower shall fail to comply with
any covenant contained in Sections 6 or 7 hereof ("Affirmative Covenants" and
"Negative Covenants"), which, in the case of Borrower's failure to comply with
the covenants contained in Sections 6.1 and 6.13 above, continues for a period
of ten (10) days following Borrower's receipt of written notice thereof from the
Agent.
(c) Breach of Representation or Warranty. Any representation or
warranty made or deemed to be made by Borrower in this Agreement or in any other
Bridge Loan Document (and
38
in any statement or certificate given under this Agreement or any other Bridge
Loan Document), shall be false or misleading in any material respect when made
or deemed to be made.
(d) Breach of Other Covenants. Borrower shall fail to comply with
any covenant contained in this Agreement or any other Bridge Loan Document,
other than as set forth in Section 10.1(b), and such failure shall continue for
ten (10) Business Days after its occurrence.
(e) Cross Default. There shall occur any default or event of default
on the part of any Borrower under (i) any agreement, document or instrument to
which Borrower is a party or by which Borrower or any of its property is bound,
creating or relating to any indebtedness (other than the Obligations), the
unpaid principal balance of which is in excess of $100,000, if the payment or
maturity of such indebtedness is accelerated in consequence of such event of
default or demand for payment of such indebtedness is made or (ii) the Debenture
and Warrant Purchase Agreement.
(f) Dissolution, etc. Borrower shall cease to do business, take
steps to wind-up or dissolve or shall suffer the appointment of a receiver,
trustee, examiner, custodian or similar fiduciary, or shall make an assignment
for the benefit of creditors.
(g) Bankruptcy, etc.. Borrower (i) shall generally not, or be unable
to, or shall admit in writing its inability to, pay its debts as such debts
become due; (ii) shall make an assignment for the benefit of creditors, petition
or apply to any tribunal for the appointment of a custodian, receiver or trustee
for it or a substantial part of its assets; (iii) shall commence any proceeding
under any bankruptcy, reorganization, arrangement, readjustment of debt,
dissolution or liquidation law or statute of any jurisdiction, whether now or
hereafter in effect; (iv) shall have had any such petition or application filed
or any such proceeding shall have been commenced, against it, in which an
adjudication or appointment is made or order for relief is entered, or which
petition, application or proceeding remains undismissed for a period of 30 days
or more; or shall be the subject of any proceeding under which its assets may be
subject to seizure, forfeiture or divestiture; (v) by any act or omission shall
indicate its consent to, approval of or acquiescence in any such petition,
application or proceeding or order for relief or the appointment of a custodian,
receiver or trustee for all or any substantial part of its property; (vi) shall
suffer any such custodianship, receivership or trusteeship to continue
discharged for a period of 30 days or more; or (vii) shall cease to be Solvent.
(h) Judgments. One or more judgments, decrees or orders for the
payment of money in excess of $100,000 in the aggregate shall be rendered
against Borrower, and such judgments, decrees, or orders shall continue
unsatisfied and in effect for a period of 30 consecutive days without being
vacated, discharged, satisfied or stayed or bonded pending appeal.
(i) Forfeiture Proceeding. Any Forfeiture Proceeding shall have been
commenced against Borrower.
9.2. Acceleration. Upon the occurrence and during the continuance of any
Event of Default, without prejudice to the rights of any Lender to enforce its
claims against Borrower and by
39
delivery of written notice to Borrower from Agent on behalf of Lenders, all
Obligations shall be immediately due and payable (except with respect to any
Event of Default set forth in Section 9.1(f) or (g) hereof, in which case all
Obligations shall automatically become immediately due and payable without the
necessity of any notice or other demand to Borrower) without presentment,
demand, protest or any other action or obligation of Lenders.
9.3. Remedies.
(a) Upon the occurrence of an Event of Default, Majority Holders may
at any time (unless all defaults shall theretofore have been remedied) at its or
their option, by written notice or notices to the Company (i) declare all the
Notes to be due and payable, whereupon the same shall forthwith mature and
become due and payable, together with interest accrued thereon, without
presentment, demand, protest or notice, all of which are hereby waived; and (ii)
declare any other amounts payable to the Lenders under this Agreement or as
contemplated hereby due and payable.
(b) Notwithstanding anything contained in Section 9.3(a), if, at any
time after the principal of the Notes shall so become due and payable and prior
to the date of maturity stated in the Notes all arrears of principal of and
interest on the Notes (with interest at the rate specified in the Notes on any
overdue principal and, to the extent legally enforceable, on any interest
overdue) shall be paid by or for the account of the Company, then Majority
Holders, by written notice(s) to the Company, may (but shall not be obligated
to) waive such Event of Default and its consequences and rescind or annul such
declaration; but no such waiver shall extend to or affect any subsequent Event
of Default or impair any right resulting therefrom. If any holder of a Note
shall give any notice or take any other action with respect to a claimed
Default, the Company, forthwith upon receipt of such notice or obtaining
knowledge of such other action will give written notice thereof to all other
holders of the Notes then outstanding, describing such notice or other action
and, the nature of the claimed Default.
9.4. Application of Proceeds; Surplus; Deficiencies. The net cash proceeds
resulting from Agent's exercise of any of the foregoing rights against any
Collateral (after deducting all of Lenders' Expenses related thereto) shall be
applied by Agent to the payment of the Obligations, whether due or to become
due, in the order set forth in Section 2.9. Borrower shall remain liable to
Lenders for any deficiencies, and Lenders in turn agree to remit to Borrower or
its successors or assigns, any surplus resulting therefrom.
SECTION 10.
GENERAL PROVISIONS
10.1. GOVERNING LAW. THE VALIDITY, INTERPRETATION AND ENFORCEMENT OF THIS
AGREEMENT AND THE OTHER BRIDGE LOAN DOCUMENTS AND ANY DISPUTE ARISING OUT OF OR
IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE BRIDGE LOAN DOCUMENTS, WHETHER
SOUNDING IN CONTRACT, TORT, EQUITY OR OTHERWISE, SHALL BE GOVERNED BY THE
INTERNAL LAWS (AS
40
OPPOSED TO THE CONFLICTS OF LAWS PROVISIONS) AND DECISIONS OF THE STATE OF NEW
YORK.
10.2. SUBMISSION TO JURISDICTION. ALL DISPUTES AMONG BORROWER AND LENDERS,
WHETHER SOUNDING IN CONTRACT, TORT, EQUITY OR OTHERWISE, SHALL BE RESOLVED ONLY
BY STATE AND FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK, AND THE COURTS TO
WHICH AN APPEAL THEREFROM MAY BE TAKEN; PROVIDED, HOWEVER, THAT LENDERS SHALL
HAVE THE RIGHT, TO THE EXTENT PERMITTED BY APPLICABLE LAW, TO PROCEED AGAINST
BORROWER OR ITS PROPERTY IN ANY LOCATION REASONABLY SELECTED BY LENDERS IN GOOD
FAITH TO ENABLE LENDERS TO REALIZE ON SUCH PROPERTY, OR TO ENFORCE A JUDGMENT OR
OTHER COURT ORDER IN FAVOR OF LENDERS. BORROWER AGREES THAT IT WILL NOT ASSERT
ANY PERMISSIVE COUNTERCLAIMS, SETOFFS OR CROSS-CLAIMS IN ANY PROCEEDING BROUGHT
BY LENDERS. BORROWER WAIVES ANY OBJECTION THAT THEY MAY HAVE TO THE LOCATION OF
THE COURT IN WHICH LENDERS HAS COMMENCED A PROCEEDING, INCLUDING, WITHOUT
LIMITATION, ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON FORUM NON
CONVENIENS.
10.3. SERVICE OF PROCESS. BORROWER HEREBY IRREVOCABLY AGREES THAT SERVICE
OF PROCESS IN ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR
ANY OTHER BRIDGE LOAN DOCUMENT MAY BE AFFECTED BY MAILING A COPY THEREOF BY
REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO BORROWER AT ITS RESPECTIVE
ADDRESS SET FORTH IN SECTION 10.6.
10.4. JURY TRIAL. BORROWER, AGENT AND LENDERS EACH HEREBY WAIVE ANY RIGHT
TO A TRIAL BY JURY.
10.5. LIMITATION OF LIABILITY. NEITHER AGENT NOR ANY OF THE LENDERS SHALL
HAVE ANY LIABILITY TO BORROWER (WHETHER SOUNDING IN TORT, CONTRACT, OR
OTHERWISE) FOR LOSSES SUFFERED BY BORROWER IN CONNECTION WITH, ARISING OUT OF,
OR IN ANY WAY RELATED TO THE TRANSACTIONS OR RELATIONSHIPS CONTEMPLATED BY THIS
AGREEMENT, OR ANY ACT, OMISSION OR EVENT OCCURRING IN CONNECTION THEREWITH,
UNLESS IT IS DETERMINED BY A FINAL AND NONAPPEALABLE JUDGMENT OR COURT ORDER
BINDING ON LENDERS, THAT THE LOSSES WERE THE RESULT OF ACTS OR OMISSIONS
CONSTITUTING GROSS NEGLIGENCE OR WILLFUL MISCONDUCT.
10.6. Notices. Except as otherwise provided herein, all notices and
correspondences hereunder shall be in writing and sent by certified or
registered mail, return receipt requested, or by overnight delivery service,
with all charges prepaid, or by facsimile transmission, promptly confirmed in
writing sent by first class mail:
41
If to any Lender then to Agent, as follows:
Mr. Srini Conjeevaram
Galen Partners III, L.P.
Rockefeller Center
610 Fifth Avenue, 5th Floor
New York, New York 10020
With copies to:
Wolf, Block, Schorr and Solis-Cohen LLP
250 Park Avenue
New York, New York 10177
Attention: George N. Abrahams, Esq.
Fax no. (212) 986-0604
If to Borrower:
Halsey Drug Co., Inc.
695 N. Perryville Road
Rockford, Illinois 61107
Attention: Mr. Michael Reicher
Fax no. (815) 399-9710
With copies to:
St. John & Wayne LLC
Two Penn Plaza East
Newark, New Jersey 07105-2249
Attention: John P. Reilly, Esq.
Fax no. (973) 491-3555
All such notices and correspondence shall be deemed given (i) if sent by
certified or registered mail, three Business Days after being postmarked, (ii)
if sent by overnight delivery service, when received at the above stated
addresses or when delivery is refused and (iii) if sent by telex or facsimile
transmission, when receipt of such transmission is acknowledged.
10.7. Indemnification. Borrower hereby indemnifies and agrees to defend
and hold harmless Agent, each of the Lenders and their respective partners,
directors, officers, agents, employees and counsel from and against any and all
losses, claims, damages, liabilities, deficiencies, judgments or expenses
incurred by any of them (except to the extent that it is finally judicially
determined to have resulted from their own gross negligence or willful
misconduct) arising out of or by reason of (a) any litigations, investigations,
claims or proceedings which arise out of or are in any way related to (i) this
Agreement or the transactions contemplated hereby, (ii) any actual or
42
proposed use by Borrower of the proceeds of the Consolidated Bridge Loan or
Lenders entering into this Agreement, the other Bridge Loan Documents or any
other agreements and documents relating hereto, including, without limitation,
amounts paid in settlement, court costs and the fees and disbursements of
counsel incurred in connection with any such litigation, investigation, claim or
proceeding or any advice rendered in connection with any of the foregoing and
(b) any remedial or other action taken by Borrower or Lenders in connection with
compliance by Borrower, or any of its property, with any federal, state or local
environmental laws, acts, rules, regulations, orders, directions, ordinances,
criteria or guidelines.
10.8. Amendments and Waivers. This Agreement may not be amended,
discharged or terminated (or any provision hereof waived) without the written
consent of Borrower and the Lenders as set forth below:
(a) Holders of at least fifty one percent (51%) in aggregate
principal amount of the Notes then outstanding may by written instrument amend
or waive any term or condition of this Agreement, except that no such amendment
or waiver shall (i) except as otherwise permitted in Section 2.3(f) hereof with
respect to voluntary prepayments of the Notes by the Borrower, extend the fixed
maturity of any Notes, the rate or the time of payment or mandatory prepayment
of principal thereof or payment of interest thereon, or the principal amount
thereof, without the consent of the holders of the Notes so affected, (ii)
change the aforesaid percentage of Notes, the holders of which are required to
consent to any such amendment or waiver, without the consent of the holders of
all the Notes then outstanding or (iii) change the percentage of the amount of
the Notes, the holders of which may declare the Notes to be due and payable
under Section 9.1.
Borrower and each holder of a Note then or thereafter outstanding
shall be bound by any amendment or waiver effected in accordance with the
provisions of this Section 10.8, whether or not such Note shall have been marked
to indicate such modification, but any Note issued thereafter shall bear a
notation as to any such modification. Promptly after obtaining the written
consent of the holders herein provided, Borrower shall transmit a copy of such
modification to all of the holders of the Notes then outstanding.
(b) Holders of at least a majority of the Conversion Shares and the
Warrant Shares in the aggregate then outstanding may by written instrument amend
or waive any term or condition of this Agreement relating to the rights or
obligations of holders of Conversion Shares and Warrant Shares, which amendment
or waiver operates for the benefit of such holders but in no event shall the
obligation of any holder of Conversion Shares and Warrant Shares hereunder be
increased, except upon the written consent of such holder of Conversion Shares
and Warrant Shares.
Borrower and each holder of a Conversion Share or a Warrant Share
then or thereafter outstanding shall be bound by any amendment or waiver
effected in accordance with the provisions of this Section 10.8, whether or not
such Conversion Share or Warrant Share shall have been marked to indicate such
modification, but any Conversion Share and Warrant Share issued thereafter shall
bear a notation as to any such modification. Promptly after obtaining the
written consent of the
43
holders herein provided, Borrower shall transmit a copy of such modification to
all of the holders of the Conversion Shares and the Warrant Shares then
outstanding.
10.9. Construction. Unless the context of this Agreement clearly requires
otherwise, references to the plural include the singular, references to the
singular include the plural, the term "including" is not limiting, and the term
"or" has, except where otherwise indicated, the inclusive meaning represented by
the phrase "and/or." The words "hereof," "herein," "hereby," "hereunder," and
similar terms in this Agreement refer to this Agreement as a whole and not to
any particular provision of this Agreement. Article, Section, subsection,
paragraph, clause, schedule, and exhibit references are to this Agreement unless
otherwise specified. Any reference in this Agreement shall include all
alterations, amendments, changes, extensions, modifications, renewals,
replacements, substitutions, and supplements, thereto and thereof, as
applicable.
10.10. Counterparts and Effectiveness. This Agreement and any waiver or
amendment hereto may be executed in any number of counterparts and by the
different parties hereto in separate counterparts, each of which when so
executed and delivered shall be an original, but all of which shall together
constitute one and the same instrument. This Agreement shall become effective on
the date on which all of the parties hereto shall have signed a copy hereof
(whether the same or different copies) and shall have delivered the same to
Lenders pursuant to Section 10.6 or shall have given to Lenders written,
telecopied or telex notice (actually received) at such office that the same has
been signed and mailed to it.
10.11. Severability. In case any provision in or obligation under this
Agreement or any Note or the other Bridge Loan Documents shall be invalid,
illegal or unenforceable in any jurisdiction, the validity, legality and
enforceability of the remaining provisions or obligations, or of such provision
or obligation in any other jurisdiction, shall not in any way be affected or
impaired thereby.
10.12. Entire Agreement; Successors and Assigns. This Agreement and the
other Bridge Loan Documents constitute the entire agreement among Borrower and
Lenders, supersedes any prior agreements among them, and shall bind and benefit
Borrower and Lenders and their respective successors and assigns.
10.13 Assignments and Participations.
(a) Each Lender may assign its rights and delegate its obligations
under this Agreement and further may assign, or sell participations in, all or
any part of the Consolidated Bridge Loan, such Lender's Total Commitment or any
other interest herein to an Affiliate or to another Person. In the case of an
assignment authorized under this Section 10.13, the assignee shall have, to the
extent of such assignment, the same rights, benefits and obligations as it would
if it were a Lender hereunder, shall be deemed to be a Lender for all purposes,
and such assigning Lender shall be relieved of its obligations hereunder with
respect to such Lender's Total Commitment or assigned portion thereof. Borrower
hereby acknowledges and agrees that any assignment will give rise to a direct
obligation of Borrower to the assignee and that the assignee shall be considered
to be a
44
"Lender". Any such Lender may furnish any information concerning Borrower and
its Subsidiaries in its possession from time to time to assignees and
participants (including prospective assignees and participants).
(b) The Borrower and the Lenders hereby authorize the Agent to
modify this Agreement by unilaterally amending or supplementing Exhibit A to
reflect the assignment by a Lender of all or any part of its Total Commitment to
any other Lender hereunder or to any Person whatsoever, and to reflect the Total
Commitment of any Person that elects to become a Lender after the date hereof by
extending a new loan to Borrower.
10.14 No Brokers. Each Lender and Borrower represents and warrants to each
other that it has not employed or dealt with any broker in connection with any
transactions contemplated by this Agreement and each of Lender and the Borrower
shall indemnify and hold harmless the other from and against any and all claims
at any time heretofore or hereafter made for broker's or finder's fees or
commissions, which claim or claims arise from, out of, or in connection with any
of the transactions contemplated by this Agreement.
10.15 No Novation. This Agreement amends and restates in its entirety the
Original Bridge Loan Agreement and consolidates the Original Bridge Loan with
the Additional Bridge Loan. Neither this Agreement nor any of the Notes creates
a novation of or in any manner diminishes or extinguishes the unpaid principal
balance of, or the accrued interest on, Borrower's indebtedness to Lenders
originally evidenced by the Original Notes. Such unpaid principal balance of,
and such accrued interest on, such indebtedness continues to be due and owing by
Borrower to Lenders, as of the date hereof, and Borrower hereby reaffirms and
confirms same.
[SIGNATURE PAGE FOLLOWS]
45
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed in the state of New York, and delivered by their proper and duly
authorized officers and representatives as of the date set forth above.
Borrower: HALSEY DRUG CO., INC.
By: /s/
------------------------------
Name: Michael Reicher
Title: Chief Executive Officer
Lenders: GALEN PARTNERS III, L.P.
By: Claudius, L.L.C., General Partner
By: /s/
------------------------------
Name: Bruce F. Wesson
Title: Managing Member
GALEN PARTNERS INTERNATIONAL III, L.P.
By: Claudius, L.L.C., General Partner
By: /s/
------------------------------
Name: Bruce F. Wesson
Title: Managing Member
GALEN EMPLOYEE FUND III, L.P.
By: Wesson Enterprises, Inc., General Partner
By: /s/
------------------------------
Name: Bruce F. Wesson
Title: President
/s/
----------------------------------
Michael Weisbrot
/s/
----------------------------------
Susan Weisbrot
|
46
Exhibit 10.46
[First Amendment to Amended, Restated and Consolidated Bridge Loan Agreement
dated December 7, 1998 between the Company and the lenders listed
on the signature page thereto]
Execution Copy
FIRST AMENDMENT
TO
AMENDED, RESTATED AND CONSOLIDATED
BRIDGE LOAN AGREEMENT
THIS FIRST AMENDMENT TO AMENDED, RESTATED AND CONSOLIDATED BRIDGE LOAN
AGREEMENT (the "First Amendment") dated as of December 7, 1998 by and among
HALSEY DRUG CO., INC., a New York corporation ("Borrower"), GALEN PARTNERS III,
L.P. ("Galen", an "Initial Lender" or a "Lender") a Delaware limited
partnership, GALEN PARTNERS INTERNATIONAL III, L.P. and GALEN EMPLOYEE FUND III,
L.P., each a Delaware limited partnership (each an "Initial Lender", a "Lender",
and collectively, with Galen, the "Galen Entities"), PATRICK COYNE ("Coyne", a
"First Amendment Lender" or a "Lender"), an individual residing at 477 Margo
Lane, Berwyn, Pennsylvania 19312, ALAN SMITH ("Smith", a "First Amendment
Lender" or a "Lender"), an individual residing at 21 Bedlow Avenue, Newport,
Rhode Island 02840, MICHAEL WEISBROT AND SUSAN WEISBROT (collectively, the
"Weisbrots" or jointly and severally, with respect to the Initial Commitment, an
"Initial Lender", with respect to the First Amendment Commitment, a "First
Amendment Lender" or a "Lender"), individuals residing at 1136 Rock Creek Road,
Gladwyne, Pennsylvania 19035, GREG WOOD ("Wood", a "First Amendment Lender" or a
"Lender"), an individual residing at c/o D.R. International, 7474 Figueron
Street, Los Angeles, California 90041, (Coyne, Smith, the Weisbrots and Wood,
each a "First Amendment Lender" and collectively, the "First Amendment Lenders"
and the First Amendment Lenders, together with the Galen Entities and the
Weisbrots, each a "Lender", and collectively, the "Lenders"), and GALEN, as
agent for the Lenders (in such capacity, the "Agent") to the Amended, Restated
and Consolidated Bridge Loan Agreement dated as of December 2, 1998 by and among
Borrower, the Galen Entities and the Weisbrots
(the Weisbrots and the Galen Entities, each an "Initial Lender", a "Lender" and
collectively, the "Initial Lenders", as amended through the date hereof, the
"Consolidated Bridge Loan Agreement"). Terms that are capitalized in this First
Amendment and not otherwise defined shall have the meaning ascribed to such
terms in the Consolidated Bridge Loan Agreement.
WITNESSETH:
WHEREAS, the Borrower and the Initial Lenders have entered into the
Consolidated Bridge Loan Agreement;
WHEREAS, Borrower has requested that certain Lenders consider making an
additional $283,000 bridge loan ("First Amendment Bridge Loan") available to
Borrower, the proceeds of which will be used by Borrower solely for Borrower's
working capital purposes and other general
business purposes, in each case pursuant to the Consolidated Bridge Loan
Agreement and in accordance with the terms thereof and hereof.
WHEREAS, Borrower and the Lenders have agreed to add Smith, Wood and Coyne
as a party to the Consolidated Bridge Loan Agreement effective from the First
Amendment Closing Date;
NOW, THEREFORE, in consideration of the mutual promises contained herein,
and for other good and valuable consideration, the recipient and sufficiency of
which are hereby acknowledged, the parties hereto hereby agree as follows:
SECTION 1.
AMENDMENTS
A. Amendment of Section 1. Definitions.
1. Paragraph 1.1 is amended by:
(i) adding thereto, in the appropriate alphabetical order, each of
the terms "Agency Agreements", "Agent", "Consents and Waivers", "Consolidated
Bridge Loan", "First Amendment", "First Amendment Agency Agreement", "First
Amendment Bridge Loan", "First Amendment Closing Date", "First Amendment Closing
Fees", "First Amendment Commitment", "First Amendment Consent and Waiver",
"First Amendment Conversion Price", "First Amendment Lenders", "First Amendment
Loan", "First Amendment Notes", "First Amendment Warrants", "Initial Agency
Agreement", "Initial Closing Date", "Initial Commitment", "Initial Consent and
Waiver", "Initial Consolidated Bridge Loan", "Initial Consolidated Bridge Loan
Agreement", "Initial Conversion Price", "Initial Lenders", "Initial Notes",
"Initial Warrants", "Note 1", "Note 2", "Note 3", "Note 4", "Note 5", "Note 6",
"Note 7", "Note 8" and the definitions thereof, as hereinafter provided, and
(ii) deleting the definitions of the terms "Agreement", "Bridge Loan
Documents", "Lenders", "Notes", "Obligations", "Warrants" and substituting the
definitions set forth below in lieu thereof:
"Agency Agreements" mean the Initial Agency Agreement and the First
Amendment Agency Agreement.
"Agent" means Galen acting as agent to the Lenders pursuant to the
Initial Agency Agreement and the First Amendment Agency Agreement.
"Agreement" means the Initial Consolidated Bridge Loan Agreement, as
amended by the First Amendment, as the same may hereafter be further amended,
extended, modified, restated or supplemented from time to time.
2
"Bridge Loan Documents" means, collectively, this Agreement, the
Notes, the Warrants, the Agency Agreements, the Consents and Waivers, each of
the Collateral Documents and all other documents, agreements, instruments,
opinions and certificates now or hereafter executed and delivered in connection
herewith or therewith, as modified, amended, extended, restated or supplemented
from time to time.
"Consents and Waivers" mean the Initial Consent and Waiver and the
First Amendment Consent and Waiver.
"Consolidated Bridge Loan" has the meaning set forth in Section
I(B)(1) hereto.
"First Amendment" means the First Amendment to the Initial
Consolidated Bridge Loan Agreement dated as of December 7, 1998 by and among
Borrower, the Lenders and Agent, as the same may hereafter be further amended,
extended, modified, restated or supplemented from time to time.
"First Amendment Agency Agreement" means the Agency Agreement by and
among the First Amendment Lenders dated the date hereof and entered into
simultaneously herewith, substantially in the Form of Exhibit E attached hereto.
"First Amendment Bridge Loan" has the meaning set forth in the
Recitals to this Agreement.
"First Amendment Closing Date" means the date upon which the last of
the events, the fulfillment of each of which is condition precedent to the
effectiveness of this First Amendment, as set forth in Section II of this First
Amendment, shall have occurred.
"First Amendment Closing Fees" means the expenses as set forth in
Section II(4) of this First Amendment.
"First Amendment Commitment" means the commitment of each First
Amendment Lender to fund the dollar amount of its share of the First Amendment
Loan in the amount set forth opposite such Lender's name on Exhibit A, a copy of
which is attached hereto and made a part hereof.
"First Amendment Consent and Waiver" means a consent and waiver of
lien, indebtedness and registration rights restrictions executed by the Majority
Holders in connection with this First Amendment dated the date hereof and
executed simultaneously herewith, substantially in the form of Exhibit D
attached hereto.
"First Amendment Conversion Price" means $1.3133.
3
"First Amendment Lenders" has the meaning set forth in the Section
entitled "Pari Passu and Pro Rata Relationship of the Initial Lenders to the
First Amendment Lenders" (Section I(B)(4) hereof).
"First Amendment Notes" mean Note 5, Note 6, Note 7 and Note 8.
"First Amendment Warrants" means the warrants to purchase 28,300
shares, in the aggregate, of the Common Stock, dated the date hereof and issued
by Borrower to each of the First Amendment Lenders, substantially in the form of
Exhibit C attached hereto.
"Initial Agency Agreement" means a certain Agency Agreement by and
among the Agent and each of the Initial Lenders dated as of December 2, 1998
entered into in connection with the Initial Consolidated Bridge Loan Agreement.
"Initial Closing Date" means the Closing Date.
"Initial Commitment" means the Total Commitment of each Initial
Lender.
"Initial Consent and Waiver" means a certain consent and waiver of
lien, indebtedness and registration rights restrictions executed by the Majority
Holders in connection with the Initial Consolidated Bridge Loan Agreement dated
as of December 2, 1998.
"Initial Consolidated Bridge Loan" has the meaning set forth in
Section I(B)1 hereof.
"Initial Consolidated Bridge Loan Agreement" means the agreement
dated as of December 2, 1998 by and among Borrower, the Initial Lenders and the
Agent.
"Initial Conversion Price" means $1.3688.
"Initial Lenders" has the meaning set forth in the Section entitled
"Pari Passu and Pro Rata Relationship of the Initial Lenders to the First
Amendment Lenders" (Section I(B)(4) hereof).
"Initial Notes" means Note 1, Note 2, Note 3 and Note 4.
"Initial Warrants" mean the warrants dated December 2, 1998 and
issued to the Initial Lenders to purchase 689,722 shares, in the aggregate, of
the Common Stock.
"Lenders" mean the Initial Lenders and the First Amendment Lenders.
"Note 1" means a certain promissory note dated as of December 2,
1998 payable by Borrower to the order of Galen Partners III, L.P. in the amount
of $7,052,621.
4
"Note 2" means a certain promissory note dated as of December 2,
1998 payable by Borrower to the order of Galen Partners International III, L.P.
in the amount of $638,389.
"Note 3" means a certain promissory note dated as of December 2,
1998 payable by Borrower to the order of Galen Employee Fund III, L.P. in the
amount of $28,880.
"Note 4" means a certain promissory note dated as of December 2,
1998 payable by Borrower to the order of Michael Weisbrot and Susan Weisbrot in
the amount of $101,222.
"Note 5" means a promissory note dated the date hereof payable by
Borrower to the order of Alan Smith in the amount of $8,000, substantially in
the form of Exhibit B attached hereto.
"Note 6" means a promissory note dated the date hereof payable by
Borrower to the order of Michael Weisbrot and Susan Weisbrot in the amount of
$150,000, substantially in the form of Exhibit B.
"Note 7" means a promissory note dated the date hereof payable by
Borrower to the order of Greg Wood in the amount of $100,000, substantially in
the form of Exhibit B.
"Note 8" means a promissory note dated the date hereof payable by
Borrower to the order of Patrick Coyne in the amount of $25,000, substantially
in the form of Exhibit B.
"Notes" means Note 1, Note 2, Note 3, Note 4, Note 5, Note 6, Note
7, and Note 8, or any one of the Notes ("Note").
"Obligations" means the unpaid principal and interest hereunder,
expenses and all other obligations and liabilities of Borrower to the Lenders
under this Agreement, the Notes or any other Bridge Loan Document, and includes,
but is not limited to, any and all indebtedness of Borrower to the Lenders,
whether now existing or hereafter incurred, of every kind and character, direct
or indirect, and whether such indebtedness is from time to time reduced and
thereafter increased, or entirely extinguished and thereafter reincurred,
including, without limitation: (a) indebtedness not yet outstanding, but
contracted for, or with respect to which any other commitment by the Lenders
exists; (b) all interest provided in any instrument, document, or agreement
(including this Agreement) which accrues on any indebtedness until payment of
such indebtedness in full; and (c) any moneys payable as hereinafter provided.
"Warrants" mean the Initial Warrants and the First Amendment
Warrants.
5
B. Amendment of Section 2. Terms of the Consolidated Bridge Loan.
1. Section 2.2 of the Agreement is amended in its entirety to read as
follows:
"2.2 Initial Consolidated Bridge Loan; Consolidated Bridge Loan.
(a) Initial Consolidated Bridge Loan. Borrower warrants,
represents and confirms that, as of the Initial Closing Date,
(i) the aggregate outstanding principal balance of the
Original Bridge Loan equals $4,500,000, (ii) the aggregate
accrued interest on such principal balance equals $71,111 and
(iii) the aggregate outstanding principal balance of the
Additional Bridge Loan equals $3,250,000. Borrower and Lenders
agree that effective on the Initial Closing Date, upon the
consolidation of the outstanding principal balances of the
Original Bridge Loan and the Additional Bridge Loan, and the
addition to principal of the accrued interest on the Original
Bridge Loan, Lenders shall be deemed to have made a single
loan to Borrower in the aggregate principal amount of
$7,821,111 (the "Initial Consolidated Bridge Loan").
(b) Consolidated Bridge Loan. Borrower warrants,
represents and confirms that, as of the First Amendment
Closing Date (i) the aggregate outstanding principal balance
of the Original Bridge Loan equals $4,500,000, (ii) the
aggregate accrued interest on such principal balance equals
$71,111, (iii) the aggregate outstanding principal balance of
the Additional Bridge Loan equals $3,250,000 and (iv) the
aggregate outstanding principal balance of the First Amendment
Loan equals $283,000. Borrower and the Lenders agree that
effective on the First Amendment Closing Date, the total
amount of funds advanced by the Lenders equals, in the
aggregate principal amount $8,104,111 (the "Consolidated
Bridge Loan")."
2. Section 2.3(a) of the Agreement is amended in its entirety to read as
follows:
"2.3 Amended, Restated and Consolidated Notes.
(a) The Amount. The Initial Consolidated Bridge Loan is
evidenced by the Initial Notes and the First Amendment Loan is
evidenced by the First Amendment Notes (each of the Initial
Notes and the First Amendment Notes, a " Note" and
collectively, the "Notes")."
3. Section 2.4 of the Agreement is amended in its entirety to read as
follows:
"2.4 Warrants. Subject to the terms of Initial Consolidated Bridge
Loan Agreement and the terms of the Initial Warrants, Borrower has
issued Initial Warrants to purchase in the aggregate, 689,722 shares
of the Common Stock, initially, at a price per share equal to
Initial Conversion Price, in the amounts set
6
forth opposite each Initial Lender's name on Exhibit A. Subject to
the terms of this First Amendment and the terms of the First
Amendment Warrants substantially in the form of Exhibit C, Borrower
will issue Warrants to purchase in the aggregate, 28,300 shares of
the Common Stock, initially, at a price per share equal to the First
Amendment Conversion Price. The First Amendment Warrants shall be
issued to each of the First Amendment Lenders in the amounts set
forth opposite each First Amendment Lender's name on Exhibit A. For
purposes of this Agreement, the term "Warrant Shares", shall mean
the shares of Common Stock that may be issued from time to time
pursuant to the exercise of the Warrants."
4. The following Section 2.10 is to be added after Section 2.9 of
Agreement:
"2.10.Pari Passu and Pro Rata Relationship of the Initial Lenders to
the First Amendment Lenders. Until such time as the unpaid principal
balance of the Initial Notes, in the original aggregate principal
amount of $7,821,111 and the First Amendment Notes, in the original
aggregate principal amount of $283,000, shall have been paid in
full, or in a manner otherwise satisfactory to the Agent, (i) the
Initial Lenders' Lien on the Borrower's Collateral with respect to
the Obligations of Borrower to the Initial Lenders under this
Agreement, any other Bridge Loan Documents and the Initial Notes, on
the one hand, and the Obligations of Borrower to the First Amendment
Lenders under this Agreement, any other Bridge Loan Documents and
the First Amendment Notes, on the other hand, shall rank pari passu
with one another, and (ii) each of the Initial Lenders and the First
Amendment Lenders shall share pro rata in the proceeds of the
Borrower's Collateral in accordance with a fraction, the denominator
of which shall equal the unpaid principal balance of the
Consolidated Bridge Loan, and the numerator of which shall equal, in
the case of the Initial Lenders, the unpaid principal balance of the
Initial Notes, and in the case of the First Amendment Lenders, the
unpaid principal balance of the First Amendment Notes, all such
amounts to be calculated as of (A) the Maturity Date, or (B) the
date each Note becomes due and payable, whether by acceleration or
otherwise, whichever date is sooner to occur."
SECTION II.
CONDITIONS PRECEDENT.
This First Amendment shall become effective on the date when all of the
following conditions, the fulfillment of each of which is a condition precedent
to the effectiveness of this First Amendment, shall have occurred or shall have
been waived in writing by Borrower and the Agent:
7
1. First Amendment Closing Documents. Each Lender shall have received a
duly executed original of, as is appropriate:
(i) this First Amendment;
(ii) its Note, if applicable;
(iii) its Warrant, if applicable;
(iv) the First Amendment Agency Agreement; and
(v) the First Amendment Waiver and Consent;
each conforming to the requirements hereof and executed as of the date of this
First Amendment by a duly authorized representative of Borrower, the Lenders and
the Agent, as the case may be.
2. Legal Opinion of Counsel to Borrower. The Agent shall have received an
opinion, dated as of the First Amendment Closing Date, of St. John & Wayne,
L.L.C., counsel to Borrower, which opinion shall be reasonably satisfactory to
the Agent and its counsel.
3. Officer's Certificate. Borrower shall have received an Officer's
Certificate from Borrower dated as of the First Amendment Closing Date,
certifying as to the (i) Certificate of Incorporation of Borrower and all
amendments thereto, (ii) accuracy and completeness of all By-Laws attached
thereto, (iii) validity of the updated Certificates of Good Standing from the
Secretaries of State of New York and Illinois with respect to Borrower, (iv)
validity of the resolutions of the Board of Directors of Borrower approving the
transactions relating to this First Amendment and each of the Bridge Loan
Document to which it or they are a party and any other certificate or other
document to be delivered pursuant thereto, together with evidence of the
incumbency of such officer signing the same.
4. First Amendment Closing Fees. All expenses outstanding as of the date
of this Agreement, including legal fees, relating to the Initial Consolidated
Bridge Loan Agreement and the First Amendment and any and all documents relating
thereto shall have been paid on or prior to the First Amendment Closing Date.
5. Updated Certificates of Good Standing. The Agent shall have received
updated Certificates of Good Standing with respect to Borrower from the
Secretaries of the State of New York and of Illinois.
6. Representations and Warranties. Upon the effectiveness of this First
Amendment, all representations and warranties set forth in the Initial
Consolidated Bridge Loan Agreement (except for such inducing representations and
warranties that were only required to be true and correct as of a prior date),
shall be true and correct in all material respects on and as of the effective
date hereof, and no Default or Event of Default shall have occurred and be
continuing and Agent shall have received a certificate of the President of
Borrower to the same effect.
8
7. Material Adverse Effect. No event or development shall have occurred
since the date of delivery to the Agent of Borrower's most recent Form 10-Q and
most recent financial statements which event or development has had or is
reasonably likely to have a Material Adverse Effect.
8. President's Certificate. The Agent shall have received a certificate
from the President of Borrower, as to the satisfaction of paragraphs 6, 7 and 10
of this Section II.
9. Additional Documents. All corporate and legal proceedings and all
documents and instruments executed or delivered in connection with this First
Amendment shall be satisfactory in form and substance to the Lenders, the Agent
and their respective counsel, and the Lenders, the Agent and their respective
counsel shall have received all information and copies of all documents which
the Lenders, the Agent and their respective counsel may have requested in
connection herewith and the matters contemplated hereunder, such documents, when
requested by them, to be certified by the appropriate authorities.
10. Litigation. There shall be no action, suit or proceeding pending or
threatened against Borrower before any court (including bankruptcy court),
arbitrator or governmental or administrative body or agency that challenges or
relates to the performance of this First Amendment or any other transactions
contemplated herein.
11. Consents and Filings. Subject to (i) the receipt of shareholder
approval to amend Borrower's Certificate of Incorporation to increase the
authorized shares of Common Stock and the filing of such amendment with the
Office of the Secretary of State of the State of New York, (ii) the receipt of
the approval of the American Stock Exchange to the extent required under Section
713 of the American Company Stock Exchange Guide, to authorize the issuance of
the Conversion Shares and the Warrant Shares in the event of a dilution
adjustment to the Notes or the Warrants results in issuances of the Conversion
Shares or the Warrant Shares at less than fair market value and (iii) the
approval required under the Hart-Scott-Rodin Antitrust Improvements Act of 1976,
as amended (the "HSR Act"); and except as otherwise obtained, no consent of any
Person (including, without limitation, shareholders or creditors of such
Borrower, as the case may be) other than the Majority Holders, the Agent shall
have received such further agreements, consents, certificates, instruments and
documents as may be necessary or proper in the reasonable opinion of the Agent
and its counsel to carry out the provisions and purposes of this First
Amendment.
12. No Liens. From the date of effectiveness of the Fourth Amendment to
the date of effectiveness of this First Amendment, no Liens shall have arisen or
been recorded against the Collateral.
9
SECTION III.
REPRESENTATIONS AND WARRANTIES
Borrower hereby represents and warrants (which representations and warranties
shall survive the execution and delivery hereof) to each Lender and the Agent
that:
1. Authority. Borrower has the corporate power, authority and legal right
to execute, deliver and perform this First Amendment, and the instruments,
agreements, documents and transactions contemplated hereby, and has taken all
actions necessary to authorize the execution, delivery and performance of this
First Amendment, and the instruments, agreements, documents and transactions
contemplated hereby.
2. Consents and Filings. Subject to (i) the receipt of shareholder
approval to amend Borrower's Certificate of Incorporation to increase the
authorized shares of Common Stock and the filing of such amendment with the
Office of the Secretary of State of the State of New York, (ii) the receipt of
the approval of the American Stock Exchange to the extent required under Section
713 of the American Company Stock Exchange Guide, to authorize the issuance of
the Conversion Shares and the Warrant Shares in the event of a dilution
adjustment to the Notes or the Warrants results in issuances of the Conversion
Shares or the Warrant Shares at less than fair market value and (iii) the
approval required under the Hart-Scott-Rodin Antitrust Improvements Act of 1976,
as amended (the "HSR Act"); and except as otherwise obtained, no consent of any
Person (including, without limitation, shareholders or creditors of such
Borrower, as the case may be) other than the Majority Holders, no consent,
permit, approval or authorization of, exemption by, notice or report to, or
registration, filing or declaration with, any governmental authority is required
in connection with the execution, delivery, performance, validity or
enforceability of this First Amendment, and the instruments, agreements,
documents and transactions contemplated hereby.
3. Due Execution. This First Amendment has been duly executed and
delivered on behalf of Borrower, and constitutes the legal, valid and binding
obligation of Borrower, enforceable in accordance with its terms.
4. No Default. Borrower is not in default in any material respect under
any indenture, mortgage, deed of trust, agreement or other instrument to which
it is a party or by which it may be bound. Except as otherwise described on
Borrower's Form 10-Q for the quarter ended September 30, 1998, Borrower knows of
no dispute regarding any such indenture, contract, lease, agreement, instrument
or other commitment. Neither the execution and delivery of this First Amendment
nor any Bridge Loan Document, nor the performance of the transactions herein or
therein contemplated, nor compliance with the provisions hereof or thereof will
(i) violate any law or regulation, or (ii) result in or cause a violation by
such Borrower of any order or decree of any court or government instrumentality,
or (iii) conflict with, or result in the breach of, or constitute a default
under, any indenture, mortgage, deed of trust, agreement or other instrument to
which such Borrower is a party or by which it may be bound, or (iv) result in
the creation or imposition of any lien, charge, or encumbrance upon any of the
property of such Borrower, except in favor of the Agent, on behalf of
10
the Lenders, to secure the Obligations, or (v) violate any provision of the
Certificate of Incorporation, By-Laws, or any capital stock provisions of such
Borrower, except as otherwise provided in Section III(2) above.
5. No Event of Default. No Event of Default has occurred and is
continuing.
6. Recitals. The recitals contained in this First Amendment are true and
correct in all respects.
SECTION IV.
GENERAL PROVISIONS
1. Except as herein expressly amended, the Consolidated Bridge Loan
Agreement and all other agreements, documents, instruments and certificates
executed in connection therewith, are ratified and confirmed in all respects and
shall remain in full force and effect in accordance with their respective terms.
2. All references in the Bridge Loan Documents to the Consolidated Bridge
Loan Agreement shall mean the Consolidated Bridge Loan Agreement as amended as
of the effective date hereof, and as amended hereby and as hereafter amended,
extended, modified, restated or supplemented from time to time. From and after
the date hereof, all references in the Consolidated Bridge Loan Agreement to
"this Agreement," "hereof," "herein," or similar terms, shall mean and refer to
the Consolidated Bridge Loan Agreement as amended by this First Amendment.
3. The headings preceding the text of the sections and subsections of this
First Amendment are used solely for convenience of reference and shall not
affect the meaning, construction, or effect of the Agreement.
4. The validity and effect of this First Amendment shall be determined by
reference to the substantive laws of the State of New York without regard to
that State's principles of conflicts of laws, except to the extent that such
other laws may govern the grant and perfection of a security interest in the
Collateral.
5. This Amendment may be executed in any number of counterparts, each of
which shall be an original and all of which together shall constitute but one
and the same First Amendment.
[THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK]
11
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed in the state of New York, and delivered by their proper and duly
authorized officers or managers as of the date set forth above.
Borrower: HALSEY DRUG CO., INC.
By:/s/
--------------------------------------------
Name: Michael Reicher
Title: Chief Executive Officer
The Lenders: GALEN PARTNERS III, L.P.
By: Claudius, L.L.C., General Partner
By:/s/
--------------------------------------------
Name: Bruce F. Wesson
Title: Managing Member
|
GALEN PARTNERS INTERNATIONAL III, L.P.
By: Claudius, L.L.C., General Partner
By:/s/
--------------------------------------------
Name: Bruce F. Wesson
Title: Managing Member
|
GALEN EMPLOYEE FUND III, L.P.
By: Wesson Enterprises, Inc.
By:/s/
--------------------------------------------
Name: Bruce F. Wesson
Title: President
|
12
/s/
-----------------------------------------------
Alan Smith
/s/
-----------------------------------------------
Michael Weisbrot
/s/
-----------------------------------------------
Susan Weisbrot
/s/
-----------------------------------------------
Greg Wood
/s/
-----------------------------------------------
Patrick Coyne
|
13
Exhibit 10.47
SECOND AMENDMENT
TO
AMENDED, RESTATED AND CONSOLIDATED
BRIDGE LOAN AGREEMENT
THIS SECOND AMENDMENT dated as of March 8, 1999 to Amended Restated and
Consolidated Bridge Loan Agreement dated as of December 2, 1998 (as amended
through the date hereof, the "Consolidated Bridge Loan Agreement") by and among
HALSEY DRUG CO., INC., a New York corporation ("Borrower"), GALEN PARTNERS III,
L.P. ("Galen", an "Initial Lender", a "Second Amendment Lender" or a "Lender") a
Delaware limited partnership, GALEN PARTNERS INTERNATIONAL III, L.P. and GALEN
EMPLOYEE FUND III, L.P., each a Delaware limited partnership (each an "Initial
Lender", a "Second Amendment Lender", a "Lender", and collectively, with Galen,
the "Galen Entities"), THOSE PERSONS WHOSE NAMES ARE SET FORTH ON THE SIGNATURE
PAGE HERETO ( each a "Second Amendment Lender", a "Lender", and collectively,
with the Galen Entities, the "Lenders") and GALEN, as agent for the Lenders (in
such capacity, the "Agent") to the Amended, Restated and Consolidated Bridge
Loan Agreement dated as of December 2, 1998 by and among Borrower, the Galen
Entities and Michael Weisbrot and Susan Weisbrot (collectively, the "Weisbrots"
or jointly and severally, an "Initial Lender", a "First Amendment Lender" or a
"Lender" (the Weisbrots and the Galen Entities, each an "Initial Lender", a
"Lender" and collectively, the "Initial Lenders"; as amended through the date
hereof, the "Consolidated Bridge Loan Agreement"). Terms that are capitalized in
this Second Amendment and not otherwise defined shall have the meaning ascribed
to such terms in the Consolidated Bridge Loan Agreement.
WITNESSETH:
WHEREAS, the Borrower and the Initial Lenders have entered into the
Consolidated Bridge Loan Agreement;
WHEREAS, the Borrower, the Initial Lenders and the First Amendment Lenders
amended the Consolidated Bridge Loan Agreement pursuant to a certain First
Amendment to Amended, Restated and Consolidated Bridge Loan Agreement dated as
of December 7, 1998 (the "First Amendment") pursuant to which the First
Amendment Lenders made an additional bridge loan of $283,000 (the "First
Amendment Loan") available to the Borrower pursuant to the terms of the
Consolidated Bridge Loan Agreement;
WHEREAS, Borrower has requested that the Galen Entities consider making an
additional One Million Four Hundred Thousand Dollars ($1,400,000) bridge loan
("Second Amendment Bridge Loan") available to Borrower, the proceeds of which
will be used by Borrower solely for Borrower's working capital purposes and
other general business purposes, in each case pursuant to the Consolidated
Bridge Loan Agreement and in accordance with the terms thereof and hereof.
NOW, THEREFORE, in consideration of the mutual promises contained herein, and
for other good and valuable consideration, the recipient and sufficiency of
which are hereby acknowledged, the parties hereto hereby agree as follows:
SECTION 1.
AMENDMENTS
A. Amendment of Section 1. Definitions.
1. Section 1.1 of the Consolidated Bridge Loan Agreement entitled "General
Definitions", is amended by the First Amendment:
(i) adding thereto, in the appropriate alphabetical order, each of
the terms "Second Amendment", "Second Amendment Agency Agreement", "Second
Amendment Bridge Loan", "Second Amendment Closing Date", "Second Amendment
Closing Fees", "Second Amendment Commitment", "Second Amendment Consent and
Waiver", "Second Amendment Conversion Price", "Second Amendment Lenders",
"Second Amendment Loan", "Second Amendment Notes", "Second Amendment Warrants",
"Note 9", "Note 10", "Note 11", and the definitions thereof, as hereinafter
provided, and
(ii) deleting the definitions of the terms "Agency Agreements",
"Agent", "Agreement", "Bridge Loan Documents", "Consents and Waivers",
"Consolidated Bridge Loan", "Lenders", "Notes", "Obligations", "Warrants" and
substituting the definitions set forth below in lieu thereof:
"Agency Agreements" mean the Initial Agency Agreement, the First
Amendment Agency Agreement and the Second Amendment Agency Agreement.
"Agent" means Galen acting as agent to the Lenders pursuant to the
Initial Agency Agreement, the First Amendment Agency Agreement and the Second
Amendment Agency Agreement.
"Agreement" means the Initial Consolidated Bridge Loan Agreement, as
amended by the First Amendment, as further amended by the Second Amendment, and
as the same may hereafter be further amended, extended, modified, restated or
supplemented from time to time.
"Bridge Loan Documents" means, collectively, the Consolidated
Bridge Loan Agreement, the First Amendment, the Second Amendment, the Notes, the
Warrants, the Agency Agreements, the Consents and Waivers, each of the
Collateral Documents and all other documents, agreements, instruments, opinions
and certificates now or hereafter executed and delivered in connection herewith
or therewith, as modified, amended, extended, restated or supplemented from time
to time.
2
"Consents and Waivers" mean the Initial Consent and Waiver, the
First Amendment Consent and Waiver and the Second Amendment Consent and Waiver.
"Consolidated Bridge Loan" has the meaning set forth in Section
I(B)(2) hereto.
"Lenders" mean the Initial Lenders, the First Amendment Lenders and
the Second Amendment Lenders.
"Note 9" means a certain promissory note dated as of March 8, 1999
payable by Borrower to the order of Galen in the amount of $1,278,992.
"Note 10" means a certain promissory note dated as of March 8, 1999
payable by Borrower to the order of Galen Partners International III, L.P. in
the amount of $115,771.
"Note 11" means a certain promissory note dated as of March 8, 1999
payable by Borrower to the order of Galen Employee Fund III, L.P. in the amount
of $5,237.
"Notes" means Note 1, Note 2, Note 3, Note 4, Note 5, Note 6, Note
7, Note 8, Note 9, Note 10 and Note 11 or any one of the Notes (individually a
"Note").
"Obligations" means the unpaid principal and interest hereunder,
expenses and all other obligations and liabilities of Borrower to the Lenders
under this Agreement, the Notes or any other Bridge Loan Document, and includes,
but is not limited to, any and all indebtedness of Borrower to the Lenders,
whether now existing or hereafter incurred, of every kind and character, direct
or indirect, and whether such indebtedness is from time to time reduced and
thereafter increased, or entirely extinguished and thereafter reincurred,
including, without limitation: (a) indebtedness not yet outstanding, but
contracted for, or with respect to which any other commitment by the Lenders
exists; (b) all interest provided in any instrument, document, or agreement
(including this Agreement) which accrues on any indebtedness until payment of
such indebtedness in full; and (c) any moneys payable as hereinafter provided.
"Second Amendment" means the Second Amendment to the Initial
Consolidated Bridge Loan Agreement dated as of March 8, 1999 by and among
Borrower, the Lenders and Agent, as the same may hereafter be further amended,
extended, modified, restated or supplemented from time to time.
"Second Amendment Agency Agreement" means the Agency Agreement by
and among the Second Amendment Lenders dated the date hereof and entered into
simultaneously herewith, substantially in the Form of Exhibit E attached hereto.
"Second Amendment Bridge Loan" has the meaning set forth in the
Recitals to this Agreement.
3
"Second Amendment Closing Date" means the date upon which the last
of the events, the fulfillment of each of which is condition precedent to the
effectiveness of this Second Amendment, as set forth in Section II of this
Second Amendment, shall have occurred.
"Second Amendment Closing Fees" means the expenses as set forth in
Section II(4) of this Second Amendment.
"Second Amendment Commitment" means the commitment of each Second
Amendment Lender to fund the dollar amount of its share of the Second Amendment
Loan in the amount set forth opposite such Lender's name on Exhibit A, a copy of
which is attached hereto and made a part hereof.
"Second Amendment Consent and Waiver" means a consent and waiver of
lien, indebtedness and registration rights restrictions executed by the Majority
Holders in connection with this Second Amendment dated the date hereof and
executed simultaneously herewith, substantially in the form of Exhibit D
attached hereto.
"Second Amendment Conversion Price" means $1.1969.
"Second Amendment Lenders" has the meaning set forth in the Section
entitled "Pari Passu and Pro Rata Relationship of the Initial Lenders to the
First Amendment Lenders and to the Second Amendment Lenders" (Section I(B)(4)
hereof).
"Second Amendment Notes" mean Note 9, Note 10, and Note 11.
"Second Amendment Warrants" means the warrants to purchase 66,887
shares, in the aggregate, of the Common Stock, dated the date hereof and issued
by Borrower to each of the Second Amendment Lenders, substantially in the form
of Exhibit C attached hereto.
"Warrants" mean the Initial Warrants, and the First Amendment
Warrants and the Second Amendment Warrants.
B. Amendment of Section 2. Terms of the Consolidated Bridge Loan.
1. Section 2.1 of the Agreement is amended in its entirety to read as
follows:
"2.1 Commitment. Subject to the terms and conditions of this
Agreement, (i) each Lender hereby agrees to amend and restate the original Notes
and the original Bridge Loan Agreement; (ii) each of the Galen entities hereby
agrees to fund the amount of its Additional Bridge Loan Commitment; (iii) each
Initial Lender hereby agrees to consolidate the Original Bridge Loan, together
with all interest accrued thereon, with the Additional Bridge Loan; (iv) each
First Amendment Lender hereby agrees to fund the amount of its First Amendment
Commitment; and (v)
4
each First Amendment Lender hereby agrees to fund the amount of its Second
Amendment Commitment."
2. Section 2.2 of the Agreement is amended in its entirety to read as
follows:
"2.2 Initial Consolidated Bridge Loan; Consolidated Bridge Loan.
(a) Initial Consolidated Bridge Loan. Borrower warrants,
represents and confirms that, as of the Initial Closing Date,
(i) the aggregate outstanding principal balance of the
Original Bridge Loan equals $4,500,000, (ii) the aggregate
accrued interest on such principal balance equals $71,111 and
(iii) the aggregate outstanding principal balance of the
Additional Bridge Loan equals $3,250,000. Borrower and Lenders
agree that effective on the Initial Closing Date, upon the
consolidation of the outstanding principal balances of the
Original Bridge Loan and the Additional Bridge Loan, and the
addition to principal of the accrued interest on the Original
Bridge Loan, Lenders shall be deemed to have made a single
loan to Borrower in the aggregate principal amount of
$7,821,111 (the "Initial Consolidated Bridge Loan").
(b) Consolidated Bridge Loan. Borrower warrants,
represents and confirms that, as of the First Amendment
Closing Date (i) the aggregate outstanding principal balance
of the Original Bridge Loan equals $4,500,000, (ii) the
aggregate accrued interest on such principal balance equals
$71,111, (iii) the aggregate outstanding principal balance of
the Additional Bridge Loan equals $3,250,000 and (iv) the
aggregate outstanding principal balance of the First Amendment
Loan equals $283,000. Borrower further warrants, represents
and confirms that, as of the Second Amendment Closing Date,
the aggregate outstanding principal balance of the Second
Amendment Loan equals $1,400,000. Borrower and the Lenders
agree that effective on the Second Amendment Closing Date, the
total amount of funds advanced by the Lenders equals, in the
aggregate principal amount $9,504,111 (the "Consolidated
Bridge Loan")."
3. Section 2.3(a) and (b) of the Agreement is amended in its entirety to
read as follows:
"2.3 Amended, Restated and Consolidated Notes.
(a) The Amount. The Initial Consolidated Bridge Loan is
evidenced by the Initial Notes, the First Amendment Loan is
evidenced by the First Amendment Notes and the Second
Amendment Loan is evidenced by the Second Amendment Notes.
(b) General Terms. The Notes are 10% Convertible Senior
Secured Notes due on May 30, 1999. Each Note is convertible,
in whole or
5
in part, from time to time, into a number of shares of Common
Stock, initially at the rate set forth in the Notes. For
purposes of this Agreement, the term "Conversion Shares" shall
mean the shares of Common Stock which may be issued upon
conversion of all or a portion of the principal amounts of the
Notes."
4. Section 2.4 of the Agreement is amended in its entirety to read as
follows:
"2.4 Warrants. Subject to the terms of Initial Consolidated Bridge
Loan Agreement and the terms of the Initial Warrants, Borrower has
issued Initial Warrants to purchase in the aggregate, 689,722 shares
of the Common Stock, initially, at a price per share equal to
Initial Conversion Price, in the amounts set forth opposite each
Initial Lender's name on Exhibit A. Subject to the terms of the
First Amendment and the terms of the First Amendment Warrants,
Borrower has issued Warrants to purchase in the aggregate, 28,300
shares of the Common Stock, initially, at a price per share equal to
the First Amendment Conversion Price. Subject to the terms of this
Second Amendment and the terms of the Second Amendment Warrants
substantially in the form of Exhibit C, Borrower will issue warrants
to purchase in the aggregate, 66,887 shares of the Common Stock,
initially, at a price per share equal to the Second Amendment
Conversion Price. The Second Amendment Warrants shall be issued to
each of the Second Amendment Lenders in the amounts set forth
opposite each Second Amendment Lender's name on Exhibit A. For
purposes of this Agreement, the term "Warrant Shares", shall mean
the shares of Common Stock that may be issued from time to time
pursuant to the exercise of the Warrants."
5. Section 2.10 of the Agreement is amended in its entirety to read as
follows:
"2.10.Pari Passu and Pro Rata Relationship of the Initial Lenders to
the First Amendment Lenders and to the Second Amendment Lenders.
Until such time as the unpaid principal balance of the Initial
Notes, in the original aggregate principal amount of $7,821,111, the
First Amendment Notes, in the original aggregate principal amount of
$283,000, and the Second Amendment Notes, in the original principal
amount of $1,400,000 shall have been paid in full, or in a manner
otherwise satisfactory to the Agent, (i) the Initial Lenders' Lien
on the Borrower's Collateral with respect to the Obligations of
Borrower to the Initial Lenders under this Agreement, any other
Bridge Loan Documents and the Initial Notes, the Obligations of
Borrower to the First Amendment Lenders under this Agreement, any
other Bridge Loan Documents and the First Amendment Notes, and the
Obligations of Borrower to the Second Amendment Lenders under this
Agreement, any other Bridge Loan
6
Documents and the Second Amendment Notes, shall rank pari passu with
one another, and (ii) each of the Initial Lenders, the First
Amendment Lenders and the Second Amendment Lenders shall share pro
rata in the proceeds of the Borrower's Collateral in accordance with
a fraction, the denominator of which shall equal the unpaid
principal balance of the Consolidated Bridge Loan, and the numerator
of which shall equal, in the case of the Initial Lenders, the unpaid
principal balance of the Initial Notes, in the case of the First
Amendment Lenders, the unpaid principal balance of the First
Amendment Notes, and in the case of the Second Amendment Lenders,
the unpaid principal amount of the Second Amendment Notes, all such
amounts to be calculated as of (A) the Maturity Date, or (B) the
date each Note becomes due and payable, whether by acceleration or
otherwise, whichever date is sooner to occur."
SECTION II.
CONDITIONS PRECEDENT.
This Second Amendment shall become effective on the date when all of the
following conditions, the fulfillment of each of which is a condition precedent
to the effectiveness of this Second Amendment, shall have occurred or shall have
been waived in writing by Borrower and the Agent:
1. Second Amendment Closing Documents. Each Lender shall have received a
duly executed original of, as is appropriate:
(i) this Second Amendment;
(ii) its Note, if applicable;
(iii) its Warrant, if applicable;
(iv) the Second Amendment Agency Agreement; and
(v) the Second Amendment Waiver and Consent;
each conforming to the requirements hereof and executed as of the date of this
Second Amendment by a duly authorized representative of Borrower, the Lenders
and the Agent, as the case may be.
2. Legal Opinion of Counsel to Borrower. The Agent shall have received an
opinion, dated as of the Second Amendment Closing Date, of St. John & Wayne,
L.L.C., counsel to Borrower, which opinion shall be reasonably satisfactory to
the Agent and its counsel.
3. Officer's Certificate. Borrower shall have received an Officer's
Certificate from Borrower dated as of the Second Amendment Closing Date,
certifying as to the (i) Certificate of Incorporation of Borrower and all
amendments thereto, (ii) accuracy and completeness of all By-Laws attached
thereto, (iii) validity of the updated Certificates of Good Standing from the
Secretaries of State of
7
New York and Illinois with respect to Borrower, (iv) validity of the resolutions
of the Board of Directors of Borrower approving the transactions relating to
this Second Amendment and each of the Bridge Loan Document to which it or they
are a party and any other certificate or other document to be delivered pursuant
thereto, together with evidence of the incumbency of such officer signing the
same.
4. Second Amendment Closing Fees. All expenses outstanding as of the date
of this Agreement, including legal fees, relating to the Initial Consolidated
Bridge Loan Agreement, and the Second Amendment and any and all documents
relating thereto shall have been paid on or prior to the Second Amendment
Closing Date.
5. Updated Certificates of Good Standing. The Agent shall have received
updated Certificates of Good Standing with respect to Borrower from the
Secretaries of the State of New York and of Illinois.
6. Representations and Warranties. Upon the effectiveness of this Second
Amendment, all representations and warranties set forth in the First Amendment
(except for such inducing representations and warranties that were only required
to be true and correct as of a prior date), shall be true and correct in all
material respects on and as of the effective date hereof, and no Default or
Event of Default shall have occurred and be continuing and Agent shall have
received a certificate of the President of Borrower to the same effect.
7. Material Adverse Effect. No event or development shall have occurred
since the date of delivery to the Agent of Borrower's most recent Form 10-Q and
most recent financial statements which event or development has had or is
reasonably likely to have a Material Adverse Effect.
8. President's Certificate. The Agent shall have received a certificate
from the President of Borrower, as to the satisfaction of paragraphs 6, 7 and 10
of this Section II.
9. Additional Documents. All corporate and legal proceedings and all
documents and instruments executed or delivered in connection with this Second
Amendment shall be satisfactory in form and substance to the Lenders, the Agent
and their respective counsel, and the Lenders, the Agent and their respective
counsel shall have received all information and copies of all documents which
the Lenders, the Agent and their respective counsel may have requested in
connection herewith and the matters contemplated hereunder, such documents, when
requested by them, to be certified by the appropriate authorities.
10. Litigation. There shall be no action, suit or proceeding pending or
threatened against Borrower before any court (including bankruptcy court),
arbitrator or governmental or administrative body or agency that challenges or
relates to the performance of this Second Amendment or any other transactions
contemplated herein.
8
11. Consents and Filings. Subject to (i) the receipt of shareholder
approval to amend Borrower's Certificate of Incorporation to increase the
authorized shares of Common Stock and the filing of such amendment with the
Office of the Secretary of State of the State of New York, (ii) the receipt of
the approval of the American Stock Exchange to the extent required under Section
713 of the American Company Stock Exchange Guide, to authorize the issuance of
the Conversion Shares and the Warrant Shares in the event of a dilution
adjustment to the Notes or the Warrants results in issuances of the Conversion
Shares or the Warrant Shares at less than fair market value and (iii) the
approval required under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended (the "HSR Act"); and except as otherwise obtained, no consent
of any Person (including, without limitation, shareholders or creditors of such
Borrower, as the case may be) other than the Majority Holders, the Agent shall
have received such further agreements, consents, certificates, instruments and
documents as may be necessary or proper in the reasonable opinion of the Agent
and its counsel to carry out the provisions and purposes of this Second
Amendment.
12. No Liens. From the date of effectiveness of the First Amendment to the
date of effectiveness of this Second Amendment, no Liens shall have arisen or
been recorded against the Collateral.
SECTION III.
REPRESENTATIONS AND WARRANTIES
Borrower hereby represents and warrants (which representations and warranties
shall survive the execution and delivery hereof) to each Lender and the Agent
that:
1. Authority. Borrower has the corporate power, authority and legal right
to execute, deliver and perform this Second Amendment, and the instruments,
agreements, documents and transactions contemplated hereby, and has taken all
actions necessary to authorize the execution, delivery and performance of this
Second Amendment, and the instruments, agreements, documents and transactions
contemplated hereby.
2. Consents and Filings. Subject to (i) the receipt of shareholder
approval to amend Borrower's Certificate of Incorporation to increase the
authorized shares of Common Stock and the filing of such amendment with the
Office of the Secretary of State of the State of New York, (ii) the receipt of
the approval of the American Stock Exchange to the extent required under Section
713 of the American Company Stock Exchange Guide, to authorize the issuance of
the Conversion Shares and the Warrant Shares in the event of a dilution
adjustment to the Notes or the Warrants results in issuances of the Conversion
Shares or the Warrant Shares at less than fair market value and (iii) the
approval required under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended (the "HSR Act"); and except as otherwise obtained, no consent
of any Person (including, without limitation, shareholders or creditors of such
Borrower, as the case may be) other than the Majority Holders, no consent,
permit, approval or authorization of, exemption by, notice or report to, or
registration, filing or declaration with, any governmental authority is required
in connection with the
9
execution, delivery, performance, validity or enforceability of this First
Amendment, and the instruments, agreements, documents and transactions
contemplated hereby.
3. Due Execution. This Second Amendment has been duly executed and
delivered on behalf of Borrower, and constitutes the legal, valid and binding
obligation of Borrower, enforceable in accordance with its terms.
4. No Default. Borrower is not in default in any material respect under
any indenture, mortgage, deed of trust, agreement or other instrument to which
it is a party or by which it may be bound. Except as otherwise described on
Borrower's Form 10-Q for the quarter ended September 30, 1998, Borrower knows of
no dispute regarding any such indenture, contract, lease, agreement, instrument
or other commitment. Neither the execution and delivery of this Second Amendment
nor any Bridge Loan Document, nor the performance of the transactions herein or
therein contemplated, nor compliance with the provisions hereof or thereof will
(i) violate any law or regulation, or (ii) result in or cause a violation by
such Borrower of any order or decree of any court or government instrumentality,
or (iii) conflict with, or result in the breach of, or constitute a default
under, any indenture, mortgage, deed of trust, agreement or other instrument to
which such Borrower is a party or by which it may be bound, or (iv) result in
the creation or imposition of any lien, charge, or encumbrance upon any of the
property of such Borrower, except in favor of the Agent, on behalf of the
Lenders, to secure the Obligations, or (v) violate any provision of the
Certificate of Incorporation, By-Laws, or any capital stock provisions of such
Borrower, except as otherwise provided in Section III(2) above.
5. No Event of Default. No Event of Default has occurred and is
continuing.
6. Recitals. The recitals contained in this Second Amendment are true and
correct in all respects.
SECTION IV.
GENERAL PROVISIONS
1. Except as herein expressly amended, the Consolidated Bridge Loan
Agreement and all other agreements, documents, instruments and certificates
executed in connection therewith, are ratified and confirmed in all respects and
shall remain in full force and effect in accordance with their respective terms.
2. All references in the Bridge Loan Documents to the Consolidated Bridge
Loan Agreement shall mean the Consolidated Bridge Loan Agreement as amended as
of the effective date hereof, and as amended hereby and as hereafter amended,
extended, modified, restated or supplemented from time to time. From and after
the date hereof, all references in the Consolidated Bridge Loan Agreement to
"this Agreement," "hereof," "herein," or similar terms, shall mean and refer to
the Consolidated Bridge Loan Agreement as amended by the First Amendment and as
further amended by this Second Amendment.
10
3. The headings preceding the text of the sections and subsections of this
Second Amendment are used solely for convenience of reference and shall not
affect the meaning, construction, or effect of the Agreement.
4. The validity and effect of this Second Amendment shall be determined by
reference to the substantive laws of the State of New York without regard to
that State's principles of conflicts of laws, except to the extent that such
other laws may govern the grant and perfection of a security interest in the
Collateral.
5. This Amendment may be executed in any number of counterparts, each of
which shall be an original and all of which together shall constitute but one
and the same Second Amendment.
[THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK]
11
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed in the state of New York, and delivered by their proper and duly
authorized officers or managers as of the date set forth above.
Borrower: HALSEY DRUG CO., INC.
By:/s/
--------------------------------------------
Name: Michael Reicher
Title: Chief Executive Officer
The Lenders: GALEN PARTNERS III, L.P.
By: Claudius, L.L.C., General Partner
By:/s/
--------------------------------------------
Name: Bruce F. Wesson
Title: Managing Member
|
GALEN PARTNERS INTERNATIONAL III, L.P.
By: Claudius, L.L.C., General Partner
By:/s/
--------------------------------------------
Name: Bruce F. Wesson
Title: Managing Member
|
GALEN EMPLOYEE FUND III, L.P.
By: Wesson Enterprises, Inc.
By:/s/
--------------------------------------------
Name: Bruce F. Wesson
Title: President
|
12
/s/
-----------------------------------------------
Alan Smith
/s/
-----------------------------------------------
Michael Weisbrot
/s/
-----------------------------------------------
Susan Weisbrot
/s/
-----------------------------------------------
Greg Wood
/s/
-----------------------------------------------
Patrick Coyne
|
13
Exhibit 10.48
[Form of 10% Convertible Secured Note due May 30, 1999]
THIS CONVERTIBLE SENIOR SECURED NOTE AND THE COMMON STOCK ISSUABLE UPON
CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT") NOR UNDER ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED,
SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNTIL (1) A REGISTRATION
STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE
STATE SECURITIES LAW OR (2) THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE
COMPANY OR OTHER COUNSEL TO THE HOLDER OF SUCH NOTE REASONABLY SATISFACTORY TO
THE COMPANY THAT SUCH NOTE AND/OR COMMON STOCK MAY BE PLEDGED, SOLD, ASSIGNED,
HYPOTHECATED OR TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE ACT OR APPLICABLE STATE SECURITIES LAWS.
HALSEY DRUG CO., INC.
Amended, Restated and Consolidated
10% Convertible Senior Secured Note
Due May 30, 1999
$[___________] No. [____]
December 2, 1998
HALSEY DRUG CO., INC., a corporation organized under the laws of the State
of New York (the "Company"), for value received, hereby promises to pay to the
order of [_______________________] ("________"), a Delaware limited partnership,
with its principal place of business at 610 Fifth Avenue, 5th Floor, New York,
New York 10020 or registered assigns (the "Payee" or "Holder") upon due
presentation and surrender of this Note, on May 30, 1999 (the "Maturity Date"),
the principal amount of [_____________________________] ($__________________)
and accrued interest thereon as hereinafter provided.
This Note was issued by the Company pursuant a certain Amended, Restated
and Consolidated Bridge Loan Agreement dated the date hereof among the Company
and certain persons, including the Payee, (together with the Schedules and
Exhibits thereto, the "Agreement") relating to the issuance of 10% Convertible
Senior Secured Notes maturing May 30, 1999 (the "Notes") in the original
aggregate principal amount of $8,571,111. The holders of such Notes are referred
to hereinafter as the "Holders". The Payee is entitled to the benefits of the
Agreement.
Reference is made to the Agreement with respect to certain additional rights of
the Payee and obligations of the Company not set forth herein. Terms that are
capitalized in this Note, but not otherwise defined, shall have the meanings
ascribed to them in the Agreement.
This Note evidences the amendment and restatement, in its entirety, of
Galen's share of the Original Bridge Loan, and, the consolidation of Galen's
Share of the Original Bridge Loan with Galen's share of the Additional Bridge
Loan. This Note does not create a novation of, nor does this Note, in any
manner, diminish or extinguish the unpaid principal balance of, or the accrued
interest on, the Company's indebtedness to Galen, as originally set forth in the
Original Bridge Loan Agreement, and, as evidenced by the Original Notes. Such
unpaid balance of, and such accrued interest on such indebtedness continues to
be due and owing by the Company to Galen, as described herein, and the Company
hereby reaffirms and confirms same.
ARTICLE I
PAYMENT OF PRINCIPAL AND INTEREST; METHOD OF PAYMENT
1.1 Payment of Principal and Interest. Payment of the principal and
accrued interest on the principal of this Note shall be made in such coin or
currency of the United States of America as at the time of payment shall be
legal tender for the payment of public and private debts. Interest (computed on
the basis of a 360-day year of twelve 30-day months) on the unpaid portion of
said principal amount from time to time outstanding shall be paid by the Company
at the rate of ten percent (10%) per annum (the "Stated Interest Rate") payable
to the Payee on the Maturity Date.
1.2 Method of Payment. Both principal hereof and interest thereon
are payable to the Holder at the address of the Holder above, or such other name
or address as the Holder shall designate from time to time by written notice to
the Company. The Company will pay or cause to be paid all sums becoming due
hereon for principal and interest by check sent to the Holder's above address or
to such other address as the Holder may designate for such purpose from time to
time by written notice to the Company, without any requirement for the
presentation of this Note or making any notation thereon, except that the Holder
hereof agrees that payment of the final amount due shall be made only upon
surrender of this Note to the Company for cancellation. Prior to any sale or
other disposition of this instrument, the Holder hereof agrees to endorse hereon
the amount of principal paid hereon and the last date to which interest has been
paid hereon and to notify the Company of the name and address of the transferee.
1.3 Late Payments. In the event any payment of principal or interest
or both shall remain unpaid for a period of ten (10) days or more, a late charge
equivalent to five (5%) percent of each installment shall be charged. Interest
on the indebtedness evidenced by this Note after default, or maturity
accelerated or otherwise, shall be due and payable at the rate of twelve (12%)
percent per annum, subject to the limitations of applicable law.
1.4 Miscellaneous. If this Note or any installment hereof becomes
due and payable on a Saturday, Sunday or public holiday under the laws of the
State of New York, the due date hereof shall be extended to the next succeeding
full business day and interest shall be payable at the rate of
ten (10%) percent per annum during such extension. All payments received by the
Holder shall be applied first to the payment of all accrued interest payable
hereunder.
ARTICLE II
SECURITY
2.1 The payment and performance of the Obligations of the Company
under this Note are secured by liens on and security interests in and to the
Collateral granted by the Company to the Lenders pursuant to a certain Amended
and Restated Security Agreement dated the date hereof, and executed
simultaneously herewith.
ARTICLE III
CONVERSION
3.1 Conversion at Option of Holder. At any time and from time to
time, until the payment in full of the outstanding principal and the accrued
interest on the principal of this Note, this Note and the accrued interest
thereon is convertible, in whole or in part, at the Holder's option into shares
of Common Stock upon surrender of this Note, at the office of the Company,
accompanied by a written notice of conversion in form reasonably satisfactory to
the Company duly executed by the registered Holder or its duly authorized
attorney. The outstanding principal balance of this Note is convertible into
shares of Common Stock initially at a price per share of Common Stock equal to
$1.3688 per share. Interest shall accrue to and include the day prior to the
date of conversion, and, if any accrued interest on the principal of this Note
is not converted into Common Stock , the such accrued interest shall be paid on
the last day of the month during which any conversion rights are exercised. If
the Holder elects to convert such accrued interest, then the conversion price is
to be based on the average closing price of the Common Stock for the twenty (20)
days immediately preceding the payment date of the interest as reported by the
American Stock Exchange. Instead of issuing fractional shares, or a scrip
representing fractional shares, an adjustment in cash will be made for any
fraction of a share that would otherwise have been issuable upon the conversion
of any portion of this Note. The Conversion Price is subject to adjustment as
provided in Sections 3.5 and 3.7 hereof. As soon as practicable after conversion
and upon the Holder's compliance with the conversion procedure described in
Section 3.3 below, the Company shall deliver a certificate for the number of
full shares of Common Stock issuable upon conversion and a check for any
fractional share and, if the Note is converted in part, a new Note in the
principal amount equal to the principal balance remaining under this Note after
giving effect to such partial conversion.
3.2 [INTENTIONALLY LEFT BLANK]
3.3 Registration of Transfer; Conversion Procedure. The Company shall
maintain books for the transfer and registration of the Notes. Upon the transfer
of any Note in accordance with the provisions of the Agreement, the Company
shall issue and register the Note in the names of the new holders. The Notes
shall be signed manually by the Chairman, Chief Executive Officer, President or
any Vice President and the Secretary or Assistant Secretary of the Company. The
Company shall convert, from time to time, any outstanding Notes upon the books
to be maintained by the Company for such purpose upon surrender thereof for
conversion properly endorsed and, in the case of a
conversion pursuant to Section 3.1 hereof, accompanied by a properly completed
and executed Conversion Notice attached hereto as Attachment II. Subject to the
terms of this Note, upon surrender of this Note the Company shall issue and
deliver with all reasonable dispatch to or upon the written order of the Holder
of such Note and in such name or names as such Holder may designate, a
certificate or certificates for the number of full shares of Common Stock due to
such Holder upon the conversion of this Note. Such certificate or certificates
shall be deemed to have been issued and any person so designated to be named
therein shall be deemed to have become the Holder of record of such Shares as of
the date of the surrender of this Note; provided, however, that if, at the date
of surrender the transfer books of the Common Stock shall be closed, the
certificates for the shares shall be issuable as of the date on which such books
shall be opened and until such date the Company shall be under no duty to
deliver any certificate for such shares; provided, further, however, that such
transfer books, unless otherwise required by law or by applicable rule of any
national securities exchange, shall not be closed at any one time for a period
longer than twenty (20) days.
3.4 Company to Provide Common Stock. In accordance with the
provisions of Section 6(1)(m) of the Agreement, the Company covenants to seek
the approval of its shareholders to amend its Certificate of Incorporation to
increase its authorized shares from 40,000,000 to 75,000,000 shares of Common
Stock. Promptly upon receipt of shareholder approval to amend its certificate of
incorporation to increase its authorized shares, the Company shall reserve out
of its authorized but unissued common stock a sufficient number of shares to
permit the conversion of the Notes in full. The shares of Common Stock which may
be issued upon the conversion of the Notes shall be fully paid and
non-assessable and free of preemptive rights. The Company will endeavor to
comply with all securities laws regulating the offer and delivery of the Shares
upon conversion of the Notes and will endeavor to list such shares on each
national securities exchange upon which the Common Stock is listed.
3.5 Dividends; Reclassifications, etc. At any time before the
earlier of (i) the exercise of conversion rights hereunder or (ii) the Maturity
Date, if the Company: (i) declares or pays to the holders of the Common Stock a
dividend payable in any kind of shares of capital stock of the Company; or (ii)
changes or divides or otherwise reclassifies its Common Stock into the same or a
different number of shares with or without par value, or in shares of any class
or classes; or (iii) transfers its property as an entirety or substantially as
an entirety to any other company or entity; or (iv) makes any distribution of
its assets to holders of its Common Stock as a liquidation or partial
liquidation dividend or by way of return of capital; then, upon exercising its
conversion rights, the Holder thereof shall receive, in addition to or in
substitution for the shares of Common Stock to which it would have otherwise
been entitled upon such exercise: (i) such additional shares of stock or scrip
of the Company; (ii) such reclassified shares of stock of the Company, or (iii)
such shares of the securities or property of the Company resulting from
transfer, or (iv) such assets of the Company, which it would have been entitled
to receive had it exercised these conversion rights prior to the happening of
any of the foregoing events.
3.6 Notice to Holder. If, at any time while this Note is
outstanding, the Company shall pay any dividend payable in cash or in shares of
Common Stock, shall offer to the holders of its Common Stock for subscription or
purchase by them any shares of stock of any class or any other rights, shall
enter into an agreement to merge or consolidate with another corporation, shall
propose any capital reorganization or reclassification of the capital stock of
the Company, including any
subdivision or combination of its outstanding shares of Common Stock or there
shall be contemplated a voluntary or involuntary dissolution, liquidation or
winding up of the Company, the Company shall cause notice thereof to be mailed
to the registered Holder of this Note at its address appearing on the
registration books of the Company, at least thirty (30) days before the record
date as of which holders of Common Stock shall participate in such dividend,
distribution or subscription or other rights or at least thirty (30) days prior
to the effective date of the merger, consolidation, reorganization,
reclassification or dissolution.
3.7 Adjustments to Conversion Price. In order to prevent dilution of
the conversion rights granted hereunder, the Conversion Price shall be subject
to adjustment from time to time in accordance with this Section 3.7. The
Conversion Price in effect at the time of the exercise of conversion rights
hereunder, shall be subject to adjustment, or further adjustment, from time to
time as follows:
(a) If at any time after the date of issuance hereof and prior
to the payment in full of the principal and the accrued interest on the
principal of this Note, the Company shall grant or issue any shares of Common
Stock, or grant or issue any rights or options for the purchase of, or stock or
other securities convertible into, Common Stock (such convertible stock or
securities being herein collectively referred to as "Convertible Securities") or
any combination whatsoever of Common Stock or Convertible Securities, other
than:
(i) shares issued in a transaction described in
subsection (b) of this Section 3.7; or
(ii) shares issued, subdivided or combined in
transactions described in Section 3.5 if and to the extent that the number of
shares of Common Stock received upon conversion of this Note shall have been
previously adjusted pursuant to Section 3.5 as a result of such issuance,
subdivision or combination of such securities;
for a consideration per share which is less than the Conversion Price in effect
immediately prior to such issuance or sale, then the Conversion Price, and
thereafter upon each issuance or sale for a consideration per share which is
less than the Conversion Price in effect immediately prior to such issuance or
sale, the Conversion Price shall, simultaneously with such issuance or sale, be
adjusted, so that the Conversion Price immediately prior to such issuance or
sale, shall be reduced to the consideration received by the Company for each
share of Common Stock in such issuance.
Upon each adjustment of the Conversion Price pursuant to this
subsection (a), the total number of shares of Common Stock into which this Note
shall be convertible shall be such number of shares (calculated to the nearest
tenth) purchasable at the Applicable Conversion Price multiplied by a fraction,
the numerator of which shall be the Applicable Conversion Price in effect
immediately prior to such adjustment and the denominator of which shall be the
conversion price in effect immediately after such adjustment.
(b) Anything in this Section 3.7 to the contrary
notwithstanding, no adjustment in the Conversion Price shall be made in
connection with:
(i) the grant, issuance or exercise of any Convertible
Securities pursuant to the Company's qualified or non-qualified Employee Stock
Option Plans or any other bona fide employee benefit plan or incentive
arrangement, adopted or approved by the Company's Board of Directors and
approved by the Company's shareholders, as may be amended from time to time, or
under any other bona fide employee benefit plan hereafter adopted by the
Company's Board of Directors; or
(ii) the grant, issuance or exercise of any Convertible
Securities in connection with the hire or retention of any officer, director or
key employee of the Company, provided such grant is approved by the Company's
Board of Directors; or
(iii) the issuance of any shares of Common Stock
pursuant to the grant or exercise of Convertible Securities outstanding as of
December 2, 1998 (exclusive of any subsequent amendments thereto).
(c) For the purpose of subsection 3.7(a), the following
provisions shall also be applied:
(i) In case of the issuance or sale of additional shares
of Common Stock for cash, the consideration received by the Company therefor
shall be deemed to be the amount of cash received by the Company for such
shares, before deducting therefrom any commissions, compensation or other
expenses paid or incurred by the Company for any underwriting of, or otherwise
in connection with, the issuance or sale of such shares.
(ii) In the case of the issuance of Convertible
Securities, the consideration received by the Company therefor shall be deemed
to be the amount of cash, if any, received by the Company for the issuance of
such rights or options, plus the minimum amounts of cash and fair value of other
consideration, if any, payable to the Company upon the exercise of such rights
or options or payable to the Company upon conversion of such Convertible
Securities.
(iii) In the case of the issuance of shares of Common
Stock or Convertible Securities for a consideration in whole or in part, other
than cash, the consideration other than cash shall be deemed to be the fair
market value thereof as reasonably determined in good faith by the Board of
Directors of the Company (irrespective of accounting treatment thereof);
provided, however, that if such consideration consists of the cancellation of
debt issued by the Company, the consideration shall be deemed to be the amount
the Company received upon issuance of such debt (gross proceeds) plus accrued
interest and, in the case of original issue discount or zero coupon
indebtedness, accrued value to the date of such cancellation, but not including
any premium or discount at which the debt may then be trading or which might
otherwise be appropriate for such class of debt.
(iv) In case of the issuance of additional shares of
Common Stock upon the conversion or exchange of any obligations (other than
Convertible Securities), the amount of the consideration received by the Company
for such Common Stock shall be deemed to be the consideration received by the
Company for such obligations or shares so converted or exchanged, before
deducting from such consideration so received by the Company any expenses or
commissions
or compensation incurred or paid by the Company for any underwriting of, or
otherwise in connection with, the issuance or sale of such obligations or
shares, plus any consideration received by the Company in connection with such
conversion or exchange other than a payment in adjustment of interest and
dividends. If obligations or shares of the same class or series of a class as
the obligations or shares so converted or exchanged have been originally issued
for different amounts of consideration, then the amount of consideration
received by the Company upon the original issuance of each of the obligations or
shares so converted or exchange shall be deemed to be the average amount of the
consideration received by the Company upon the original issuance of all such
obligations or shares. The amount of consideration received by the Company upon
the original issuance of the obligations or shares so converted or exchanged and
the amount of the consideration, if any, other than such obligations or shares,
received by the Company upon such conversion or exchange shall be determined in
the same manner as provided in paragraphs (i) and (ii) above with respect to the
consideration received by the Company in case of the issuance of additional
shares of Common Stock or Convertible Securities.
(d) Upon any adjustment of any Conversion Price, then and in
each such case the Company shall promptly deliver a notice to the registered
Holder of this Note, which notice shall state the Conversion Price resulting
from such adjustment, setting forth in reasonable detail the method of
calculation and the facts upon which such calculation is based.
3.8 Reorganization of the Company. If the Company is a party to a
merger or other transaction which reclassifies or changes its outstanding Common
Stock, upon consummation of such transaction this Note shall automatically
become convertible into the kind and amount of securities, cash or other assets
which the Holder of this Note would have owned immediately after such
transaction if the Holder had converted this Note at the Conversion Price in
effect immediately before the effective date of the transaction. Concurrently
with the consummation of such transaction, the person obligated to issue
securities or deliver cash or other assets upon conversion of this Note shall
execute and deliver to the Holder a supplemental Note so providing and further
providing for adjustments which shall be as nearly equivalent as may be
practical to the adjustments provided in this Article 3. The successor Company
shall mail to the Holder a notice describing the supplemental Note.
If securities deliverable upon conversion of this Note, as provided
above, are themselves convertible into the securities of an affiliate of a
corporation formed, surviving or otherwise affected by the merger or other
transaction, that issuer shall join in the supplemental Note which shall so
provide. If this section applies, Section 3.5 does not apply.
ARTICLE IV
MISCELLANEOUS
4.1 Default. Upon the occurrence of any one or more of the Events of
Default specified or referred to in the Agreement or in the other documents or
instruments executed in connection therewith, all amounts then remaining unpaid
on this Note may be declared to be immediately due and payable as provided in
the Agreement.
4.2 Collection Costs. In the event that this Note shall be placed in
the hands of an attorney for collection by reason of any Event of Default
hereunder, the undersigned agrees to pay reasonable attorney's fees and
disbursements and other reasonable expenses incurred by the Holder in connection
with the collection of this Note.
4.3 Rights Cumulative. The rights, powers and remedies given to the
Payee under this Note shall be in addition to all rights, powers and remedies
given to it by virtue of the Agreement, any document or instrument executed in
connection therewith, or any statute or rule of law.
4.4 No Waivers. Any forbearance, failure or delay by the Payee in
exercising any right, power or remedy under this Note, the Agreement, any
documents or instruments executed in connection therewith or otherwise available
to the Payee shall not be deemed to be a waiver of such right, power or remedy,
nor shall any single or partial exercise of any right, power or remedy preclude
the further exercise thereof.
4.5 Amendments in Writing. No modification or waiver of any
provision of this Note, the Agreement or any documents or instruments executed
in connection therewith shall be effective unless it shall be in writing and
signed by the Payee, and any such modification or waiver shall apply only in the
specific instance for which given.
4.6 Governing Law. This Note and the rights and obligations of the
parties hereto, shall be governed, construed and interpreted according to the
laws of the State of New York, without reference to its choice of law
principles, wherein it was negotiated and executed, and the undersigned consents
and agrees that the State and Federal Courts which sit in the State of New York,
County of New York shall have exclusive jurisdiction of all controversies and
disputes arising hereunder.
4.7 No Counterclaims. The undersigned waives the right to interpose
counterclaims or set-offs of any kind and description in any litigation arising
hereunder and waives the right in any litigation with the Payee (whether or not
arising out of or relating to this Note) to trial by jury.
4.8 Successors. The term "Payee" and "Holder" as used herein shall
be deemed to include the Payee and its successors, endorsees and assigns.
4.9 Certain Waivers. The Company hereby waives presentment, demand
for payment, protest, notice of protest and notice of non-payment hereof.
4.10 Stamp Tax. The Company will pay any documentary stamp taxes
attributable to the initial issuance of the Common Stock issuable upon the
conversion of this Note; provided, however, that the Company shall not be
required to pay any tax or taxes which may be payable for of any transfer
involved in the issuance or delivery of any certificates for the Common Stock in
a name other than that of the Holder for which such Common Stock is issued, and
in such case the Company shall not be required to issue or deliver any
certificate for the Common Stock until the person requesting the same has paid
to the Company the amount of such tax or has established, to the Company's
satisfaction, that such tax has been paid.
4.11 Mutilated, Lost, Stolen or Destroyed Notes. In case this Note
shall be mutilated, lost, stolen or destroyed, the Company shall issue and
deliver in exchange and substitution for and upon cancellation of the mutilated
Note, or in lieu of and substitution for the Note, mutilated, lost, stolen or
destroyed, a new Note of like tenor and representing an equivalent right or
interest, but only upon receipt of evidence satisfactory to the Company of such
loss, theft or destruction and an indemnity, if requested, also satisfactory to
it.
4.12 Maintenance of Office. The Company covenants and agrees that so
long as this Note shall be outstanding, it will maintain an office or agency in
New York (or such other place as the Company may designate in writing to the
holder of this Note) where notices, presentations and demands to or upon the
Company regarding of this Note may be given or made.
IN WITNESS WHEREOF, Halsey Drug Co., Inc. has caused this Note to be
signed by its President and to be dated the day and year first above written.
ATTEST [SEAL] HALSEY DRUG CO., INC.
___________________________________ By:___________________________________
Michael Reicher
Chief Executive Officer
|
ATTACHMENT I
Assignment
For value received, the undersigned hereby assigns to
________________________, subject to the provisions of Section 11.13 of the
Agreement, $_________________ principal amount of the Amended, Restated and
Consolidated 10% Convertible Senior Secured Note due May 30, 1999 evidenced
hereby and hereby irrevocably appoint _______________ attorney to transfer the
Note on the books of the within named corporation with full power of
substitution in the premises.
Dated:
In the presence of:
ATTACHMENT II
CONVERSION NOTICE
TO: HALSEY DRUG CO., INC.
The undersigned holder of this Note hereby irrevocably exercises the
option to convert $_________________ principal amount of such Note and/or
$______________________ amount of accrued interest on the principal of such Note
(which may be less than the stated amount of principal thereof or accrued
interest thereon) into shares of Common Stock of Halsey Drug Co., Inc., in
accordance with the terms of such Note, and directs that the shares of Common
Stock issuable and deliverable upon such conversion, together with a check (if
applicable) in payment for any fractional shares as provided in such Note, be
issued and delivered to the undersigned unless a different name has been
indicated below. If shares of Common Stock are to be issued in the name of a
person other than the undersigned holder of such Note, the undersigned will pay
all transfer taxes payable with respect thereto.
Name and Address of Holder
Signature of Holder
Principal amount of Note to be converted $
Amount of accrued interest on the principal
of the Note to be converted $
If shares are to be issued otherwise then to the Holder:
Name of Transferee
Address of Transferee
Social Security Number of Transferee
Exhibit 10.49
[Form of Common Stock Purchase Warrant issued pursuant to the Amended,
Restated and Consolidated Bridge Loan Agreement]
WARRANT TO PURCHASE
COMMON STOCK, PAR VALUE $.01 PER SHARE
OF
HALSEY DRUG CO., INC.
THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") NOR UNDER
ANY STATE SECURITIES LAW AND MAY NOT BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR
OTHERWISE TRANSFERRED UNTIL (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS
EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAW OR (2) THE
COMPANY RECEIVES AN OPINION OF COUNSEL TO THE COMPANY OR OTHER COUNSEL TO THE
HOLDER OF SUCH WARRANT REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH WARRANT
AND/OR COMMON STOCK MAY BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR TRANSFERRED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE
SECURITIES LAWS.
This certifies that, for value received, [ ]or registered
assigns ("Warrantholder"), is entitled to purchase from HALSEY DRUG CO., INC.
(the "Company"), subject to the provisions of this Warrant, at any time during
the Exercise Period (as hereinafter defined) [ ] shares of the
Company's Common Stock, par value $.01 per share ("Warrant Shares"). The
purchase price payable upon the exercise of this Warrant shall be $1.3313 per
Warrant Share. The purchase price and the number of Warrant Shares which the
Warrantholder is entitled to purchase are subject to adjustment upon the
occurrence of the contingencies set forth in this Warrant, and as adjusted from
time to time, such purchase price is hereinafter referred to as the "Warrant
Price."
For purposes of this Warrant, the term "Exercise Period" means the
period commencing on the date of issuance of this Warrant and ending on the
seventh anniversary of such date.
This Warrant is subject to the following terms and conditions:
|